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Cancer is a group of related diseases with more than 200 types, arising from different 
cell types within the body. Cancer is the second leading cause of death globally with an 
estimated 9.6 million deaths in 2018 (WHO, 2020). Cancer cells are able to grow and divide 
unchecked altering tissue architecture and invading distant sites, eventually leading to 
a partial or total loss of function of the affected tissues and organs resulting in death. 
The majority of cancer-related deaths are a result of metastases from the primary tumour. 
There are many risk factors for developing cancer, some of which are inherent such as age 
and genetics, but a person’s lifestyle choices such as smoking, alcohol consumption and 
diet strongly affect risk by increasing the risk of spontaneous errors in DNA replication 
and repair. Exposure to carcinogens increases the DNA damage caused to cells within 
the body, increasing the chance of mutations which can ultimately lead to cancer. 
There are a number of hallmarks that cancers possess which are, sustaining proliferative 
signalling, evading growth suppressors, deregulating cellular energetics, resisting cell 
death, enabling replicative immortality, inducing angiogenesis, activating invasion and 
metastasis and avoiding immune destruction (Hanahan & Weinberg, 2011). These have 
been coined the hallmarks of cancer and are common to all types of cancer. Genome 
instability and mutation, and tumour-promoting inflammation have also been described 
as ‘enabling characteristics’ and facilitate the acquisition of the hallmarks of cancer. The 
surrounding tumour micro-environment containing the normal non-cancerous cells has 
also been found to play a pivotal role in cancer progression and treatment response.
Hypoxia
The high proliferation rate of cancer cells requires a steady supply of oxygen, however the 
high proliferation rate can force blood vessels apart reducing the vasculature density within 
the tumour creating a population of cells that become more distant from the blood vessels 
(Thomlinson & Gray, 1955). This problem is exacerbated by poor vascular architecture (Sevick 
& Jain, 1991), irregular blood flow (Chaplin et al., 1987; Dewhirst et al., 1998) and cancer cell-
induced compression of blood & lymphatic vessels (Padera et al., 2004). This leads to areas of 
hypoxia (low oxygen conditions) which is a feature of many solid tumours (Brahimi-Horn et 
al., 2007; Thomlinson & Gray, 1955). There are two main types of hypoxia. The first is chronic 
or diffusion-limited hypoxia which is caused by the limited distance that oxygen is able to 
diffuse from the vasculature. Areas far from the tumour vasculature experience chronic 
hypoxia and those areas furthest from vessels become necrotic due to extended oxygen 
deprivation. The second type is acute or cycling hypoxia which is caused by the temporary 
occlusion of the vasculature stopping the supply of oxygen for a period of time before it is 
restored and the tumour bed area is reoxygenated (Dewhirst, 2009; Salem et al., 2018).
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This combination of acute and chronic hypoxia makes the oxygenation of the tumour 
dynamic and leads to a very heterogeneous oxygenation profile of the tumour which is 
constantly changing (Peter Vaupel et al., 2004). 
The main cellular response to hypoxia is the stabilisation of the oxygen regulated HIF-α 
proteins HIF-1α, HIF-2α and HIF-3α (Figure 1). The HIF-α proteins contain basic helix loop 
helix domains for DNA binding, PAS domains which facilitate dimerization with the HIF-β 
protein, transactivation domains (N-TAD & C-TAD) which mediate transcriptional activity 
and an oxygen-dependent degradation (ODD) domain which regulates the stability of 
the protein in an oxygen-dependent manner.  The HIF-α proteins are constitutively 
expressed and are principally regulated post-translationally. Oxygen-dependent prolyl 
and asparagine hydroxylases, hydroxylate specific asparagine and proline residues in 
the ODD domain of HIF-α. Hydroxylation of asparagine (N851) inhibits binding of p300, a 
transcriptional coactivator. Hydroxylation of 2 proline residues (Pro402 & Pro564) promotes 
interaction with von Hippel-Lindau (pVHL) protein, which recruits E3 ubiquitin ligases, 
targeting the protein for proteasomal degradation (Ivan et al., 2001; Lando et al., 2002). 
Under hypoxic conditions, the function of prolyl hydroxylases (PHDs) is attenuated 
allowing the accumulation of HIF-α which can then translocate to the nucleus and bind to 
the constitutively expressed HIF-1β and form a complex with the co-activator p300. This 
complex can then bind to a core consensus sequence 5’-(A/G)CGTG-3’  within hypoxia 
response elements (HREs) which are found in the regulatory elements of target genes 
(Wenger et al., 2005). In addition to the HRE, promoters of several HIF-1α target genes 
possess a reversed imperfect repeat of the consensus sequence (5’-CAGGT-3’) known as 
the HIF ancillary sequence (HAS) (Kimura et al., 2001). 
HIF target genes play a role in an abundance of pathways many of which tailor the 
cellular response to hypoxia by reducing the demand for oxygen while also inducing 
systems to increase the oxygen supply. Examples include many genes in the glycolytic 
pathway such as PGK and GLUT-1 which alter the cellular metabolism to favour glycolysis 
even in aerobic conditions known as the Warburg effect. This increased glycolytic activity 
leads to an increase of intracellular lactate and CO2 which increases the intracellular acidity. 
To combat this hypoxic cells upregulate lactate transporters such as monocarboxylate 
transporter 4 (MCT-4) which export lactate leading to acidification of the tumour 
microenvironment (Damaghi et al., 2013). CAIX upregulation in hypoxia also controls pH 
by catalysing the conversion of CO2 to HCO3
- and H+ leading to intracellular alkalisation 
and extracellular acidification (Sedlakova et al., 2014). HIF-α also promotes increased 
oxygen supply by inducing angiogenesis via vascular endothelial growth factor (VEGF) 
and increased erythropoiesis via the release of erythropoietin (EPO). Other pathways that 
are upregulated include those involved in cell proliferation (TGF-α), Cell adhesion (MIC2), 
cell invasion and EMT (LOX, LOXL2)  among others (LaGory & Giaccia, 2016; Muz et al., 
2015; Schietke et al., 2010; Wilson & Hay, 2011). The DNA damage response is also affected 




repair pathway genes (Kaplan & Glazer, 2020; Leszczynska et al., 2016). Downregulation of 
these pathways is linked to genomic instability and an increased mutation rate. 
Hypoxia also affects epigenetics adding another layer of complexity. Hypoxic tumour 
cells display a distinct epigenetic profile which affects the transcription of many genes 
including upregulation of Histone deacetylase 1 (HDAC1) which was linked to decreased 
expression of the tumour suppressors TP53 & VHL (Kim et al., 2001; Ramachandran et al., 
2015). Hypoxia also epigenetically downregulates DICER expression, suppressing miRNA 
processing which has been shown to promote a stem cell phenotype and poor prognosis 
in breast cancer patients (van den Beucken et al., 2014). 
Hypoxia has been shown to inhibit proliferation in many cell types including cancer 
cells, with HIF overexpression alone being able to induce cell cycle arrest (Hackenbeck et 
al., 2009; Hubbi et al., 2013). The mechanism is both transcriptional through HIFs regulation 
of CDK, p21 & p27 and non-transcriptional through HIFs direct effects on the pre-
replication complex (Hubbi & Semenza, 2015). There are many conflicting reports on HIFs 
role in apoptosis with HIF-1α and HIF-2α reported to have opposing effects and for these 
effects to be dependent on cell type. HIFα have been shown to regulate a host of proteins 
involved in apoptosis (BNIP, Noxa, Bcl-2, Bid, Bad, Bax MCL-1) giving rise to both pro and 
anti-apoptotic effects (Sendoel & Hengartner, 2014). HIFs are also known to interact with 
the tumour suppressor TP53. A number of mechanisms have been postulated including the 
direct interaction between the two proteins (An et al., 1998), indirect regulation through 
the ubiquitin ligase Mdm2 (D. Chen et al., 2003), competition for the coactivator p300 
(Schmid et al., 2004) and regulation by HIF target genes such as nucleophosmin which 
directly interacts with p53 regulating its activation by inhibiting p53 phosphorylation at 
serine 15. (J. Li et al., 2004). The net effect of HIF stabilisation on apoptosis are context-
dependent. In hepatoma HepG2 cells, hypoxia inhibited etoposide-induced apoptosis 
by decreasing p53 activity. While in the MCF-7 cell line, hypoxia promoted apoptosis by 
increasing p53 abundance and in A549 cells hypoxia did not affect etoposide-induced 
apoptosis (Cosse et al., 2007). High levels of HIF in cancer are associated with and correlate 
with more malignant tumours, immunosuppression, metastasis, therapy resistance and 
poor prognosis in a number of cancers (Giatromanolaki et al., 2001; Ioannou et al., 2009; 
LaGory & Giaccia, 2016; Ren et al., 2016; Roig et al., 2018; S.-S. Zheng et al., 2013). 
The tumour microenvironment
The tumour microenvironment (TME) is the environment around the cancer cells within 
a tumour and includes blood vessels, immune cells, fibroblasts, secreted proteins and the 
extracellular matrix (ECM), and plays an important role in cancer with much cross-talk with 
the cancer cells and the rest of the tumour ecosystem. 
Chapter 1
14
The ECM consists of approximately 300 proteins that regulate homeostasis, organ 
development, inflammation and disease (Naba et al., 2012). The majority of these are 
fibrous proteins and proteoglycans that are excreted locally and organized into a mesh 
which forms the structural framework for most tissues (Frantz et al., 2010). The most 
abundant fibrous ECM proteins are collagens, laminin, fibronectin, elastins and tenascin, 
while the proteoglycans fill up the majority of the extracellular interstitial space within the 
tissue in the form of a hydrated gel. 
Tumours are able to alter the ECM and change the expression of the components, 
this along with the increased expression of remodelling proteins such as MMP1 and 
MMP12, promotes tumour progression, metastasis and worse outcome (Chang et al., 
2005; Finak et al., 2008; Naba et al., 2012; Ramaswamy et al., 2003). These studies as well 
as histological studies reveal that solid tumours show excessive ECM deposition (fibrosis) 
(Bataller & Brenner, 2005; Boyd et al., 2000). The most well-recognised alteration that 
occurs in the tumour ECM is increased collagen deposition (Colpaert et al., 2003; Hasebe 
et al., 1997; Huijbers et al., 2010). Collagens make-up to 90% of the ECM and provide 
structural integrity and tensile strength as well as regulating the physical and biochemical 
properties of the tumour microenvironment, modulating cancer cell polarity, migration 
and signalling (Fraley et al., 2010; Levental et al., 2009). Murine studies using a model of 
increased stromal collagen in mammary tissue found an increased incidence of tumour 
formation and metastasis compared with wild type controls (Provenzano et al., 2008). 
Moreover, histological studies have shown that fibrosis is localised to areas of hypoxia 
within the tumour and correlates with CAIX expression with the most fibrotic tumours also 
containing the highest CAIX immune reactivity, which can also predict patient relapse and 
is a predictor of shorter disease survival  (Colpaert et al., 2003; Hasebe et al., 1997; Trastour 
et al., 2007).
Fibroblasts and myofibroblasts within the primary tumour are believed to be the 
mediators of tumour fibrosis. There is also evidence that hypoxia drives the recruitment of 
fibroblasts to the tumour via VEGF upregulation which induces microvascular permeability, 
which in turn mediates an influx of fibroblasts as well as inflammatory and endothelial 
cells (ECs) (Brown et al., 1999). Cancer cells secrete proteins such as transforming growth 
factor-β (TGFβ) which activate fibroblasts stimulating the synthesis of the ECM proteins 
such as connective tissue growth factor (CTGF), periostin and multiple MMPs. These 
altered fibroblasts are termed cancer-associated fibroblasts and secrete higher levels of 
normal ECM constituents especially in areas of hypoxia, and proliferate more than their 
normal counterparts. Under conditions of hypoxia, there is evidence that cancer cells, 
as well as fibroblasts, contribute to fibrosis (Eisinger-Mathason et al., 2013; Gilkes et al., 
2013). HIF-1 also regulates the expression of collagen modifying enzymes that increase 
collagen crosslinking, stability, and stiffness (Cox et al., 2013). High ECM stiffness enhanced 
mechanical and molecular reprogramming of cancer cells by enhancing growth factor 




metastasis (Wei et al., 2017). Expression of the HIF regulated LOX family of enzymes has 
also been shown in mice, to re-model existing collagen structures in the lung to establish a 
pre-metastatic niche facilitating metastasis (Janine T Erler et al., 2009). Reducing the levels 
of HIF-1α or some of these remodelling enzymes decreased fibrosis and stiffness as well 
as inhibiting spontaneous metastasis of breast cancer cells by reducing collagen fibres 
which are required for cancer cell adhesion and invasion (Gilkes et al., 2013; Xiong et al., 
2014). HIF1 and HIF2 also regulate the expression of enzymes that degrade the ECM such 
as the matrix metalloproteinases. As well as increased ECM degradation, hypoxic cancer 
cells show increased proteolytic activity via induction of urokinase plasminogen activator 
surface receptor which promotes cell invasion by altering the interaction between the 
ECM and integrins (Graham et al., 1999).
In conclusion, HIFs are able to promote the degradation of the basement membrane 
while simultaneously increasing the synthesis of fibrillar collagens, facilitating tumour 
invasion.
Immune cells are also an important component of the tumour microenvironment. 
Hypoxia-induced growth factor secretion promotes the recruitment of macrophages 
whose gene expression is changed in response to the hypoxic conditions promoting the 
conversion to and immunosuppressive activity of M2 macrophages while repressing M1 
macrophages as well as reducing their antigen expression (Multhoff & Vaupel, 2020). These 
immunosuppressive macrophages are often termed tumour-associated macrophages and 
they can stimulate fibrosis through the production of growth factors such as TGFα, TGFβ1, 
TNFα, FGF, interleukin-1 (IL-1) and IL-8 which attract additional macrophages, fibroblasts 
and ECs and can also further activate stromal cells (Brown et al., 1999). Macrophages also 
promote cancer cell intravasation into nearby blood vessels (Condeelis & Pollard, 2006). 
On top of this, macrophages secrete matrix metalloproteases (MMPs) which contribute 
to ECM degradation giving macrophages a role in both ECM promotion and degradation 
affecting the level of tumour fibrosis.(Chi et al., 2006).
Cancer stem cells (CSCs) are a subpopulation of tumour cells that demonstrate 
properties similar to that of normal stem cells. They are cells within the tumour that 
possess the capability to self-renew and can initiate new tumours and produce the 
heterogeneous lineages of cancer cells that make up the tumour (Clarke et al., 2006). It 
has been demonstrated that it is these cells that mainly contribute to cancer initiation and 
growth. Two separate studies have shown that a small subpopulation of cancer cells were 
able to generate a tumour following xenotransplantation into immunosuppressed mice 
(Hope et al., 2004; O’Brien et al., 2007). There is increasing evidence that hypoxia regulates 
the subpopulations of CSCs, with CSCs preferentially located in areas of hypoxia in several 
brain tumours. HIFs were also shown to be able to increase stemness features and markers 
of CSCs in a number of cancers including glioblastoma, leukaemia and lung cancer 
(Deynoux et al., 2016; Shi et al., 2015; Sun et al., 2015). The HIFs are also able to inhibit the 
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differentiation of glioblastoma stem cells while inducing their self-renewal capacity (Lee 
et al., 2016). The impact of hypoxia is believed to be partially mediated through induction 
of the Hippo signalling pathway in breast CSCs, through the HIF-1α target TAZ (Samanta et 
al., 2014; Semenza, 2015). Oct-4, a transcription factor essential for maintaining stem cell 
pluripotency, has also been found to be a target of HIF-2α (Covello et al., 2006). Knockdown 
of HIF-1α or HIF2-α in glioblastoma stem cells inhibited neurosphere formation in vitro as 
well as attenuating tumour-initiating potential in vivo (Z. Li et al., 2009).
The tumour microenvironment contains a large variety of cells which have 
complex functions and interactions. Hypoxia influences many aspects of the tumour 
microenvironment and its impact is profound yet still not fully understood.
Hypoxia and Metastasis
Tumour metastasis is the dissemination of cancer cells from the primary tumour to 
distant organs where they grow and form secondary tumours. 90% of cancer deaths can 
be attributed to metastasis, however, treatments that prevent or cure metastasis remain 
elusive. Patients whose primary tumour is poorly oxygenated have an increased risk of 
metastasis and poorer prognosis (Bos et al., 2003; P Vaupel et al., 2007; Peter Vaupel et 
al., 2004). Hypoxia is strongly linked to metastasis and in a mouse model of melanoma, 
inactivation of HIF-1α and HIF-2α abrogated metastasis (Hanna et al., 2013).  However, 
many of the mechanisms by which metastasis occur and hypoxia’s influence on the process 
remain to be elucidated. Much of this is due to the complexity of the in vivo environment 
which cannot be effectively mimicked in vitro. 
The metastatic process is complex and contains a series of steps. First is an epithelial-
mesenchymal transition (EMT) where cancer cells lose cell to cell contact and gain 
motility. The next step is local tissue invasion which is aided by the degradation of the 
ECM facilitating cell movement. This is followed by intravasation into the blood. The cells 
must then survive in the blood and reach a distant site in a process called homing. Once 
at the distant site the cells extravasate out of the blood into the tissue where they survive 
proliferate and form secondary tumours. 
EMT is characterised by cellular changes that include the loss of cell to cell adhesion. 
HIF-1 promotes EMT through upregulation of EMT associated transcription factors and 
repressors, activating the EMT associated pathways as well as modulating EMT associated 
inflammatory cytokines and affecting epigenetic regulators. The regulation of EMT by HIF 
is complex but involves multiple direct effects. HIFs control the transcription of a number 
of proteins in this process including the direct HIF targets LOX and LOXL2 which repress 
the cell adhesion molecule E-cadherin (Schietke et al., 2010). Further to this the HIF target 
genes, Snail, TCF3, ZFHX1A and ZFHX1B have also been shown to repress E-Cadherin 




the HIF target genes TWIST1 induces dramatic transcriptional changes in extracellular 
compartment and cell-matrix adhesion genes including E-cadherin, which have been 
shown to induce the dissemination of cells (Gort et al., 2008; Shamir et al., 2014). HIF-1 
may also regulate EMT through regulation of non-coding RNAs and calcium signalling to 
promote cancer cell invasion (Davis et al., 2014; Matouk et al., 2014). 
HIF-1 also mediates invasion. Several mechanisms of ECM remodelling and 
degradation have been mentioned earlier such as expression of MMPs, and these proteins 
promote invasion and motility of cancer cells. Further to this, when tumour size increases 
collagen fibres straighten and align, which facilitates cancer cell invasion (Provenzano et 
al., 2006). Hypoxia also regulates proteins associated with re-modelling of the extracellular 
matrix, for example, LOX upregulation correlates with poor distant metastasis-free overall 
survival in breast and head and neck tumours and LOX blockade was able to decrease 
the frequency of metastasis (Janine T. Erler & Giaccia, 2006). Hypoxia also regulates the 
expression of a specific variant of the scaffold protein A-kinase anchor protein 12 which 
regulates protein kinase A (PKA) mediated phosphorylation events promoting, tumour 
cell invasion and migration in vitro and metastasis in vivo (Finger et al., 2015). In vivo data 
suggests that there are two phenotypes of cell migration. Slow migratory cells which 
display increased invadopodia, matrix degradative ability and intravasation over time 
(Gligorijevic et al., 2014), and fast migratory cells which comigrate with macrophages 
along collagen fibres (Sidani et al., 2006). Both phenotypes are required for metastatic 
dissemination.
Intravasation occurs throughout the tumour and not just at the invasive front. 
Intravasation is hypothesised to occur at sites called tumour microenvironment of 
metastasis (TMEM) which is composed of a tumour cell, macrophage and an EC all in 
direct contact. TMEM act as doorways for tumour cell dissemination into the blood and 
their number has been shown to be prognostic for distant metastatic recurrence in breast 
cancer (Harney et al., 2015; Karagiannis et al., 2016). However, only a fraction of cancer cells 
that enter the blood are able to survive the harsh conditions and form metastases (Fidler, 
1970). Godet et al. were able to show in vivo through lineage tracing, that post-hypoxic 
tumour cells maintain a ROS-resistant phenotype. This provides a survival advantage in 
the bloodstream, promoting their ability to form distant metastases (Godet et al., 2019). 
To extravasate from the blood, a cancer cell must adhere to ECs and then disrupt the 
tight interactions between ECs to permeate out of the blood vessel. This extravasation 
requires invadopodia which extend through the endothelium into the extravascular 
stroma prior to their extravasation at endothelial junctions (H. S. Leong et al., 2014).
Inhibition of HIF in breast cancer cells inhibited metastasis to the lungs by blocking the 
expression of L1CAM and ANGPTL4 which facilitate binding to ECs and inhibit EC-EC 
interaction (Huang et al., 2011; Zhang et al., 2012).




HIF-1 has been shown in a number of studies to regulate pre-metastatic niche formation 
at distant organs prior to cancer cell arrival (Janine T Erler et al., 2009; Wong et al., 2011). 
The LOX family of enzymes have been shown to be able to remodel the ECM at distant 
sites as well as the primary tumour. LOX secreted by the primary tumour enters circulation 
causing collagen crosslinking in metastatic tissues. This facilitates the recruitment of bone 
marrow-derived cells which form clusters and form the pre-metastatic niche facilitating 
tumour cell colonisation (Janine T Erler et al., 2009; Wong et al., 2011; Xing et al., 2011). 
Tumour hypoxia and therapy resistance
Tumour hypoxia has been found to have a strong association with worse outcome 
in a plethora of different cancers irrespective of treatment (P Vaupel & Mayer, 2007). 
Radiotherapy is known to have reduced efficacy in areas of hypoxia owing to the fact that 
DNA damage produced is not ‘fixed’ by oxygen (Azzam et al., 2012; Peter Vaupel et al., 2001). 
Radiosensitivity increases with increasing oxygen concentration, with anoxic cells roughly 
3 times more resistant to radiation than well-oxygenated cells (Gray et al., 1953). Evidence 
also suggests that the cellular hypoxic response increases the levels of heat-shock proteins, 
decreasing the apoptotic potential while increasing the proliferation potential of selected 
clones which has been linked to radioresistance (Samali & Cotter, 1996; Zhivotovsky et al., 
1999). This is in addition to the reduced DNA repair under hypoxia and increased genomic 
instability of hypoxic cancer cells which along with a reduced proliferation rate granting 
more time for repair allows them to avoid programmed cell death. This hypoxia conferred 
radiation protection leads to tumour recurrence as the hypoxic population of cells is able 
to survive radiotherapy and repopulate the tumour. Direct O2 measurements in clinical 
studies of neck squamous cell carcinoma, prostate cancer and cervix cancer treated with 
radiotherapy show that hypoxia is strongly associated with local-regional control (Fyles et 
al., 1998; Milosevic et al., 2012; Nordsmark et al., 2005). 
Many chemotherapeutics also have reduced efficacy in areas of hypoxia due to a 
number of factors. The larger distances that the drug must penetrate as well as irregular 
blood flow and compressed blood and lymphatic vessels limit the amount of drug that 
can reach the target cells. On top of this, the structure and composition of the extracellular 
matrix (ECM) can further limit the delivery of the drug (Minchinton & Tannock, 2006). 
Further to this hypoxia is known to upregulate the expression of multidrug resistance 
protein (MDR1) and multidrug resistance-associated protein (MRP1). These proteins pump 
chemotherapeutic drugs out of the cell decreasing their intracellular concentrations, 
conferring increased resistance as has been reported in a number of different cancer types 
(Ding et al., 2010; Kruh & Belinsky, 2003; Liu et al., 2008). Hypoxia-induced downregulation 
of pro-apoptotic proteins such as Bax and Bid has been shown in a colon xenograft model 




proteins, Bim and Bmf in normal breast epithelial cells has been shown to result in ductal 
carcinoma in situ-like phenotype (Whelan et al., 2010). Survivin, an anti-apoptotic protein 
is also regulated by HIF-1α and high levels correlated with doxorubicin resistance in a 
panel of organotypic human breast tumours (Faversani et al., 2014). 
Hypoxia has been shown to induce the DDR including both ATM and ATR in the 
absence of detectable DNA damage in a background of repressed DNA repair. ATR has 
been shown to mediate p53 accumulation and cell cycle arrest in S phase cells, in hypoxia 
through phosphorylation, with ATR inhibition leading to a reduction in p53 accumulation 
(E. M. Hammond et al., 2002; Ester M. Hammond & Giaccia, 2005) ATM has also been shown 
to phosphorylate and stabilise HIF-1α in milder hypoxic conditions (0.2-1% O2) leading 
to a reduction of mTORC1 signalling which coordinates cell growth and metabolism 
(Cam et al., 2010). ATR also has an effect on HIF-1α. ATR inhibition was shown to delay 
HIF-1α stabilisation and slow down hypoxia-induced cell motility in a HIF-1α dependent 
manner (Olcina & Hammond, 2014). ATR has also been shown to positively regulate HIF-1α 
translation at 0.1% O2 (Fallone et al., 2013). Hypoxia-induced DDR can act as a mechanism 
to protect against genomic instability, however, this induction has been shown to be 
transient and is repressed following exposure to chronic hypoxia (Pires, Bencokova, 
McGurk, et al., 2010; Pires, Bencokova, Milani, et al., 2010). Genetic instability is also 
promoted under hypoxic conditions. Aberrant DNA replication (Young et al., 1988), gene 
amplification, (Rice et al., 1986) and base substitutions and DNA deletions have all been 
linked to the hypoxic microenvironment (Reynolds et al., 1996). Defects in double-strand 
break sensing have also been implicated, with irradiated cells under chronic hypoxia or 
anoxia showing increased residual double-strand breaks and chromosomal aberrations 
(Kumareswaran et al., 2012). Moreover, hypoxia leads to the repression of a number of DNA 
repair pathways, driving genomic instability (Klein & Glazer, 2010). This genomic instability 
allows cells that have been targeted by DNA damaging chemotherapeutics to survive and 
can result in more heterogeneous and aggressive tumours. However, downregulation of 
DNA repair proteins opens up the possibility of targeting the hypoxic regions through 
synthetic lethality for example through PARP inhibition in Homologous recombination 
deficient hypoxic cells (Chan et al., 2010) 
Additionally the acidic pH in the tumour microenvironment can limit the capacity 
of small molecules to pass the cellular membrane or cause localisation to unfavourable 
cellular compartments due to their altered pH. This phenomenon is called ‘ion trapping’ 
and reduces the intracellular concentration or concentration in the desired location of 
the drug. If a drug requires active transport to enter a cell, the abnormal pH environment 
can also lead to reduced efficiency of these transport proteins limiting the transport of 
the drugs into the cell. As well as impaired transport, the activity of some of these drugs 
may be pH-dependent as well (Stubbs et al., 2000). Many chemotherapeutics have been 
shown to be less effective under hypoxic conditions including bleomycin, procarbazine, 
streptonigrin, actinomycin D, vincristine, Sorafenib, Irinotecan and docetaxel (Strese et al., 
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2013; Teicher et al., 1981). The combination of reduced uptake and the upregulation of 
survival pathways and reduced proliferation leads to many drugs being less effective in 
hypoxic tumour cells. 
Hypoxia also plays an important role in reducing the effectiveness of immunotherapy. 
Anaerobic glycolysis by tumour cells results in increased production and secretion of 
adenosine into the extracellular matrix which is a potent suppressor of NK and T-cells 
(Facciabene et al., 2011; Sitkovsky et al., 2014). Moreover, HIF-1α has been shown to 
be inhibitory to the cells of the adaptive immune system (Hatfield & Sitkovsky, 2016). 
Areas of hypoxia within the tumour have been shown to be infiltrated by high levels of 
immunosuppressive cells including myeloid-derived suppressor cells (MDSCs), tumour 
associated macrophages and T-regulatory cells (Tregs) (Noman et al., 2015). Hypoxic 
cells within the tumour express stromal cell-derived factor 1α which binds to IL-6 and 
IL-8, directly regulating the function and differentiation of MDSCs within the tumour 
microenvironment which show increased immunosuppressive function (Alfaro et al., 
2011; Hong et al., 2015). Accumulation of Tregs in areas of hypoxia suppresses the anti-
tumour response while also promoting neo-angiogenesis (Facciabene et al., 2011). HIF-1α 
can also promote immune evasion through upregulation of immune checkpoint proteins 
such as CD47, PD-L1 and HLA-G. On top of this, the hypoxia-induced acidic tumour 
microenvironment is believed to hamper the anti-tumour effects of the immune system 
and aid in immune evasion (Y. Li et al., 2018). 
Many of the drug resistance mechanisms described above are found in the CSC 
subpopulation. CSCs have high expression of drug efflux proteins and anti-apoptotic 
factors. They also often maintain a quiescent state to avoid the induction of apoptosis 
when they receive DNA damage (Gottesman et al., 2002).  This combined with their 
localisation in areas of hypoxia protecting them from radiotherapy as well as increased 
activation of the DDR (Bao et al., 2006) implicates them in the recurrence of tumours after 
treatment as they have the innate capacity to repopulate the tumour. Altogether this data 
shows the negative impact that hypoxia has on treatment efficacy and shows its pivotal 
role in treatment resistance and recurrence. 
Overcoming hypoxia-induced therapy resistance
Several approaches have been taken to overcome tumour hypoxia, one is the development 
of hypoxia-activated prodrugs (HAPs). These are drugs which are inert until they reach 
areas of hypoxia where they are reduced usually by one or two-electron reductases 
producing the cytotoxic form of the drug (Y. Chen & Hu, 2009). This spares normal tissues 
while targeting the hypoxic population of tumours. Once activated the drug can also 
diffuse into the more well-oxygenated areas of the tumour in a bystander effect. Another 




micro/nanocapsules. They use drug delivery nanocarriers that are susceptible to reduction 
by the increased expression of reducing agents such as glutathione in hypoxia releasing 
their cargo of drugs in the hypoxic environment, however, they are still in the design and 
research stages of development (Meng et al., 2009; Zeng et al., 2018).  Although many 
HAPs such as evofosfamide have been promising in pre-clinical studies this has not 
translated into the clinic. Evofosfamide was studied in a phase III clinical trial and was 
found to improve progression-free survival and had a higher objective response rate, it 
failed because it did not significantly improve the overall survival time which was the 
primary endpoint (Van Cutsem et al., 2016). 
A second approach to overcoming hypoxia is to increase the oxygen concentrations in 
the tumour itself, either by supplying more oxygen or reducing the oxygen consumption 
of tumours. Strategies include hyperbaric oxygen therapy which involves inhalation of 
pure oxygen under elevated pressure to systemically increase oxygen tension (Daruwalla 
& Christophi, 2006). Hyperthermia has also been tested to locally increase the temperature, 
leading to vasodilation and increased blood and therefore oxygen supply (Song et al., 
2001).  Accelerated radiotherapy with carbogen and nicotinamide (ARCON) which involves 
breathing carbogen (95% oxygen 5% carbon dioxide) in combination with nicotinamide, 
a vasodilator, to improve tumour oxygenation has also been tested. In a phase III clinical 
trial, ARCON showed limited success, with improved 5-year regional control, specifically 
in patients with hypoxic tumours, however no improvement in overall or disease-free 
survival was found (Janssens et al., 2012). Metformin, an inhibitor of mitochondrial 
complex I has been used to decrease oxygen consumption in tumours and is currently 
in phase II clinical trial in cervix cancer in combination with cisplatin and radiation 
(NTC02394652). A systematic review of 10,108 patients in 86 clinical trials designed to 
modify tumour hypoxia in patients receiving primary radiotherapy alone showed that 
overall modification of tumour hypoxia significantly improved the effect of radiotherapy 
but had no effect on metastasis (Overgaard, 2007). While many clinical trials have been 
unsuccessful, many have failed due to underpowered studies, dose-limiting toxicity in 
tissues that experience mild hypoxia,  lack of hypoxia biomarkers to stratify patients and 
differences between murine and human tolerances (Spiegelberg et al., 2019). As well as 
this, a greater understanding of tumour hypoxia and the tumour microenvironment are 
needed to aid in drug development and other therapies for overcoming tumour hypoxia.
Hypoxia Biomarkers & models
Differences observed between in vitro cell line responses to hypoxia and the responses 
seen in vivo and primary human tumours have also been part of the problem that has lead 
to hypoxia modification and targeting strategies failing. This is due to the dynamic nature 
of hypoxia being hard to recapitulate in vitro as well as the complexity of the tumour 
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microenvironment being lost. One study compared the hypoxia transcriptome differences 
in bladder cancer, between the cell line EJ28 and 39 bladder tumour specimens. Of the 
6000 genes measured 32 were induced in EJ28 while only eight of these 32 were found to 
be upregulated in more than 5 of the 39 tumour samples (Ord et al., 2005). 
Another study in breast cancer compared the hypoxic signatures and their prognostic 
value of in vitro cell lines and in vivo models compared to patient material. The in vitro 
signature of upregulated genes showed little prognostic power, however the repressed 
in vitro genes and in vivo signatures did show prognostic value (Starmans et al., 2012). 
Toustrup et al. developed a 15 gene signature in head and neck cancer from 58 patient 
biopsies to predict the impact of hypoxia on radiotherapy outcome (Toustrup et al., 2011). 
They found that the hypoxic signature was able to predict higher 5-year locoregional 
failure of ‘more’ hypoxic patients from the radiotherapy only arm of the DAHANCA 5 trial, 
compared with the ‘less’ hypoxic group. In the trial arm receiving nimorazole as well as 
radiotherapy they were able to predict a benefit of nimorazole on 5-year locoregional 
failure, but only in patients whose signature classified ‘more’ hypoxic, showing the 
utility of their signature to stratify patients and as a prognostic and predictive tool. This 
signature was then used by Sørensen et al. to see if it could be applied to prostate, colon 
and oesophageal cancers (Sørensen et al., 2015). They used cell lines from each of these 
different cancers to see if the signature was conserved. They found that while there was 
definite overlap in the genes that were upregulated in hypoxia, some genes from the 
signature were not upregulated in the other cancer types tested. This is an example of the 
differential hypoxic transcriptome observed in cancers of different tissues. 
Another study used RNA sequencing of 31 breast cancer cell lines representative of 
different sub-types or normal mammary epithelial cells exposed to normoxia or 1% O2 (Ye 
et al., 2018). They found a 42 gene signature out of over 1000 hypoxia-regulated genes, 
that had a conserved response to hypoxia among all cell lines used. They found that 
lower expression of this hypoxic signature in the basal subtype correlated with a better 
prognosis than high expression in two METABRIC sample cohorts. On the other hand, one 
study in bladder cancer patients found that only 2 out of 13 published hypoxia signatures 
(Lendahl et al., 2009; Riester et al., 2012) had prognostic and predictive significance 
in a cohort of a phase III randomised trial of radiotherapy alone or with carbogen and 
nicotinamide (BCON) (Yang et al., 2017). They go on to create their own 24 gene hypoxic 
signature, of which high expression was significantly associated with poor prognosis in 4 
out of 6 independent bladder cancer patient cohorts with the other two cohorts showing 
similar trends but no significance. Their signature also predicted poorer local progression-
free survival of hypoxic patients in the BCON trial receiving either radiotherapy alone or 
BCON. 
Interestingly when they combined their signature with that of Riester et al. (Riester 
et al., 2012) it improved the prognostic value in patients only receiving radiotherapy and 




gene signature) and high Riester signature scores. Adding the Lendahl signature (Lendahl 
et al., 2009) to the 24 gene signature did not improve its prognostic significance but did 
improve its predictive power. The 24 gene signature showed little overlap with any of 
the other hypoxia signatures tested likely due to the large proportion of the genome 
that is transcriptionally responsive to changes in oxygenation. Janssens et al. found in 
a phase III clinical trial that Accelerated radiotherapy with carbogen and nicotinamide 
(ARCON) improved 5-year regional control specifically in patients with hypoxic tumours 
as measured with pimonidazole highlighting the need for reliable hypoxia biomarkers. 
These studies show that data obtained from in vitro studies is not always consistent 
with what is seen in the clinic and should be confirmed using in vivo models that tend 
to produce data that is much more clinically relevant. They also show that one universal 
hypoxia signature is unlikely and that a signature may be required for each type of cancer 
to have the greatest predictive and prognostic capabilities. 
Within the scope of in vivo models, there are also differences that affect its similarity 
to the patient. For instance, orthotopic or spontaneous tumour models better mimic the 
patient situation than Xenograft models, because the cancer grows in the same organ-
specific tissue micro-environment as it would in a patient. This exposes it to the same 
factors such as hormones, tissue architecture, blood supply etc. as is found in the human 
equivalent. On top of this, it has been shown that the phenotypic properties of metastatic 
cells are governed by genes that are regulated in large part by the interaction with the 
relevant organ environment (Killion et al., 1999; Kubota, 1994). One example of this 
is the study by Naito et al. which compared the phenotypic differences between renal 
carcinoma cells implanted in the kidney versus subcutaneously in nude mice (Naito et al., 
1987). They found that implantation into the kidney produced faster-growing tumours 
that produced more systemic metastases than subcutaneous tumours. They also observed 
that the kidney tumours were large, invasive, highly vascularised, non-encapsulated 
and contained minimal central necrosis. In contrast, the subcutaneous tumours highly 
encapsulated, with peripheral vascularisation and extensive areas of necrosis, showing 
the large phenotypic differences between xenograft and orthotopic models. On top of 
this, the immune system’s role in cancer and therapy efficacy is becoming more and more 
evident and so the use of immunocompetent models is desirable. 
Notch signalling
Notch proteins (Notch1-4) and their ligands (Delta/Jagged) are transmembrane proteins 
that provide a cell-cell communication system. The expression of Notch receptors and 
their ligands is tissue and context-specific. Notch receptors undergo a number of post-
translational modifications in the Golgi/Endoplasmic reticulum that can alter their activity 
and stability as well as maturing by cleaving Notch creating a non-covalently associated 
Chapter 1
24
heterodimer before transport to the plasma membrane (Bray, 2016). The canonical Notch 
pathway occurs through the interaction of a Notch ligand on the “signal-sending cell” 
and the receptor on the “signal receiving cell”. This interaction leads to two sequential 
proteolytic cleavage events by ADAM 10/17 and the gamma-secretase complex, which 
releases the Notch intracellular domain (NICD). The NICD then translocates to the nucleus 
where it forms a complex with CSL and MAML, allowing it to induce transcription of Notch 
downstream targets (Kopan & Ilagan, 2009). NICD is further regulated through post-
translational modifications such as methylation, hydroxylation and acetylation as well as 
being influenced by other signalling pathways (Antfolk et al., 2019). There are a number 
of non-canonical pathways downstream of Notch that have been described including 
transcriptional activation of NF-kB, the PI3K-AKT-mTOR pathway and mitochondrial 
metabolism (Hales et al., 2014; Landor et al., 2011; L. Li et al., 2014; Perumalsamy et al., 
2010). 
Notch in cancer
Notch signalling is known to be deregulated in a number of cancers. Oncogenic Notch 
signalling alters the developmental state maintaining the cells in a proliferative or 
undifferentiated state while inhibiting apoptosis and promoting cell survival. This is seen 
in a number of cancers including T-ALL, breast cancer and lung cancer. However, Notch 
can also act as a tumour suppressor in some cell types including keratinocytes (Das & 
Teoh, 2017).  Sequencing of cancer genomes has revealed 3 main patterns of mutation in 
the Notch gene, which are thought to be context-specific based on a particular selective 
pressure. 
The first is a mutation that removes or alters the negative regulatory region (NRR) 
in some way, either through truncation of the gene or point mutations within the NRR 
or within the promoter leading to a gain of function Notch mutation. These mutated 
Notch proteins undergo ligand-independent proteolysis, releasing the NICD, this was 
first discovered in T-ALL and subsequently found in triple-negative breast cancer among 
others (Ashworth et al., 2010; Robinson et al., 2011).  T-ALL and triple-negative breast 
cancers have also been shown to contain nonsense or frameshift mutations that lead to 
loss of the C- terminal PEST domain of Notch often in the same allele as mutations in the 
NRR. This leads to even higher levels of NICD because of reduced degradation. This lends 
evidence to the ongoing selective pressure that these cells experience to accumulate 
ever-increasing levels of Notch activation (K. Wang et al., 2015; Weng et al., 2004).
The second pattern is characterised by mutations which affect the PEST domains 
without any alterations to the NRR domain, leading to the NICD having an increased half-
life. This is mainly seen in B cell tumours such as leukaemias and lymphomas (Kiel et al., 




Notch signalling presumably because there is no selective pressure. This is likely because 
the levels of Notch that provide a selective benefit is lower than that of pattern 1 and they 
are in a tumour microenvironment that supplies sufficient activation from adjacent cells 
(Kluk et al., 2013).
The third pattern is described by mutations in the N-terminal portion of Notch, 
producing a loss of function. Some mutations lead to a failure to produce the protein while 
others produce a dominant-negative Notch receptor with a non-functional or deleted 
intracellular domain. These types of mutation are prevalent in cutaneous squamous cell 
carcinomas, oesophageal and lung cancers as well as others (Agrawal et al., 2012; N. J. 
Wang et al., 2011). This type of mutation was shown to increase the incidence of skin 
tumours of mice exposed to carcinogens suggesting that Notch plays a role as a tumour 
suppressor in these tissues (Nicolas et al., 2003).
Another mutation commonly found in cancer directly affecting Notch activity is the 
Fbwx7/cdc4 mutation, disrupting a ubiquitin ligase targeting Cyclin E Myc but also Notch 
(O’Neil et al., 2007; Thompson et al., 2007).
The most well characterised oncogenic function of Notch is to turn on the expression 
of genes that promote cell growth such as cMyc, a global regulator of pro-growth 
metabolism (Palomero et al., 2006). Notch is also able to enhance PI3K-Akt signalling in 
T-ALL as well as downregulating the tumour suppressor PTEN which normally functions 
to suppress PI3K-AKT signalling (Palomero et al., 2007; Trimarchi et al., 2014). AKT has a 
number of pro-oncogenic activities including upregulation of glucose transporters and 
promoting cell survival via various downstream mechanisms. There is also evidence for 
co-regulation of genes by Notch and HIF transcription factors promoting tumour cell 
migration, invasion and tumour cell metabolism. However, whether these observations 
are generally relevant to cancers with Notch alterations or are only relevant in particular 
contexts are still to be elucidated (Gustafsson et al., 2005; Sahlgren et al., 2008; X. Zheng 
et al., 2008). Notch has also been implicated in maintaining cancer stem cell populations 
in solid tumours including glioblastoma, ovarian and breast cancer (D’Angelo et al., 2015; 
McAuliffe et al., 2012; T. S. Zhu et al., 2011). Notch has also been implicated in promoting 
tumour metastasis as well as resistance to chemotherapy in a number of studies through 
a number of different mechanisms (Chanrion et al., 2014; K. G. Leong et al., 2007; Z. Wang 
et al., 2010; Xie et al., 2013).
These are just a few of the effects that Notch has in cancer, Many more have been 
characterised and many are still to be fully understood especially in context with other 
oncogenic mutations and shows the broad variety of effects that Notch has in cancer 
biology (Aster et al., 2017).
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Studying gene function and cell fate
Elucidating the role of genes can be difficult, with so many direct and indirect interactions 
as well as effects from downstream targets, compensation mechanisms and genetic 
redundancy obscuring the effects of the gene. A common way to study the effects of genes 
is to use gene overexpression in concert with gene disruption or knockout (KO) models. 
Overexpression can be achieved in a few ways. The gene can be introduced through 
viral transduction under the control of a ubiquitous promoter such as ROSA26 or EF1α. 
tissue-specific gene regulatory elements/promoters can also be used e.g. Villin to target 
gene expression to absorptive cells specifically, or GFAP to direct expression to astrocytes. 
Alternatively, the active form of the protein can be expressed or regulatory domains/amino 
acids deleted or mutated, such as expression of the NICD alone. Fluorescent proteins can 
also be added to these inserted genes either with a fusion protein of the two or with the 
use of an internal ribosome entry site so that both the fluorescent protein and the gene of 
interest are expressed separately from the same mRNA. This can aid in the visualisation of 
the localisation of the protein when a fusion protein is used, and to confirm in which cells 
there is overexpression. 
Knockout of a gene is used to study the other extreme. This can be done in a number 
of ways but CRISPR/Cas9 is the current standard. CRISPR/Cas9 allows for insertion of DNA 
into a specific site or deletion/mutation of a specific stretch of DNA through the use of 
guide RNAs. The combination of an overexpression model and a KO model can help to 
understand the effects that individual genes have. 
One caveat of using overexpression or gene deletion is that from the moment the 
gene affects cell functionality gene lineage may change and if this happens early during 
development the observed phenotypes may be a consequence of something else rather 
than a causal effect on that cell type. For studying gene KO or overexpression as well as 
cell fate in vivo it is useful to use lineage tracing. 
Lineage tracing is the method by which a specific cell or population of cells is marked 
so that they and their progeny can be traced and identified at a later timepoint. Lineage 
tracing has been useful in developmental biology to determine from which progenitor 
cells, organs and tissues are derived. An advantage of lineage tracing is that it only 
marks gene activity it does not interfere with gene activity and therefore also does not 
alter lineages such as with overexpression or gene disruption. There are a number of 
lineage tracing strategies but the most widely used method involves site-specific genetic 
recombination, a popular example of this is Cre-Lox. 
In this method, a reporter gene such as a fluorescent protein is preceded by a stop 
cassette or secondary marker flanked by loxP sites. This reporter is introduced into 
the genome of a cell line or animal under the control of a ubiquitous promoter. Cre-
recombinase (Cre) is then expressed in the cells of choice via cell-type or tissue-specific 




then recombine and delete the DNA between the loxP sites initiating expression of the 
reporter. 
Over time this strategy has been built on to allow more control over Cre induced 
recombination such as the addition of tamoxifen-inducible oestrogen receptor (ERT2). The 
ERT2  domain sequesters Cre in the cytoplasm until tamoxifen is added allowing temporal 
control of labelling as well. The use of fluorescent markers also allows live imaging in 
vivo with the advent of methods such as intravital imaging. This technique is also utilised 
in cancer research to study a specific subpopulation of cells within the tumour such as 
Notch1 expressing cells in murine intestinal tumours or to elucidate the initiation of 
tumorigenesis (Frumkin et al., 2008; Mourao et al., 2019; Vooijs et al., 2007). 




There is a need to better understand the mechanisms that promote tumour progression 
and therapy resistance. Notch signalling is known to be frequently deregulated in 
cancer and is involved in treatment resistance. Hypoxia and high levels of HIF in cancer 
are associated with and correlate with more malignant tumours, therapy resistance, 
immunosuppression, metastasis and poor prognosis. Notch and HIFs also co-regulate 
the transcription of genes promoting tumour cell migration, invasion and tumour cell 
metabolism. The aim of this thesis was to investigate the role of Notch and hypoxia in 
tumour progression and resistance to therapy. 
In chapter 2 we reviewed the role of Notch in breast cancer and targeting strategies 
to enhance current treatments and combat treatment resistance. We find that treatment-
resistant cancers can be re-sensitised by Notch inhibition, providing a strong rationale 
for a combination of Notch inhibition and current breast cancer treatment modalities in 
patients with Notch to overcome treatment resistance.  This combination would require 
stratification of patients based on Notch activity due to only a subset of cancers showing 
aberrant Notch signalling. Furthermore, Notch signalling may not become clinically 
evident until treatment initiation as a resistance mechanism.
In chapter 3 we investigate the effect of hypoxia on a cell contact independent 
mechanism of Notch activity stimulation. We use conditioned medium from H460 ΔE-
GFP lung cancer cells cultured in different oxygen concentrations and with a Notch 
gamma-secretase inhibitor to study the effect on Notch activity on receptor cells. We find 
that conditioned medium from hypoxic or anoxic cells induces Notch activity in 5XCSL 
luciferase reporter cells and upregulation of the hes1 Notch target gene. This suggests 
that that H460 Notch overexpressing cells when cultured under hypoxia secrete soluble 
factors in the medium that can stimulate notch signalling in receiver cells at a distance. 
In chapter 4 we created and utilised a novel hypoxia lineage tracing strategy termed 
MARCer. We inserted this system into the H1299 lung cancer cell line and characterised 
the lineage tracing properties of the system. In vitro, we tested the labelling characteristics 
of the cell line at different oxygen and 4OHT concentrations. We find that labelling is 
restricted to hypoxic conditions when 4OHT is present. We continue with the cell line in 
vivo using a tumour xenograft model with intravital imaging. We demonstrate its use as 
a valuable tool to study the behaviour of post-hypoxic cells both in vivo and ex vivo at 
single-cell resolution. 
In chapter 5 we build on this lineage tracing strategy with the addition of the 
diphtheria toxin receptor to the reporter allowing selective ablation of labelled cells to 
study the role of hypoxic cells on treatment resistance. We investigate this system in 
the metastatic 4T1 murine mammary carcinoma cell line. We start by characterising it in 
vitro finding it to be regulated in an oxygen and 4OHT dependent manner, labelling only 




model to study the effect of hypoxic cells on radiotherapy treatment, and their behaviour 
within the primary tumour with and without treatment. 
In chapter 6 we created a transgenic mouse model which contains the hypoxic lineage 
tracing construct inserted into the Hif-1α locus. We test the ES cells used to create the 
mouse in vitro to characterise the lineage tracing properties. We look at the stabilisation of 
the MARCer protein in normoxia and when treated with the hypoxia mimetic DFO. We go 
on to test the lineage tracing properties by inserting a reporter. We test it in normoxia and 
hypoxia and find that it only labels cells in hypoxic conditions in the presence of 4OHT. 
From this, we conclude that the generated mouse should be able to label hypoxic cells 
in a tamoxifen dependent manner and be a useful tool to study the fate of hypoxic cells.
In chapter 7 we discuss the findings from the previous chapters and outline the 
remaining challenges to be addressed in future research, and the potential for the hypoxic 
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Breast cancer is the second most common malignancy, worldwide. Treatment 
decisions are based on tumor stage, histological subtype, and receptor expression 
and include combinations of surgery, radiotherapy, and systemic treatment. These, 
together with earlier diagnosis, have resulted in increased survival. However, initial 
treatment efficacy cannot be guaranteed upfront, and these treatments may come 
with (long-term) serious adverse effects, negatively affecting a patient’s quality of 
life. Gene expression-based tests can accurately estimate the risk of recurrence in 
early stage breast cancers. Disease recurrence correlates with treatment resistance, 
creating a major need to resensitize tumors to treatment. Notch signaling is 
frequently deregulated in cancer and is involved in treatment resistance. Preclinical 
research has already identified many combinatory therapeutic options where Notch 
involvement enhances the effectiveness of radiotherapy, chemotherapy, or targeted 
therapies for breast cancer. However, the benefit of targeting Notch has remained 
clinically inconclusive. In this review, we summarize the current knowledge on 
targeting the Notch pathway to enhance current treatments for breast cancer and 
to combat treatment resistance. Furthermore, we propose mechanisms to further 










Breast cancer is the second most common malignancy, worldwide (1). Breast cancer 
screening and early detection has increased, leading to better outcome. Furthermore, 
a number of treatment options, have improved survival (2). First line therapies include 
surgery, radiotherapy, and systemic treatment (including: chemotherapy, endocrine 
therapy, and targeted therapy). Treatment options for breast cancer exist in the neo-
adjuvant (prior to surgery) and adjuvant setting (after surgery). There is strong evidence 
that tumors that respond to neo-adjuvant chemotherapy with a pathological complete 
remission (pCR) have improved long-term prognosis (3). Conversely, tumors that do not 
respond to neo-adjuvant chemotherapy have a higher chance of recurrence. Adjuvant 
therapy targets remaining (micro-metastatic) cancerous cells, thereby preventing 
recurrent disease. 
Clinical choices for the type of systemic treatment are guided by expression of estrogen 
receptor (ER), progesterone receptor (PR), and Human Epidermal Growth Factor Receptor 
2 (HER2) in tumor biopsies, in concurrence with TNM classification, tumor grade, and age. 
However, it is widely accepted that breast cancer is a heterogeneous disease, from primary 
tumor to metastatic sites (4). Gene expression profiling (involving hierarchical clustering) 
has had a significant impact on classification of breast malignancies. Molecular breast 
cancer subtypes revealed different clinical behaviors and retain distinct differences in 
biological mechanisms (Table 1)—associated with tumor aggressiveness, metastasis, and 
response (8, 10–18, 22). Based on gene expression profiling, the MINDACT trial has shown 
that tumors with genomic “low risk” features do not require chemotherapy. This included 
some node-positive tumors irrespective of molecular subtype (23). Similarly, the TAILORx 
study has recently shown that early stage, node-negative breast cancers with low or 
intermediate recurrence scores do not benefit from adjuvant chemotherapy and can be 
treated with endocrine therapy alone (24). Additionally, gene expression analysis showed a 
sub-classification in Triple Negative Breast Cancer (TNBC)into at least 4 molecular subgroups 
(12, 19, 25) with observed differences in response to chemotherapy (20), by providing 
more detailed information inter-tumor heterogeneity (26). The combination of histological 
and genetic classification of each tumor will further guide therapy selection and disease 
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Intra-Tumor Heterogeneity and Tumor Stem Cells
Regardless of clinical or molecular subtype, intra-tumor heterogeneity is a common 
feature of all human solid tumors (28), and is a major determinant of treatment outcome 
in breast cancer (15, 29). Tumor growth is thought to be driven by small populations of 
cancer cells with self-renewal and multipotential properties (30), coined cancer stem cells 
(CSC) (31). These CSCs are involved in malignant behavior (invasion and metastasis) and 
resistance to treatment (32). Thus, CSCs are of high clinical importance, and targeting CSC 
self-renewal appears necessary for obtaining a durable response. Furthermore, intratumor 
heterogeneity can be driven by mutation or deregulation of stem cell signaling pathways 
such as Notch, Wnt, Shh, and others as well as through the tumormicroenvironment; 
including nutrient-, oxygen levels, and paracrine interactions with other cell types 
(fibroblasts, blood vessels, and immune cells) (33). Herein, Notch has shown interesting 
targeting opportunities in cancer (34).
Notch
Notch Signaling
Notch signaling (Figure 1) is a cell-to-cell communication system of type I single-pass 
transmembrane Notch receptors (Notch 1-4) and transmembrane ligands (Delta/Jagged 
(JAG)). Notch receptor maturation starts in the Golgi/Endoplasmic reticulum. Glycosylation 
of Notch proteins in the Golgi and ER is known to play a role in the regulation of Notch 
activity (35). Fringe proteins can both positively and negatively regulate Notch ligands 
however the full scope of their roles in breast cancer are unclear (36). Furin-like convertases 
cleave the non-covalently associated Notch heterodimer, which is transported to the 
plasma membrane (Figure 2A). 
The extracellular domain consists of epidermal growth factor (EGF)-like repeats, 
followed by a negative regulatory region (NRR) which includes 3 LNRs (Lin12-Notch repeats) 
and a heterodimerization domain which prevents receptor activation in the absence of 
ligand(37) The intracellular portion of Notch (NICD) also contains multiple regions and 
domains, the RBPjk association module (RAM), Ankyrin repeats (ANK domain), and the TAD 
domain—which consists of Nuclear Localization Sequences (NLS) and the PEST domain 
(regulates receptor degradation) (38) (Figure 2B). Notch 1-4 have relatively short lifespans 
and undergo degradation through the ubiquitin proteasome and lysosomal pathways. The 
PEST domain contained in the NICD is likely to play a role in E3 ubiquitin mediated turnover. 
In fact, mutations in the PEST domain of Notch 1-3 in TNBCs, have been shown to increase 
Notch half-life and lead to increases in Notch downstream targets. Promisingly TNBCs with 
these mutations have been shown to be sensitive to GSIs (39). Similarly, alterations in the 
tumor suppressor and ubiquitin ligase Fbwx7/cdc4 target the PEST domain of Notch (40). 
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Figure 1: Notch receptor maturation and pathway activation, targetable options, and receptor 
functionality.  
Notch receptor maturation and pathway activation, targetable options, and receptor functionality. 
(A) Stepwise representation of the process of Notch receptor maturation until receptor activation, 
followed by transcriptional output (not shown), and possibilities in targeting the Notch receptor 
pathway. (B) Notch receptor functional domains and corresponding functions ANK, Ankyrin repeats; 
LNR, Lin12-Notch Repeats and RAM, RBP-jk association module.
The E3 ligase MDM2 has been shown to contribute to the degradation of Numb and 
through ubiquitination leading to activation of Notch in breast cancer. Treatment of MCF7 
cells with drugs targeting the acidic domain of MDM2 showed a reduction in Notch 
signaling (41). Furthermore, ubiquitination of Notch1 by MDM2 has been shown to 
activate Notch rather than leading to degradation (42). MDM2 has also been shown to 
regulate p53 degradation through ubiquitination, which, along with its role in Notch 
regulation makes it an attractive target for drug discovery along with other E1-3 ligases 
and interacting proteins. Knockdown of the E2-conjugating enzyme UBC9 and inhibition 
of the E1 activating complex SAE1/UBA2 has also been shown to impair the growth of 
Notch1-activated breast epithelial cells (43). Pevonedistat (MLN4924), is an inhibitor of 
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shown to induce apoptosis in MCF-7 & SKBR-3 cells in combination with 2-deoxyglucose 
(44), and to sensitize breast cancer cells to radiation in vivo (45). Bortezomib, an FDA 
approved proteasome inhibitor has been shown to inhibit multiple genes associated with 
poor prognosis in ERα breast cancer (46), however several clinical studies have shown 
contradictory results in advanced/metastatic breast cancer (47–49). 
Figure 2: Notch receptor maturation and pathway activation, targetable options, and receptor 
functionality.
A. Stepwise representation of the process of Notch receptor maturation until receptor activation, 
followed by transcriptional output (not shown), and possibilities in targeting the Notch receptor 
pathway. B. Notch receptor functional domains and corresponding functions Abbreviations: Ankyrin 
repeats (ANK), Lin12-Notch Repeats (LNR), and RBP-jk association module (RAM).
A number of components of post-translational modifications pathway have been 
implicated in regulating Notch stability including Fbw7, Itch, β-arrestin, Fe65 and Numb 
(50–53). Numb negative breast cancers have increased Notch signaling which can be 
reverted to basal levels with overexpression of Numb and vice versa knockdown of Numb 
in Numb positive breast cancers leads to upregulation of Notch signaling (54). Further 
research into the mechanisms of Notch post-translational modifications and degradation 
may provide novel therapeutic targets as well as for other malignant diseases. 
Signal transduction occurs through the Notch ligand on the “signal-sending cell” 
interacting with the Notch receptor on the “signal-receiving cell.” This interaction process 
involves two sequential proteolytic cleavage events – first by the ADAM10 metalloprotease 
which sheds the extracellular domain, leading to the release of the NICD. The g-secretase 
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Notch receptor maturation and pathway activation, targetable options, and receptor functionality. 
(A) Stepwise representation of the process of Notch receptor maturation until receptor activation, 
followed by transcriptional output (not shown), and possibilities in targeting the Notch receptor 
pathway. (B) Notch receptor functional domains and corresponding functions ANK, Ankyrin repeats; 
LNR, Lin12-Notch Repeats and RAM, RBP-jk association module.
The E3 ligase MDM2 has been shown to contribute to the degradation of Numb and 
through ubiquitination leading to activation of Notch in breast cancer. Treatment of MCF7 
cells with drugs targeting the acidic domain of MDM2 showed a reduction in Notch 
signaling (41). Furthermore, ubiquitination of Notch1 by MDM2 has been shown to 
activate Notch rather than leading to degradation (42). MDM2 has also been shown to 
regulate p53 degradation through ubiquitination, which, along with its role in Notch 
regulation makes it an attractive target for drug discovery along with other E1-3 ligases 
and interacting proteins. Knockdown of the E2-conjugating enzyme UBC9 and inhibition 
of the E1 activating complex SAE1/UBA2 has also been shown to impair the growth of 
Notch1-activated breast epithelial cells (43). Pevonedistat (MLN4924), is an inhibitor of 












































EGF repeats 3x LNR Heterodimerization domain RAM ANK PEST 























shown to induce apoptosis in MCF-7 & SKBR-3 cells in combination with 2-deoxyglucose 
(44), and to sensitize breast cancer cells to radiation in vivo (45). Bortezomib, an FDA 
approved proteasome inhibitor has been shown to inhibit multiple genes associated with 
poor prognosis in ERα breast cancer (46), however several clinical studies have shown 
contradictory results in advanced/metastatic breast cancer (47–49). 
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pathway. B. Notch receptor functional domains and corresponding functions Abbreviations: Ankyrin 
repeats (ANK), Lin12-Notch Repeats (LNR), and RBP-jk association module (RAM).
A number of components of post-translational modifications pathway have been 
implicated in regulating Notch stability including Fbw7, Itch, β-arrestin, Fe65 and Numb 
(50–53). Numb negative breast cancers have increased Notch signaling which can be 
reverted to basal levels with overexpression of Numb and vice versa knockdown of Numb 
in Numb positive breast cancers leads to upregulation of Notch signaling (54). Further 
research into the mechanisms of Notch post-translational modifications and degradation 
may provide novel therapeutic targets as well as for other malignant diseases. 
Signal transduction occurs through the Notch ligand on the “signal-sending cell” 
interacting with the Notch receptor on the “signal-receiving cell.” This interaction process 
involves two sequential proteolytic cleavage events – first by the ADAM10 metalloprotease 
which sheds the extracellular domain, leading to the release of the NICD. The g-secretase 
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the aspartyl protease presenilin (55) The sequential proteolysis activation mechanism 
is essentially the same for Notch1-3 receptors (56). The activation mechanism for Notch4 
-although likely similar to the other Notch family members- has not been reported yet. The 
NICD then translocates to the nucleus where it forms a protein complex with CSL (Cbf-1/
RBP-jk in mammals, Su(H) in Drosophila and Lag-1 in C. elegans) and MAML (Mastermind-
like) and induces transcription of multiple Notch downstream target genes (38) (Figure 2B). 
Additionally, a number of non-canonical pathways have been described downstream of 
Notch, including transcriptional activation of ERα-dependent genes (57), and NF-kβ (58), 
activation of the PI3K-AKT-mTOR pathway (59), and activation of mitochondrial metabolism 
(60, 61). Mammalian cells express four Notch receptors and five ligands in a highly tissue 
specific and content dependent manner (38). Activation levels of specific pathways within 
the global notch signaling pathway has been found to differ within mammary epithelial cells 
and this can lead to different phenotypic responses (62). Notch can also be phosphorylated 
which can have contradictory effects depending on the number of cleavage steps it has 
undergone and the specific kinase involved in phosphorylation (63). Phosphorylation of 
Notch by glycogen synthase kinase 3 (GSK-3) can reduce Notch transcriptional activity & 
protein levels (64, 65) and may be a target for possible therapies. Site specific methylation 
of NICD1 has been shown to make it less stable than a methylation defective mutant (66) 
indicating other possible post-translational targets (67).
Targeting Notch in Cancer
In many solid tumors the Notch signaling pathway is deregulated or mutated (68), 
affecting most hallmarks of cancer (69). Notch gene expression is frequently deregulated 
in breast cancer (70) and shows extensive crosstalk with several major signaling pathways. 
Further, there is ample evidence for the diverse role of Notch signaling in tumor formation, 
progression, and resistance to treatment in breast cancer (71).
Due to the multi-step activation process, several Notch pathway interventions 
are being explored at the level of: I. blocking receptor maturation, II. receptor–ligand 
interactions, III. receptor activation associated proteins, IV. nuclear translocation, V. 
NICD nuclear complex formation, and VI. transcriptional activation of target genes (72) 
(Figure 2A). This includes, but is not limited to antibodies, small molecule inhibitors, and 
inhibitors of γ-secretase (GSI) (72, 73).
Despite the increased evidence for deregulated Notch in numerous malignancies 
and resensitization opportunities (34, 74–81), many clinical studies investigating Notch 
targeting are on hold or have been terminated. Notably, most of these trials were 
conducted in recurrent, heavily pre-treated chemo resistant cancers and used dose-
limiting non-selective pan-Notch/GSIs. Additionally, because of a lack of biomarkers 
predicting outcome to Notch therapies, potential responders were thus not effectively 
selected [reviewed in (71)]. As a result, this has not led to effective interventions using 
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Notch inhibitors combined with standard of care. Therefore, in this review, we have focused 
on the possible role of Notch in enhancing the efficacy of breast cancer treatment.
Notch and Breast Cancer
Role of Notch in breast development.
The normal mammary gland experiences a period of rapid growth and development at puberty. 
Thereafter, and until menopause, it undergoes cycles of expansion and regression with each 
estrous cycle, pregnancy, lactation, and involution (82). This homeostasis requires stem cells 
and their existence was first demonstrated using transplantation experiments to reconstitute 
a functional mammary gland in rodents (83). Dontu et al. demonstrated the presence of early 
progenitor/stem cells capable of differentiating along all three mammary epithelial lineages 
(myoepithelial, ductal-, and alveolar epithelial). Gene expression analysis revealed similarities 
with progenitor and stem cell associated pathways, thereby identifying mammary stem cells 
(MaSCs) in 3D culture systems (84). More recently,  in vivo  imaging has identified bi-potent 
basal stem cells in the mammary gland, yielding both myoepithelial and luminal cells (85) and 
Notch plays a role in this process (86–89). Bouras et al., have performed extensive research on 
the role of Notch in MaSCs. In MaSCs, Notch1 is differentially expressed between subtypes 
(90), and its expression is higher in the luminal type cells (90,  91). Furthermore, Notch1/3 
mark the luminal progenitor cells in mammary gland development (89, 91). Downregulation 
of Cbf-1/RBP-jk resulted in increased proliferation of MaSCs, thereby influencing absolute 
stem cell numbers. However, this proliferation resulted in increased and disorganized side 
branching, with increased number of end buds and basal cells in these end buds. Therefore, 
RBP-jk downregulation regulates the formation of a more basal cell phenotype. Additionally, 
overexpression of the endocytic protein NUMB, a negative regulator of Notch, produced the 
same effects. This shows that reduced Notch signaling is important in proliferation of the basal 
cell population and MaSCs. Conversely, increased levels of Notch1 in the luminal cells showed 
that constitutive Notch activation is important for commitment to the luminal cell lineage (High 
Keratin8/18, Stat5, and p63 downregulation) (90). Moreover, it has been reported that Notch4 
is involved in promoting stem cell renewal of mammary epithelial cells (mammospheres) in 
vitro (92, 93), and is involved in stem cell activity (94)–possibly through JAG1 signaling (95) and 
PKCa-Notch4 interaction (96). Furthermore, Notch and p63 signaling guide the establishment 
of basal and luminal epithelial cells (97) and PTEN/JAG1 play an important role in mammary 
epithelial stem cells (98).
Role of Notch in breast cancer development and metastasis.
The role of different Notch pathway components in breast cancer development has 
been extensively researched. Stylianou et al. showed that in many breast cancer cell lines 
Notch ligands, receptors, and target genes are aberrantly expressed (99). Charafe-Jauffret 
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et al. identified a 413-gene CSC profile (including Notch2) using normal and malignant 
mammary tissue (100), identifying breast cancer stem cells (BCSCs) through ALDH+ (101). 
ALDH+ cells were capable of self-renewal, differentiation, tumor formation in mice, and 
showed increased metastatic potential. ALDH−  cells hardly generated tumors. Results 
from a Meta–analysis involving 3867 patients showed that Notch1 expression positively 
correlates with breast cancer progression and that higher expression is associated 
with a transition from ductal carcinoma  in situ  to invasive cancer. Furthermore notch1 
overexpression was correlated with significantly worse overall and recurrence-free 
survival. The data further suggested that Notch inhibitors may be useful in blocking early 
progression of ductal carcinoma in situ (5).
Aberrant activation of the Notch signaling pathway has been shown to promote an 
aggressive phenotype partially through NF-κB, whereas de-activation of Notch signaling 
abrogates this aggressive phenotype (58). Furthermore, in TNBC, tumor cells activated NF-
κB upregulates Jagged-1, which stimulates Notch signaling in CSCs (102).Tumor derived 
Jagged1 has been shown to be an important mediator of bone metastasis in breast 
cancer. Jagged1 activates stromal Notch signaling which in turn induces IL-6 secretion 
from osteoblasts stimulating tumor growth. Notch signaling also directly stimulates 
maturation of osteoclasts exacerbating bone metastasis. Destruction of bone matrices 
releases TGF-β upregulating Jagged1 in the tumor giving a positive feedback loop. GSIs 
treatment in turn reduces bone metastasis by targeting stromal Notch signaling (103).
In vivo studies using TNBC and ERα+ cell lines showed an association between Notch3 
expression and distant metastases which was diminished in Notch3 null cells. This finding 
was corroborated using TNBC cells from a patient-derived brain metastasis (104). An  in 
vivo  study using a more metastatic variant of the HER2+ MDA-MB435 isolated from  in 
vivo  brain metastasis showed activation of the Notch signaling pathway. Inhibition of 
Notch using the γ-secretase inhibitor DAPT or knockdown using RNAi against Notch and 
Jagged2 resulted in inhibition of the migratory and invasive phenotype (105). Furthermore 
fewer brain micrometastases were found when Notch1 was silenced in an MDA-MB-231 
model (106). Breast tumor cells in the brain highly express IL-1β which leads to surrounding 
astrocytes expressing Jagged1 which stimulates Notch signaling in CSCs (107). Oskarsson 
et al. showed that breast cancer cells that metastasize to the lungs enhance their ability 
to survive through expression of the extracellular matrix protein tenascin C. Tenascin C is 
associated with aggressiveness and pulmonary metastasis and enhances stem signaling 
components including Notch (108).
Notch1. Notch1 is aberrantly expressed in breast cancer (99) and high Notch1/4 mRNA 
expression and activity are associated with worse prognosis (30). In Ductal Carcinoma in 
situ  (DCIS), Notch1 signaling is active and associated with the development of breast 
cancer (109). Both Notch1 and Notch4 are identified as common sites of proviral 
integration in mammary mouse tumors (110,  111), and induce mammary (MMTV)-
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tumors when overexpressed in transgenic mice (112–114). Larger studies have shown 
that expression of Notch1/4 and JAG1 is associated with poor prognosis in breast cancer 
(115). Moreover, JAG1 expression is an independent predictor of poor outcome in node-
negative disease (116) and higher NICD1 expression correlated with sentinel lymph-node 
positive patients (117). Notch1 levels were progressively associated with the transition 
from DCIS to invasive basal cancer (5).
In human breast cancer, a meta-analysis including approximately 4000 cases showed 
that elevated Notch signaling is associated with increased disease recurrence (118). 
Pathway and network analysis revealed that altered Notch1 signaling occurred in ER+/PR+/
HER2+/− breast cancers (119), whereby Notch1 mutations are more prevalent in HER2− than 
HER2+ tumors (120). JAG1-Notch signaling leads to Cyclin-D1 induction (121), a gene that 
is essential for normal breast development in mice (122) and frequently deregulated 
or amplified in human breast cancer (123,  124). k Notch1 activating mutations/
rearrangements have also been observed in TNBC (in EGF repeats and NRR) (125) and 
in the basal-like phenotype (116). Additionally, Notch1 promotes stem cell maintenance 
through c-Jun signaling (126). Further, Reedijk et al. revealed that JAG1 is an independent 
predictor of poor outcome in multivariate-analysis (115) with other well-known outcome 
predictors (nodal metastases, patient age, tumor size, node status, ER positivity, and 
tumor grade) (5, 115, 127). Higher NICD1 expression correlated with sentinel lymph-node 
positive patients—strengthening Notch1’s role in the metastatic process (117).
Leong et al. provided data that JAG1 and Notch1 are involved in epithelial-mesenchymal 
transition (EMT) through SLUG and E-cadherin. They showed that SLUG facilitated E-cadherin 
repression (through Notch1 inhibition) and inhibition of HEYL blocked tumor growth and 
metastasis, showing JAG1-Notch1-SLUG dependency (128). Furthermore, NICD1 expression 
negatively correlated with E-cadherin and showed increased invasive capacity of Notch1, 
(129). This was also the case under hypoxia with differences observed in high/low Notch 
signaling cell lines (130). Mechanistically, hypoxia-induced EMT is mediated through SLUG 
and SNAIL (131). A JAG2-EMT relationship has been shown too (through Notch1), revealing 
a broader spectrum of Notch1 activation and involvement in hypoxia and metastatic 
potential of CSCs (132). Additionally, high Notch1 and HIF predict a worse prognosis 
(133). These results show that Notch1 signaling is important for EMT and downregulation 
of E-cadherin, ultimately creating a more invasive phenotype. Furthermore, as described 
above, the invasiveness of the tumor and hypoxia induced EMT requires Notch1 signaling, 
demonstrating a hypoxia/Notch1/EMT axis. Thus, inhibition of Notch1 can be tumor 
suppressive by removing the inhibition on E-cadherin expression, regardless of hypoxia.
Downregulation of JAG1 or blocking Notch with GSI in a metastatic breast cancer 
model (MDA-231) attenuates bone metastasis by reducing osteolysis in the bone 
microenvironment. Conversely, overexpression of JAG1 is sufficient to induce bone 
metastasis in this model (103). Others have demonstrated a role for Notch1 of tumor 
dormancy in the bone marrow microenvironment, instigating metastases, through a 
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Notch1/STAT3/LIFR signaling axis (134). Furthermore, circulating tumor cells “primed” 
for breast cancer brain metastases have a specific gene signature (HER2+/EGFR+/HPSE+/
Notch1+) (135,  136). These CTCs could either be derived from the primary tumor or 
from metastatic lesions. Importantly, these CTCs were EPCAM−. This would make them 
undetectable by the only FDA approved clinical test for CTCs, which is based on an 
EPCAM+ profile (136).
Notch2. Notch2 can act as a transcriptional and functional regulator of Notch1 and Notch3 
(137) and has been shown to be involved in specific mammary epithelial lineages affecting 
luminal cellular hierarchy (138). Mutations in Notch2 show increased incidence in breast 
cancer, and in addition to the TCGA database new mutations have been found (139). 
Notch2 is positively correlated with HER2 (140), low-grade tumors and improved outcome 
(141), and increased apoptosis (142). In the basal subtype, JAG1 and DLL4-induced Notch2 
activation under the influence of FYN/STAT5 maintained the mesenchymal-phenotype. 
Notch2 siRNA decreased the EMT markers VIM, SNAI1, SNAI2 (SLUG), TWIST, and ZEB1 
(143). Notch2/3 inhibition (Tarextumab) decreased CSC numbers in the UM-PE13 breast 
cancer cells (144). Furthermore, mutations in Notch2 could facilitate development of 
liver metastasis (145). However, other studies showed that, Notch2 mutations do not 
unequivocally associate with better prognosis and therapy efficacy (144, 146).
Notch3. Expression of oncogenic Notch3 in mice leads to mammary cancer (111), 
and is involved in: hormone-receptor positive breast cancer (120), the proliferation of 
HER2− breast cancer (147) and HER2+ DCIS (148), and TNBC (149). Notch3 is involved in 
HER2+ DCIS through transcriptional upregulation of the Notch pathway by HER2–whereby 
Notch3 upregulates the formation of luminal cells and increases proliferation through 
Cyclin-D1, c-MYC, and AKT (148). Furthermore, Notch3 signaling has been proposed to 
be an important regulator of the process whereby bipotent progenitors commit to the 
luminal lineage (93). Additionally, evidence from nonsense and missense mutations in 
multiple cancers, including breast cancer, showed tumor suppressor capabilities of Notch3 
through controlling of the cellular senescence pathway (150). Interestingly, no significant 
change in Notch1, Notch2, or Notch4 expression was observed in these studies.
In TNBC, ectopic NICD3 (over)expression facilitated the inhibition of EMT through 
upregulation of the HIPPO pathway and E-cadherin in a RBP-jk dependent manner, 
whereby knockdown of Notch3 abrogated this effect (151). Furthermore, a correlation was 
shown between Notch3 and p21, a well-known senescence-involved protein. A significant 
decrease in Notch3 was observed in primary breast cancer, compared with normal tissue, 
suggesting a protective mechanism against Notch3-initiated cellular senescence. Re-
introduction of Notch3 resulted in growth inhibition and activation of cellular senescence, 
suggesting that loss of Notch3 expression facilitates senescence induction and could play 
a critical role in tumor progression. Notch3 silencing has recently been shown to sensitize 
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TNBC cells to the EGFR inhibitor gefitinib by promoting EGFR tyrosine dephosphorylation 
and internalization (152). Notch3/4 were shown to have increased expression in low-
burden metastatic cells relative to the primary tumor (153).
Notch4. The oncogenic function of Notch4 was first demonstrated by retroviral insertion 
in MMTV-induced mammary tumors (110). Additionally, Notch4 is highly expressed, and 
gain of function mutations have been identified, in mouse mammary cancer models 
[reviewed in (154)]. Expression of activated Notch4 in mammary epithelial cells lead to 
transformation (155) and rapid development of poorly differentiated adenocarcinoma in 
transgenic mice (110, 156). Additionally, truncated human Notch4/Int3 (activated Notch4) 
instigated mammary tumors (112), through transcription of RBP-jk (157) and ANK repeats 
(158). Interestingly, transgenic expression of Notch4 NICD caused mammary tumors in the 
absence of RBP-jk in mice harboring conditional knockout of RBP-jk (157). This suggests 
that non-canonical pathways may participate in the oncogenic activity of Notch4.
PEST domain. The PEST domain is a degradation domain that regulates the stability of 
all NICDs through ubiquitination and proteasomal degradation (39). Nonsense mutations 
are common in T-ALL (159, 160) and have been observed in Notch1/2/3 receptors in TNBC 
(39). Furthermore, Notch pathway and target genes, including Notch1/3, HES1, HEY2, 
HES4, MYC, Cyclin-D1, and NRARP, were highly overexpressed in TNBC (39,  125). Notch 
mutation-activated dependency was shown using GSI, as wild type tumors showed little 
to no response (39).
Notch pathway-associated proteins
Fringe.  Fringe is an important regulator of the Notch receptor-ligand interaction (161) 
through modification (glycosylation) of EGF repeats in the extracellular domains of 
Notch receptors (162). Fringe enzymes add N-acetyl glucosamine to fructose residues 
in the extracellular domains of Notch receptors. More glycosylated receptors retain high 
affinity for Delta ligands but have reduced affinity for Serrate/JAG ligands. Hence, loss 
of Fringe glycosylation enhances Notch affinity for Serrate/JAG ligands. There are three 
Fringe genes in mammals: Lunatic Fringe (LF), Manic Fringe (MF), and Radical Fringe (RF). 
In breast stem or progenitor cells, and especially the terminal end bud cap cells termed 
“leader cells” (163), LF is highly expressed (93). Conversely, the majority of basal tumors 
and a subset of claudin-low tumors show reduced LF expression (164). In MMTV-driven 
tumors, absence of LF exclusively caused triple negative tumors. Furthermore, deletion of 
LF was enough to cause Notch-driven (Notch1-4) basal-like tumors via enhanced stem/
progenitor cell proliferation (163). These tumors resembled “claudin-low” (mesenchymal) 
subtype of TNBC. p53 loss of function in these tumors resulted in a clear EMT profile 
(Vimentin, TWIST, E-cadherin) (165). Cells showed increased levels of Vimentin and 
E-cadherin and decreased expression of cytokeratin 8/14–this coincided with decreased 
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differentiation, increased levels of proliferation, and stem cells. Co-deletion of LF and 
p53 resulted in upregulated NICD3 and HES5, and downregulation of HES1. These data 
connect expression of LF, Notch (signaling), and p53 to impaired luminal differentiation.
In contrast to LF, MF is highly expressed in the claudin-low subtype of breast cancer 
and is associated with Notch4 (166). Deletion of MF shifted the tumor resemblance to 
a less claudin-low like, more luminal subtype—through increased levels of the luminal 
marker CK8 and basal marker CK14, and decreased levels of stem cell marker ALDH1. 
Furthermore, MF was shown to be able to regulate cancer stem cells and their migration 
in a spheroid model by increasing NICD1 expression and PIK3CG (encoding the g catalytic 
subunit of PIK3-γ) (166). These data show that Fringe is involved in a Notch-dependent 
manner in breast cancer with different roles observed for different Fringes (no data has 
been reported yet on RF)—causing a Fringe-dependent subtype switch (basal-luminal).
NUMB. NUMB is a cell fate determinant and endocytic protein that acts as a negative 
regulator of the Notch signaling pathway (54, 167, 168). NUMB is frequently down-regulated 
in breast cancer and suppresses the growth of breast cancer cells in vitro (169, 170) often 
involving the attenuation of the p53 tumor suppressor pathway (168). NUMB can drive 
Notch toward endocytic degradation. Additionally, NUMB inhibits ubiquitin ligase MDM2, 
which targets p53 for degradation. Hence Loss of NUMB results in a high-Notch, low p53 
phenotype. Mechanistically, NUMB forms a ternary complex with MDM2 and TP53 and 
inhibits the activity of MDM2 (168, 171). In a cohort of breast cancer patients receiving 
adjuvant chemotherapy, NUMB, and indirectly Notch activation, were inversely correlated 
with clinical and pathological parameters indicative aggressive disease progression (168). 
In NUMB-deficient cells, p53 is ubiquitinated and degraded, resulting in chemoresistance 
and high Notch activity. MDM2 also ubiquitinates NUMB, which results in nuclear 
translocation and degradation (172). Thus, NUMB connects the MDM2/p53 pathway, the 
most frequent mutated pathway in human cancers, with Notch signaling.
MAST. In many breast cancers, gene translocations and fusions have been described. 
Recurrent gene arrangements involve MAST and Notch family members (Notch1/2), both 
showing phenotypic effects in breast cancer (e.g., greater proliferation). Notch fusions 
were found, almost exclusively, in ER− breast carcinomas. All the fusion transcripts retained 
the exons that encode for the NICD. Furthermore, higher Notch responsive transcriptional 
activity was seen in breast cancer cell lines carrying MAST-Notch fusions, and showed 
dependence on Notch signaling for proliferation and survival (173). The discovery of 
these Notch fusions warrants further investigation and may identify a biomarker for Notch 
based therapeutics.
Nicastrin. Nicastrin is an essential component of the γ-secretase complex; it encodes an 
integral membrane protein which associates with the catalytic subunit of γ-secretase, 
2
Moving Breast Cancer Therapy up a Notch
61
Presenilin (174). Nicastrin is crucial for maturation of Presenilin and cells that lack 
Presenilin are γ-secretase and Notch-deficient (175, 176). In breast cancer, high Nicastrin is 
mainly observed in the ER+ subtypes. Nicastrin expression correlates with age and tumor 
grade–and predicts worse tumor survival (177). Additionally, a set of 22 genes (located 
on chromosome 1) has been co-identified with Nicastrin amplification and breast cancer 
(178), however, these genes showed no clear Notch signature. Furthermore, Nicastrin 
seems to play a role in EMT (177, 179). Targeting of Nicastrin affects breast cancer stem cells 
and inhibits tumor formation in vivo (179). Inhibiting Nicastrin in TNBC, using monoclonal 
antibodies, showed anti-tumor activity (180). Thus, aiming at Nicastrin provides another 
opportunity to target the involvement of Notch in breast cancer.
These data suggest that (deregulated) Notch receptor/ligand signaling influences 
cell renewal in the mammary gland and reaches far beyond mammary development, 
as it possesses the ability to influence the pre-malignant lesions, primary tumors, the 
metastatic potential of tumors, and therapy resistance.
Figure 3: Overview of the role and opportunities for Notch in breast cancer therapy. 
Summary of the 4 fields of breast cancer therapy [radiotherapy, chemotherapy, endocrine therapy, 
and targeted therapy (HER2)] in which Notch targeting can play a significant role.
Notch Signaling in the Tumor Microenvironment
The breast microenvironment consists of a number of cell types including fibroblasts, 
adipocytes, endothelial and immune cells as well as extracellular matrix.
Mollen et al. Moving Therapy Up a Notch
must be carefully considered. In treatment-naïve tumors, Notch
activation might not become clinically evident until treatment
initiation, as a resistance mechanism triggered by treatment, or
after occurrence of metastases with different mutational profiles
compared to primary tumors (4). Selecting patients most likely
to benefit from Notch inhibition will require molecular profiling
and screening to show possible co-targeting options (298).
The identification of predictive biomarkers is of paramount
importance.
In this review, we have highlighted several opportunities
for Notch targeting in the context of first line breast cancer
treatment and resistance. Additionally, we have discussed its
extensive communication with many other pathways (59, 256,
257, 292, 293), its role in recurrent disease and involvement in the
metastatic process (103, 134, 136, 145), and its association with
clinically relevant allmarks in breast cancer (69).
Research in the past decade has focused on preventing or
treating tumor recurrence by targeting CSCs. Multiple different
stem-like cell populations have been proposed within tumors,
based on the expression of CD44high/CD24−, ALDH+, CD133,
CD29high/CD61+, CD49f+, and CD90 (299–302). These cells
showed increased levels of therapy resistance and distinctive
gene expression patterns, irrespective of their potential origin
(e.g., from transformation of mammary stem cells or from
de-differentiation of non-stem-like tumor cells)—as stem cell
plasticity occurs within tumors (32, 303). Notch signaling plays
an important role in mammary stem cells as well as breast
cancer stem cells (BCSCs) (84, 92, 304)—well documented
for triple-negative breast cancer (94, 109, 153, 244, 253,
304–307). Furthermore, Notch4 has been shown to maintain
the BCSC population (94, 307). Notch-PTEN signaling is
important in the expansion of these stem-like cells (98, 308).
PTEN/PIK3CA mutations are often observed in breast cancer
and loss of PTEN decreases radiation sensitivity (309). In the
future, combining radiotherapy and small molecule targeting
in BCSC may improve the efficacy of radiation therapy
FIGURE 3 | Overview of the role and opportunities for Notch in breast cancer therapy. Summary of the 4 fields of breast cancer therapy [radiotherapy, chemotherapy,
endocrine therapy, and targeted therapy (HER2)] in which Notch targeting can play a significant role.
Frontiers in Oncology | www.frontiersin.org 15 November 2018 | Volume 8 | Article 518
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Cancer associated fibroblasts (CAFs) have been shown to induce Notch activation in 
breast cancer cell lines through secretion of IL-6 (181). There is also evidence supporting 
a role for fibroblast-derived microvesicles in endocrine resistance. Cancer-Associated-
Fibroblast (CAF)-derived microvesicles, containing oncomiR-221 promoted de novo 
endocrine resistance—as overexpression of oncomiR-221/222 in luminal breast cancer 
cells reduces ER expression (182) Furthermore CAFs can promote the cancer stem cell 
phenotype by secreting CCL2, inducing Notch1 (183). Stromal cells including fibroblasts 
have also been shown to promote therapy resistance in breast cancer cells through 
expression of Jagged1 and exosomal transfer leading to Notch3 and STAT1 signaling 
in cancer cells (184). GPER signaling from both CAFs and cancer cells has been shown 
to upregulate Notch signaling. 17β-estradiol and GPER ligand G-1 induces γ-secretase-
dependent activation of Notch1. Furthermore, the 17β-estradiol and GPER induced 
migration of breast cancer cells and CAFs is attenuated with GSI treatment (185).
17β-estradiol also promoted increased Jagged1 as well as Notch1 expression in 
MCF7 cells and was similarly found in endothelial cells. The endothelial cells formed 
cord-like structures in matrigel in contrast to cells expressing a dominant negative form 
of Notch1. 17β-estradiol treatment was also able to increase tumor microvessels in vivo, 
which correlated with Notch1 expression (186). Clinical data has shown higher Notch1 
activation in tumor endothelial cells compared to non-malignant tissue. A correlation 
between the rate of NICD1-positve vs negative tumor endothelial cells was higher 
in patients with positive sentinel lymph nodes (117) Co-culture  in vitro  and  in vivo  has 
demonstrated upregulation of notch ligands in endothelial cells after contact with breast 
cancer cells. Proliferation and survival was significantly reduced along with a reduction in 
the stem-cell population when co-cultures were treated with GSI. Knockdown of Jagged1 
in endothelial cells reduced the survival ability of breast cancer cells under starvation 
conditions. Knockdown also reduced tumor cell proliferation but did not reduce survival 
of knockdown epithelial cells (187). Wnt signaling is known to be up-regulated in breast 
cancer. Aberrant wnt signaling has been shown to give a tumorigenic phenotype to 
primary epithelial cells. This conversion is in part caused by up-regulation of the Notch 
ligands Dll1, Dll3 & Dll4 which are required for the tumorigenic phenotype (188).
Mammospheres enriched with stem/progenitor cells from node invasive breast 
carcinoma tissue expressed more IL-6 than matched non-neoplastic mammary glands. 
Il-6 was only detected in basal-like breast carcinoma tissue which contained stem cell 
features. Il-6 upregulated Jagged1 and lead to growth and a hypoxia-resistant/invasive 
phenotype through Notch3 dependent expression of CAIX (189).
Adipocytes within the tumor microenvironment secrete leptin and IL-6. Leptin and 
IL-6 signaling in breast cancer cells adjacent to adipocytes upregulate multiple pathways 
including Notch promoting a stem-like phenotype as well as epithelial-mesenchymal 
transition (190). Leptin is able to induce Notch 1,3 & 4 however Notch3 appears to be cell 
dependent. The leptin-Notch signaling axis is involved in proliferation and migration and 
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leads to higher incidence and aggressiveness in obese patients. Leptin inhibitors were 
able to reduce Notch receptor, ligand and target expression (191).
Dll4 and Jag1 have opposite effects on regulating angiogenesis. Jag1 induces 
maturation of blood vessels, while Dll4/Notch regulates sprouting angiogenesis (192). Thus 
targeting Dll4 or Jag1 will have different effects. Targeting Dll4 using antibodies promotes 
non-productive angiogenesis (193). GSI treatment however targets both and leads to a 
decrease in angiogenesis (194). These differences in targeting may explain the contrasting 
in angiogenesis seen in pre-clinical models treated with GSI or Dll4 antibodies. In a phase 
I clinical trial, enoticumab, a Dll4 monoclonal antibody targeting the tumor vasculature, 
showed stable disease as best response in 2 of the 6 breast cancer patients enrolled. The 
antibody also gave a number of side effects, seen with previous Notch targeting therapeutics, 
as well as ventricular dysfunction and pulmonary hypertension (195).
Notch and the immune response
The role of Notch signaling in the immune response to tumors is complex and is 
dependent on the tumor type and microenvironment factors. Notch signaling is a key 
regulator of hematopoietic development and controls self-renewal, lineage commitment 
and terminal differentiation of the innate and adaptive immune system including B cells, 
T cells, myeloid cells, dendritic cells and natural killer cells (196, 197) Notch signaling, both 
canonical and non-canonical, also plays a role in tumor induced immuno-suppression.
It has been established that most stages of the tumor development from initiation 
to malignant conversion, invasion, metastasis, therapy resistance and relapse involve the 
inflammatory response (198). The interaction between tumor cells and immune cells in 
the tumor microenvironment controls the overall immune surveillance and response 
to therapies and patient outcome. The role of Notch signaling in the immune response 
to tumors is complex and is dependent on the tumor type and microenvironment 
factors Notch as well as regulating many aspects of the immune system regulates many 
components of the tumor microenvironment (199, 200).
There is a strong causal relationship between endocrine resistance and Jagged NOTCH 
signaling in breast cancer which promotes macrophage differentiation toward tumor-
associated macrophages (TAMs), the most common immune cell found in the breast 
tumor microenvironment (200). TAMs can be pro or anti-inflammatory depending on 
micro environmental factors, which in most breast cancers develop the anti-inflammatory 
phenotype (200, 201). The anti-inflammatory phenotype in breast cancer plays a role in 
suppressing immune surveillance as well as promoting proliferation, angiogenesis and 
tissue remodeling (198). In a model of basal-like breast cancer, tumor cells secrete the 
CCL2 & IL-1β cytokines in a Notch dependent manner, which work to recruit monocytes 
(202). Within the tumor microenvironment monocytes differentiate into TAMs with a pro 
tumor phenotype supporting tumor growth and metastasis (203). TAMs also interact 
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with cancer cells via TGFβ, promoting Jagged 1 expression, causing a feedback loop that 
amplifies cytokine/chemokine secretion.
Myeloid-derived suppressor cells (MDSCs) promote tumor progression through a 
variety of mechanisms including immune suppression and enhancing angiogenesis and 
metastasis. MDSCs have been shown to have lower Notch activity in conditioned media 
from breast cancer cell lines through an inhibitory phosphorylation of NICD by casein 
kinase 2, disrupting NICD/ CSL interaction (204). MDSCs in breast cancer have also been 
shown to induce Notch signaling in cancer cells and promote CSC capacity through IL6/
STAT3 & Nitric Oxide/Notch cross talk signaling (205,  206). Cancer cells also increase 
Jagged-1 & Jagged-2 expression in MDSCs leading to a positive feedback loop between 
cancer cells, immune cells and CSCs.
Notch has been shown to be important in the regulation of Tregs, a subtype of T cells, 
which is important in peripheral self-tolerance and plays a role in tumor immunosuppression 
(207). Tregs promote evasion of immune surveillance and are linked to tumor invasiveness 
and poor prognosis. Notch-1-TGF-β signaling directly induces peripheral Tregs through 
upregulation of Foxp3 (208). Both Jagged-1 and Jagged-2 increase the generation of Tregs 
(209) and are highly expressed in TNBC, CSCs and treatment resistant populations (95, 132).
On the other hand CD8+  cytotoxic T cells, which have been shown to have anti-
tumor function, require Notch to become activated (210), and Notch2 has been shown 
to be required for the anti-tumor effect of cytotoxic T lymphocytes (211). Furthermore, 
selective activation of the Notch pathway in hematopoietic environments enhances T-cell 
activation and infiltration, inhibiting tumor growth in mouse models.
Research into targeting the immune response and the tumor microenvironment is 
ongoing and detailed reviews strategies and treatments can be found here (212, 213). GSI 
treatment has been shown to reduce the numbers of TAMs, MDSCs and TRegs, however it 
can’t be excluded that this was in part due to inhibiting tumor growth (214). More research 
is needed to fully elucidate the complex interplay between Notch, tumor microenvironment 
and the immune system in breast cancer and to develop strategies that enhance the anti-
tumorigenic effect but do not suppress the anti-tumor immune response.
Notch in Breast Cancer Therapies
Radiotherapy
For breast cancer, radiotherapy is mainly implemented in the adjuvant setting and involves 
the targeting of remaining tumor cells, with the aim to prevent recurrence of residual 
disease. Gene signatures (IGKC, RGS1, ADH1B, DNALI1) in primary breast cancers predict low 
and high risk groups for local regional recurrence after Radiotherapy (215, 216). Generally, 
cancer stem cells are often radiation resistant (217,  218). Radiotherapy resistance could 
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be intrinsic or acquired through changes in gene expression profiles and radiotherapy-
resistant CSCs have been observed in breast cancer (219,  220). More specifically, BCSCs 
(CD44+/CD24−/low) were shown to be resistant to radiation (compared to non- CD44+/CD24−/
low mono-layer cultures), and contributed to tumor recurrence after fractionated radiation. In 
a clinically more relevant culture system (mammospheres) higher radiation resistance was 
observed correlating with lower levels of ROS compared to monolayer cultures. Consistently, 
mammosphere cultures showed higher radiation resistance than irradiated single cell 
suspensions. Thus, during fractionated radiation, repopulation derives from the more 
resistant subpopulation of CSCs. Increased levels of Notch1/JAG1 signaling could stimulate 
the more resistant phenotype of CD44+/CD24−/low CSCs (219). Lagadec et al. showed that 
radiotherapy-exposed cancer cells have increased mammosphere formation, increased 
tumorigenicity, and (re)expressed stemness-related genes (transcription factors Oct4, Y-box 
2, Nanog, and Klf4). Interestingly, both NICD1 and JAG1 expression were upregulated only 
in response to fractionated radiation (5 × 3Gy) and not after a single dose (10Gy) (221). 
Additionally, other research showed that a singular dose of 3Gy did upregulate NICD1 and 
JAG1 (222). Thus, induction of Notch pathway genes is radiation (multi)dose-dependent 
(222). Furthermore, targeting of Notch using siRNA (221) or GSI (222) decreased the induced 
BCSCs population after irradiation of non-tumorigenic cells. These data indicate that Notch is 
involved in the induction of radiation-induced CSCs from partially differentiated tumor cells. 
Recently it has been shown that, that Notch1 directly regulates the DNA damage response, 
through physical interaction and suppression of phosphorylation of ATM kinase (223). A 
plausible hypothesis is that after repeated irradiation, Notch1 could suppress apoptosis-
inducing signals from the activated DNA damage response.
Chemotherapy
Chemotherapy is an important component of standard cancer treatment and includes 
anthracyclines, cyclophosphamide, and taxanes. Resistance to chemotherapy is the main 
cause of treatment failure in 90% of the patients with metastatic cancers (224). Importantly, 
chemo-resistance accompanies endocrine resistance, so that ER-positive recurrent tumors 
that are resistant to endocrine therapy are also almost invariably chemo-resistant. One of 
the main underlying causes for treatment failure is intra-tumor heterogeneity, a process 
affected by the presence of CSCs (168, 225).
Anthracycline/Cyclophosphamide
A role of Notch in doxorubicin sensitivity and resistance has been reported by Zang et al. 
(226). They showed that Notch1 inhibition (RNAi) and doxorubicin treatment led to a 50 
and 70% growth inhibition, and increased apoptosis, compared to chemotherapy alone–
in the MCF7 and MDA-MB-231 cell lines respectively. Li et al. showed that the efficacy of 
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doxorubicin could be increased when used in combination with a GSI (227). Additionally, 
chemotherapy increases the percentage of treatment resistant CD44+/CD24low breast cancer 
cells in patients. In tumor xenografts combination treatment with GSI and doxorubicin led 
to better tumor control–by reducing CD44+/CD24low population (168).
Interestingly, ALDH expression has been shown to inactivate chemotherapeutics 
such as doxorubicin and cyclophosphamide (228–230). In addition, Suman et al. (231) 
showed that Notch inhibition was effective in both ALDH−  and ALDH+  cells, though 
ALDH− cells were more sensitive. Additionally, they showed that Notch1 downregulation 
(using Psoralidin) and silencing resulted in inhibition of cell viability and proliferation, and 
a downregulation of EMT factors SLUG and TWIST.
In ER+ cell lines (MCF7 and T47D) Notch target genes HES1 and HEY1 were induced by 
doxorubicin, and could be inhibited using a GSI–suggesting a Notch signaling dependent 
effect. Furthermore, expression of Notch was associated with expression of multi drug 
resistance protein 1 (MRP1), a potential predictor of chemotherapy response and clinical 
outcome, in a dose-dependent manner (232). Importantly, in patients treated with 
neoadjuvant chemotherapy (anthracyclines ± taxanes), pre-treatment NICD1 levels were 
very low or absent, while post-therapy NICD1 was significantly upregulated (232).
In a doxorubicin resistant engineered-cell line, MCF7-AMD, Notch3 was shown 
to be downregulated in chemo-resistant cells, and EMT was activated. Furthermore, in 
ER+ patients, low Notch3 predicted distant relapse-free survival, with Fos-related antigen 
1 (Fra1) being negatively regulated by Notch3 (233).
Taxanes
The two most common used taxanes for breast cancer treatment are docetaxel and 
paclitaxel (234,  235). Qiu et al. showed that docetaxel treatment resulted in increased 
primary mammosphere formation. Notch1 inhibition increased chemotherapy efficacy in 
TNBC BCSCs (CD44+/CD24−/low population) in vitro and in a patient-derived xenograft breast 
cancer model (236). In line with this, Zhang et al. reported similar findings, using a GSI in 
multiple xenograft models (237). “Tumor debulking” by docetaxel resulted in an increased 
BCSC population, quantified using ALDH+/CD133+/CD44+. Interestingly, the CD44+/
CD24−/low population was not altered, however, this might be due to differential targeting 
methods (Qiu et al. (236): mAb vs. Zhang et al. (237): GSI). Docetaxel-treated tumors showed 
increased NICD1. Combination of GSI with docetaxel showed significant improved effect 
compared to docetaxel alone. Mechanistically, treatment with docetaxel caused an increase 
in survivin (inhibitor of apoptosis) and drug transporters, which could be inhibited by GSI. 
Furthermore, decreased expression of NUMB was observed in docetaxel treated tumors but 
not after dual treatment with GSI. Docetaxel treatment increased EMT markers SNAIL, SLUG 
and N-cadherin, which could be blocked by Notch inhibition. These findings indicate that 
Notch1 is involved in the resistance mechanisms of docetaxel treated tumors and that dual 
treatment could block enrichment of the BCSC population and increase therapy efficacy.
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Schott et al. showed a residual BCSC subpopulation to be insensitive to docetaxel alone 
(238). However, in tumor-derived xenografts treatment with GSI (MK-0752) reduced the 
BCSC population; this resulted in reduced mammosphere formation and decreased NICD 
and HES1 expression. A concurrent clinical study, including 30 patients with recurrent 
disease after anthracycline treatment, showed that repeated cycles of GSI resulted in 
partial response in 11 patients and evidence for a reduction in CD44+/CD24−/low  and 
ALDH+ cells. Repeated biopsies showed an initial increase in BCSC populations until after 
the 1st treatment cycle, after which it declined—this is consistent with the ability of GSIs to 
decrease BCSCs. However, additional treatment cycles where needed to additionally reduce 
BCSCs and tumor burden. An additive effect of Notch inhibitors and docetaxel has been 
recently observed in a phase 1b trial in TNBC, whereby docetaxel and GSI (PF-03084014) 
showed 4 partial responses and 9 had stable disease out of 25 patients, with a manageable 
safety profile (by dose reduction) (239). All in all, the combination of docetaxel and Notch1 
targeting showed synergy, with a manageable toxicity profile (238, 239).
In TNBC cells treated with the microtubule stabilizing agent paclitaxel, surviving 
breast cancers cells expressed Notch1, Sox2, Oct3/4, c-Myc, c-SRC, c-MET, Nanog, 
and E-cadherin, and were highly tumorigenic. Surviving cells also became resistant 
to the BCR-Abl/Src family kinase inhibitor dasatinib (240). In parental MDA-231 cells, 
dasatinib reduced NICD1 and Cyclin-D1 levels, but in paclitaxel resistant clones NICD1 
levels were not affected. Dasatinib resistant MDA-231 clones were not cross-resistant to 
doxorubicin or docetaxel. Targeting Notch1 signaling in TNBC (using GSI) was additive to 
paclitaxel treatment, as Notch wildtype tumors showed no additive effect (125). These 
results support a protective mechanism whereby Notch1 is upregulated to protect the 
survival of paclitaxel-treated TNBC cells. In the TNBC UM-PE13 xenograft, blockage of 
DLL-4, decreasing Notch1 signaling, resulted in delayed tumor regrowth after paclitaxel 
treatment, with additionally decreasing the CSC frequency (241). Paclitaxel is capable 
of preventing breast cancer bone metastases. However, resistance emerges over time 
through induction of osteoblast JAG1 expression. Hence, metastatic seeding could be 
prevented using a JAG1 antibody (15D11). Synergistic effects (100x, compared to IgG) 
were observed when used in combination with paclitaxel (242).
All together, these data indicate that Notch inhibition may sensitize breast cancer 
to chemotherapeutics and that this involves a treatment-resistant BCSC population 
characterized by CD44+/CD24−/low cells. Further, chemotherapy resistant cell lines may be 
resensitized after treatment with Notch inhibitors.
Endocrine Therapy
In ER+ breast cancers, estrogen receptor signaling plays a pivotal role in tumor development 
and progression (243). Treatments that target the ER include blocking of receptor 
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with an antagonist (e.g., selective estrogen receptor modulators such as tamoxifen or 
selective estrogen receptor disruptors such as fulvestrant) or depriving the tumor of 
estrogen (aromatase inhibitors). This mainly targets the tumor bulk, however, important 
implications have been made for hormone receptor-positive stem cells (244, 245). Despite 
similar expression of hormone receptors, some tumors are more sensitive to endocrine 
therapy than others, resulting in inter- and intra-patient differences. Additionally, 
differences in clinical outcome are observed based on breast cancer subtype (Table 1). 
Notably, expression of ER/PR is not universal in both tumor and metastases (246), and this 
does affect tumor prognosis (247). Receptor conversion and intra-tumor heterogeneity 
of ER expression in primary and metastatic tumors are therefore still a barrier to effective 
endocrine therapy. Point mutations in the ESR1 gene, encoding ERα, have been shown to 
arise during endocrine therapy and lead to endocrine resistance (248, 249).
Notch, Estrogen Receptor Interactions, and Therapy Sensitivity/
Resistance
It has been suggested that in endocrine-resistant tumors, the ER is not the main 
survival pathway of breast cancer cells. Additionally, ER-targeting treatment resistance 
mechanisms are already in place (250,  251), and these resistance mechanisms show 
potential activating crosstalk with Notch (57). Endocrine resistant breast cancers show 
increased BCSCs numbers (9, 252) with Notch3/4 expression (94, 252, 253). Interestingly, 
in BCSCs paracrine EGFR and Notch signaling (under the influence of estrogen), is capable 
of activating estrogen signaling in ER− BCSCs (253).
Estradiol inhibits the activation of Notch1/4, causing membrane accumulation 
of uncleaved receptors (254), and upon estrogen deprivation or anti-estrogen drugs 
increased Notch signaling was observed (254). Luminal breast cancers with Notch1 
remain hormone responsive (9). Hence, decreasing Notch signaling using GSI in cell lines 
and xenografts resulted in G2 growth arrest (254). Additionally, estrogen deprivation of 
luminal ER+ cells (MCF-7) inhibits tumor growth. Conversely, in the engineered HER2+ MCF-
7 cell line, tamoxifen stimulated growth, even in combination with estrogen deprivation. 
This was accompanied by molecular crosstalk between ER and HER2 (255). Furthermore, 
involvement of the Akt and MAPK pathways were observed, with possible roles for Notch 
in this resistance (59, 256, 257). These experiments indicate that HER2 expression plays an 
important role in endocrine therapy resistance mechanism; however luminal cells are still 
dependent on estrogen receptor activation.
Interestingly, when grown orthotopically, original ER+/PR+/CK5−  tumors showed an 
increased population of ER−/PR−/CK5+ “luminobasal cells,” this population further increased 
when estrogen was withdrawn, revealing receptor conversion when exposed to a new 
environmental niche (9). However, others have stated that this ER−/PR−/CK5+ population 
doesn’t increase over time, is under the influence of progesterone signaling, and is 
capable of surviving extensive ER-targeting (258). Many Notch1 pathway genes were 
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included in this new so-called luminobasal gene signature—involving TWIST1 and SLUG 
upregulation. These luminobasal cells resemble a more TNBC basal-like phenotype (CK5+) 
while retaining their luminal origin, expand (at higher rates) within luminal tumors when 
deprived of estrogen signaling due to their independence of the estrogen receptor, and 
showed sensitivity to Notch1 silencing. These data suggest an important link between 
ovarian endocrine sensitivity (both progesterone and estrogen) and Notch1, and support 
a luminal origin of basal-like cells (9, 258).
Elevated Notch1/3 signaling upregulates IL6 and activates the JAK/STAT pathway, 
however, dependent on p53/IKKa/IKKb status, and through a non-canonical mechanism. 
Furthermore, Notch signaling upregulation resulted in different Notch target genes 
in different molecular subtypes of breast cancer (basal vs. luminal B) (259). This growth 
promoting effect can also be instigated by fibroblasts secreting IL6, in relation with Notch3 
and JAG1 (181). Pioneering research by Sansone et al. showed that Notch3-IL6 signaling 
is under indirect control of hypoxia and that it promotes self-renewal and survival in 
mammary gland stem cells (260, 261). CD133high cells express low levels of ER, but high 
levels of Notch3 (252), are endocrine resistant and promote metastases. This process is 
regulated through IL6-Notch3 signaling (261). IL6 expression could be induced either by 
Tamoxifen or HER2. CD133high expressing cells could be resensitized to endocrine therapy 
through IL6R blockade, which reduced Notch3, STAT3, and CD133. Knockdown of STAT3 
resulted in reduced Notch3 mRNA levels and re-expression of ERα, without changes in 
CD133 expression. Notch3 thus, indirectly, plays an important role in endocrine resistance 
observed in metastatic breast cancer by influencing stem cell behavior (260, 261).
As described earlier fibroblast-derived microvesicles containing oncomiR-221 
promoted  de novo  endocrine resistance—as overexpression of oncomiR-221/222 in 
luminal breast cancer cells reduces ER expression (182). These microvesicles were capable 
of blocking endocrine therapy Notch3 down regulation and causing an estrogen-
independent phenotype in breast cancer cells (96,  262). This was also observed in 
endocrine resistant luminal breast cancers whereby blockage of Notch3 abrogated the 
growth of these ER-resistant cells (262).
Moreover, Notch4 is a crucial mediator of endocrine therapy resistance in models 
of luminal breast cancers (95,  261–263). BCSC induced by endocrine treatment are 
characterized by upregulation of Notch target genes [and additionally induces an EMT 
phenotype (263)], and endocrine resistance in BCSC is driven through JAG1/Notch4 
signaling (95). This could be inhibited through targeting of Notch4 using GSI RO4929097. 
Notch4 inhibition reduced HES1 and HEY1 expression, reversed EMT, decreased CSC 
populations, thereby attenuating proliferation and invasion. Notch4 thus promotes 
estrogen-independent, endocrine therapy resistant growth of breast cancer cell lines 
(95, 263) possibly through a Notch4/STAT3/EMT regulated axis (264). Very recent evidence 
shows that mutations in the ligand binding domain of ERα, which occur in patients and 
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are associated with endocrine therapy resistance, promote a stem-cell-like phenotype 
through activation of Notch4 (265).
Targeted Therapy (HER2)
HER2, a family member of the ERBB transmembrane receptor tyrosine kinases (ERBB1-4 or 
also known as EGFR and HER2-4) is a well-known target in HER2-amplified breast cancer 
therapy for both primary tumors (266, 267) and metastases (268–270). However, it is still 
unclear whether HER2+ cells are truly addicted to oncogenic HER2 signaling as other EGFR 
members can compensate after HER2 blockade (266). Moreover, a single copy of HER2 (in 
the absence of genomic amplification) can elicit an expression signature associated with 
HER2 dependence. Thus, HER2-non-amplified tumors may in some cases benefit from 
HER2 targeted therapy. Yet, such tumors are currently not being selected for treatment 
(267,  271). HER2+  breast cancer is mainly treated with combinations including taxane-
based chemotherapy plus trastuzumab (272), pertuzumab (273), the tyrosine kinase 
inhibitor lapatinib (274, 275), or combinations thereof (266, 276). Many trials have shown 
remarkable response rates (277–281), and therefore HER2-targeted therapy is standard of 
care. However, intrinsic and acquired resistance may still result in relapse and progression 
of HER2+  disease. This resistance can occur on many levels, including activation of the 
downstream signaling pathways, constitutively activated HER2, and crosstalk of HER2 
with other growth factor receptors such as other EGFR-members and IGF (282–285).
HER2 is a direct Notch target gene and bidirectional crosstalk between Notch and 
HER2 has been extensively reviewed (286). Under trastuzumab treatment, Notch activation 
occurs and contributes to trastuzumab resistance (284, 287). Trastuzumab-resistant cells 
(treated with trastuzumab for 6 months) expressed higher levels of Notch pathway genes, 
and this could be reversed by Notch inhibition (siRNA). GSIs decreased proliferation (288). 
In HER2+ xenograft experiments, GSI MK0752 alone did not affect tumor volume, while 
trastuzumab alone caused complete regression of tumors. However, trastuzumab-treated 
tumors recurred in approximately 50% of the cases. When trastuzumab was combined with 
GSI MK0752, complete cures were obtained with no observed recurrences. This suggests 
that the combination trastuzumab/GSI targeted stem-like cells responsible for recurrent 
disease. Notch inhibition resulted in HER2 down regulation (under the influence of Notch/
RBP-jk binding sites in HER2 promotor sequences), followed by decreased mammosphere 
formation (286, 289).
Furthermore, Notch signaling is upregulated after treatment with lapatinib, a clinically 
active small molecule EGFR/HER2 inhibitor. Blockade of HER2 signaling in HER2-dependent 
primary tumor cells led to upregulation of Notch signaling [NICD1, HEY1, and HEY2 (266)]. 
The feedback signaling between these pathways was confirmed by the ability of HER2 to 
represses Notch signaling through HES1 and NRARP. In a HER2-inducible mouse model, 
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Notch1 gain-of-function constructs identified Notch dependency in tumors recurring after 
suppression of HER2 expression in an HER2 inducible mouse model. After HER2 removal, 
the rate of recurrence was much higher in primary tumors that overexpressed NICD1, and 
this could be blocked using GSIs (118). The GSI sensitivity of these tumors suggests that 
other wild-type Notch paralogs (e.g., Notch3) induced by NICD1, may play a role. Moreover, 
a meta-analysis (17 studies, including 4,463 patients) revealed increased Notch activity in 
a subset of breast cancers associated with poor clinical outcomes (including basal-like 
tumors). These data suggest that Notch is positively associated with tumor recurrence in 
breast cancer patients and implicate that Notch targeting might prevent recurrent disease 
by targeting the dormant residual tumor cells.
Interestingly, HER2 expression can be heterogeneous both in bulk tumor cells 
(290) and BCSCs (291), and shows plasticity (291). ER+/HER2−  and TNBC acquire a 
HER2+  subpopulation following therapy exposure (267,  291). Cultured BCSCs from ER+/
HER2−  patients retained HER2+/−  subpopulations and switching between these HER2 
states is dependent on environmental stimuli (291). Notch was inversely correlated with 
HER2 expression and HER2− cells were sensitive to Notch inhibition. HER2+ cells showed 
higher proliferation but were not addicted to HER2 oncogenic signaling. Following these 
sub-profiles, a proliferative state/niche favored the HER2+ phenotype, whereas oxidative 
stress or chemotherapy selected for, or initiated transition to, HER2− BCSCs. Thus, Notch 
might mediate a protective mechanism by functioning in the switch between proliferative 
and survival-prone phenotypes of HER2+/− BCSCs.
Besides a direct link between Notch and HER2, Notch also interacts with downstream 
or parallel HER2 signaling pathways. Co-suppressing the activation of these pathways upon 
resistance (267) might bypass these resistance mechanisms. Alternative mechanisms to 
activate signaling pathways such as PI3K/AKT and/or MAPK can be triggered in response 
to trastuzumab or through constitutive activation of HER2. These pathways may mediate 
treatment resistance in selected clones. The communication between Notch and PI3k/
AKT has been shown extensively in hematological cancers (59, 292) and to lesser extent 
in breast cancer (293). Bidirectional MAPK-Notch interactions have been described 
(256, 257). Additionally, when the HER2 receptor is inhibited, signaling might still occur 
due to dimerization with IGF1-R (285) and Notch interaction (294), possibly resulting in 
therapy resistance.
Discussion, Conclusion, and Future Perspectives
There is overwhelming evidence for a role of the Notch signaling pathway in breast 
cancer development and progression through upregulation of Notch receptors, ligands, 
and regulators. Overall, high Notch pathway activity is associated with more aggressive 
disease and poor outcomes. Only a limited number of breast cancers harbor Notch gain of 
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function mutations, but in many breast cancers Notch is expressed, active, and crosstalks 
with other oncogenic pathways. Further, many studies support an important role for 
Notch in the response to radiation, chemotherapy, hormonal therapy, and targeted 
therapies. Importantly, there is compelling evidence that treatment-resistant breast 
cancer and other malignancies can be resensitized by Notch inhibition (77, 78, 295–297). 
Taken together, this provides a strong rationale for studies combining Notch inhibitors 
with current breast cancer treatment modalities.
However, an important and complicating feature of Notch signaling is its receptor-
ligand specific and context dependent signaling in different cancer subtypes. Furthermore, 
the optimal timing to initiate treatment to achieve therapeutic efficacy must be carefully 
considered. In treatment-naïve tumors, Notch activation might not become clinically 
evident until treatment initiation, as a resistance mechanism triggered by treatment, or 
after occurrence of metastases with different mutational profiles compared to primary 
tumors (4). Selecting patients most likely to benefit from Notch inhibition will require 
molecular profiling and screening to show possible co-targeting options (298). The 
identification of predictive biomarkers is of paramount importance.
In this review, we have highlighted several opportunities for Notch targeting in the 
context of first line breast cancer treatment and resistance. Additionally, we have discussed 
its extensive communication with many other pathways (59, 256, 257, 292, 293), its role in 
recurrent disease and involvement in the metastatic process (103, 134, 136, 145), and its 
association with clinically relevant hallmarks in breast cancer (69).
Research in the past decade has focused on preventing or treating tumor recurrence 
by targeting CSCs. Multiple different stem-like cell populations have been proposed 
within tumors, based on the expression of CD44high/CD24−, ALDH+, CD133, CD29high/
CD61+, CD49f+, and CD90 (299–302). These cells showed increased levels of therapy 
resistance and distinctive gene expression patterns, irrespective of their potential 
origin (e.g., from transformation of mammary stem cells or from de-differentiation 
of non-stem-like tumor cells)—as stem cell plasticity occurs within tumors (32,  303). 
Notch signaling plays an important role in mammary stem cells as well as breast cancer 
stem cells (BCSCs) (84,  92,  304)—well documented for triple-negative breast cancer 
(94, 109, 153, 244, 253, 304–307). Furthermore, Notch4 has been shown to maintain the 
BCSC population (94, 307). Notch-PTEN signaling is important in the expansion of these 
stem-like cells (98, 308). PTEN/PIK3CA mutations are often observed in breast cancer and 
loss of PTEN decreases radiation sensitivity (309). In the future, combining radiotherapy 
and small molecule targeting in BCSC may improve the efficacy of radiation therapy and 
forestall radiation resistance. However, the timing and sequencing of treatments should be 
carefully optimized in order to achieve maximum efficacy. Radiotherapy dose scheduling 
might be easily adapted from the current schedule standards (310–312).
The effects of chemo-, radio- and targeted therapy on Notch signaling require further 
investigation. Observations have been made for Notch and tumor vascularization under 
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the influence of both anthracycline and taxane-based chemotherapy (313). Taxane 
(paclitaxel) therapy resistance coincides with the development of metastatic bone lesions, 
preventable by targeting JAG1 in osteoblasts (242).
BCSCs in ER+ tumors show responsiveness to hormone signaling/targeting despite 
often lacking ER and PR (244,  245). This may be mediated by paracrine crosstalk 
with ER+/PR+  bulk tumor cells. Many endocrine therapy resistance mechanisms have 
been revealed (314–317). This has guided research toward the development of new 
therapeutic regimens (318), such as CDK4/6 inhibitors (319)—which have been clinically 
implemented. Notch inhibition could play a significant role in combinations targeting 
these resistance mechanisms. For instance, Notch inhibition could reverse ER-targeted-
treatment resistance and improve the efficacy of CDK4/6 inhibitors through decreasing 
Cyclin-D1 (121).
Notch has been shown to crosstalk with the HER2 receptor (289) and development 
of breast cancer metastases is affected by HER2 (268–270, 320) and progesterone (268). 
Interestingly, plasticity of HER2 expression has been observed in circulating tumor cells—
with a distinctive role for Notch1 (291). Thus, Notch is involved in the heterogeneity and 
plasticity observed in HER2−/+ breast cancer, and the development of distant metastases. 
Combining CDK4/6 inhibitors (321,  322) and Notch inhibitors, it may be possible to 
simultaneously attenuate two main drivers in breast cancer, HER2 and Cyclin-D, promoting 
local control and preventing distant relapse.
A step forward, for individualized patient care, could be the use of patient-
representative culture models, such as organoids, to capture information on individual 
tumor drug sensitivity ex-vivo (323). In general, organoids can provide rapid insight into 
individual treatment combinations and relationships between Notch signaling and breast 
cancer treatment (resistance), before the start of treatment. These models more closely 
represent individual tumors, and may enable us to rationally investigate the context-
dependence of Notch signaling in each tumor. Breast cancer organoids have recently 
been developed, but to what extent they will be strong predictors of treatment response 
and their use as prospective platforms for individualized precision treatment remains to 
be established (324).
This review summarizes the evidence supporting the hypothesis that targeting 
Notch could a promising option in re-sensitizing breast cancer to current standard of 
care treatments (Figure 3). When biomarker quantification and patient stratification allow 
Notch targeting to live up to its potential, this strategy may be applicable to other cancers 
as well, targeted with concurrent chemo-radiation or targeted inactivation of other 
growth promoting pathways. However, clinical evidence in solid tumors showed that 
therapy timing is highly important to reach maximum effectivity (325). Thus, additional 
clinical and translational research will be required to determine the exact role of Notch 
in each disease- and treatment-specific context and fine-tune the use of Notch targeting 
agents to prevent or treat or acquired resistance. With the benefit of sufficient mechanistic 
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knowledge, we propose that in some cancer patients targeting Notch can be a major part 
of an effective strategy to address therapy resistance.
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Intratumoural hypoxia is a common characteristic of malignant treatment-resistant 
cancers. However, hypoxia-modification strategies for the clinic remain elusive. To 
date, little is known on the behaviour of individual hypoxic tumour cells in their 
microenvironment. To explore this issue in a spatial and temporally controlled 
manner, we developed a genetically encoded sensor by fusing the O2-labile 
hypoxia-inducible factor 1α (HIF-1α) protein to eGFP and a tamoxifen-regulated Cre 
recombinase. Under normoxic conditions, HIF-1α is degraded but, under hypoxia, 
the HIF-1α-GFP-Cre-ERT2 fusion protein is stabilised and in the presence of tamoxifen 
activates a tdTomato reporter gene that is constitutively expressed in hypoxic 
progeny. We visualise the random distribution of hypoxic tumour cells from hypoxic 
or necrotic regions and vascularised areas using immunofluorescence and intravital 
microscopy. Once tdTomato expression is induced, it is stable for at least 4 weeks. 
Using this system, we could show  in vivo  that the post-hypoxic cells were more 
proliferative than non-labelled cells. Our results demonstrate that single-cell lineage 
tracing of hypoxic tumour cells can allow visualisation of their behaviour in living 
tumours using intravital microscopy. This tool should prove valuable for the study of 
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Introduction
Many solid tumours contain areas of hypoxia, which is the result of O2 demand (rapid 
proliferation) exceeding O2 supply (aberrant vasculature) (Thomlinson and Gray, 1955; 
Brahimi-Horn, Chiche and Pouysségur, 2007). Due to limits on O2 diffusion from the blood 
vessels, tumours experience chronic hypoxia and necrosis in regions distant from the 
vasculature. Acute or cycling hypoxia also occurs in tumours due to temporary occlusion 
of blood vessels obstructing perfusion leading to areas of hypoxia, which become 
re-oxygenated when the obstruction is relieved (Dewhirst, 2009; Salem et al., 2018). 
Tumour hypoxia is strongly associated with a worse outcome in many different cancers 
irrespective of treatment (Vaupel and Mayer, 2007) and tumour hypoxia is a direct factor 
in resistance to some chemotherapy and radiation therapy. Direct O2 measurements in 
clinical studies using oxygen needle electrodes indicate hypoxia is strongly associated 
with local regional control in head and neck squamous cell carcinoma (Nordsmark et al., 
2005), prostate (Milosevic et al., 2012) and cervix (Fyles et al., 1998) cancer patients treated 
with radiotherapy. Hypoxia imaging using PET tracers such as 18F-Hx4,18F-MISO, and 
18F-FAZA have demonstrated strong associations of tracer uptake with outcome (Lehtiö et 
al., 2004; Dubois et al., 2011; Fleming et al., 2015).
The main adaptive response to hypoxia is the stabilisation of the oxygen regulated 
hypoxia inducible factor alpha (HIF-α) proteins HIF-1α HIF-2α and HIF-3α. HIF-α proteins 
are predominantly regulated post-translationally through oxygen dependent prolyl and 
asparagine hydroxylases, which hydroxylate specific proline and asparagine residues on 
the HIF-α oxygen dependent degradation (ODD) domain. Hydroxylation of asparagine 
inhibits the recruitment of the transcriptional regulator p300. Prolyl hydroxylation 
promotes interaction with the von Hippel-Lindau (pVHL) protein, which recruits an E3 
ubiquitin ligase, targeting HIF-α for proteasomal degradation (Ivan et al., 2001). Under 
hypoxic conditions, the activity of prolyl and asparagine hydroxylases is attenuated 
leading to accumulation of HIF-α proteins. HIF-α then translocates to the nucleus where 
it binds the constitutively expressed HIF-1β protein and the co-activator p300. The HIF 
transcriptional complex is known to trans-activate over 1,500 target genes through 
binding to hypoxia response elements (HREs) located in the target genes or flanking 
sequences (Prabhakar and Semenza, 2015). HIF target genes play a role in a broad range 
of pathways including those involved in angiogenesis (VEGF), metabolism (GLUT-1), cell 
proliferation (TGF-α), cell adhesion (MIC2), pH regulation (CAIX) and cell survival (TGF-α) 
among others (Jubb, Buffa and Harris, 2010; Wilson and Hay, 2011; Muz et al., 2015; LaGory 
and Giaccia, 2016). It has long been known that the concentration of oxygen within 
the tumour correlates with the efficacy of radiotherapy (Gray et al., 1953). HIF-α can be 
stabilised in relatively mild hypoxia however much more severe hypoxia plays a larger 
role in radiotherapy resistance due to the decreased effectiveness of radiotherapy at these 
very low oxygen conditions. Even so, hypoxia and higher levels of HIF are associated with, 
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and their presence also correlates with more aggressive tumours, therapy resistance, 
immunosuppression, metastasis, and poor prognosis (LaGory and Giaccia, 2016). Elevated 
HIF-1α and HIF-2α levels have also been shown to be associated with poor prognosis in a 
number of cancers (Giatromanolaki et al., 2001; Ioannou et al., 2009; Zheng et al., 2013; Ren 
et al., 2016; Roig et al., 2018). 
Because of its strong correlation with adverse patient outcome, hypoxic modification 
in tumours has been an area of intense basic and translational research and drug 
development. A systematic review of 10,108 patients across 86 trials that were designed to 
modify tumour hypoxia in patients that received primary radiotherapy alone showed that 
overall modification of tumour hypoxia significantly improved the effect of radiotherapy 
but had no effect on metastasis (Overgaard, 2007). 
Accelerated radiotherapy with carbogen and nicotinamide (ARCON) which increases 
tumour oxygenation to improve radiotherapy treatment has shown limited success in a 
Phase III clinical trial. ARCON with improved 5 year regional control specifically in patients 
with hypoxic tumours, however, no improvement in disease free or overall survival was 
found (Janssens et al., 2012).
The hypoxia activated pro-drug Evofosfamide was studied in a Phase III clinical trial. 
Evofosfamide improved progression free survival as well as higher objective response 
rate, however the trial failed as the primary endpoint (overall survival time) was not 
significantly improved (Van Cutsem et al., 2016). Unfortunately, while a few clinical trials 
have been successful, many hypoxia modification or targeting trials have failed because of 
underpowered studies and  the lack of hypoxia biomarkers to stratify responders among 
others (Spiegelberg et al., 2019).
Although many of the molecular mechanisms of how cells respond to hypoxia are 
known, how the hypoxic cells may contribute to poor prognosis is still poorly understood. 
It is known that hypoxic cells are more resistant to treatment and more likely to disseminate 
and develop into metastases (Harada et al., 2012; Muz et al., 2015; Godet et al., 2019). 
However, a direct demonstration of the cell autonomous phenotypes of hypoxic tumour 
cells within the primary tumour and their interplay with the tumour microenvironment 
remains understudied.
Using the ODD domain of the HIF-1α protein as an oxygen sensor fused to a tamoxifen 
inducible CreERT2 recombinase, Harada and colleagues elegantly used lineage tracing of 
hypoxic cells and their progeny in colon carcinoma xenografts (Harada et al., 2012). They 
showed that hypoxic cells were able to survive irradiation and formed a large proportion 
of the recurrent tumour after 25 Gy irradiation. High HIF-1 activity was also found in cells 
that experience radiation-induced re-oxygenation. HIF-1 positive cells after irradiation 
induced re-oxygenation also translocated towards blood vessels and this translocation 
was suppressed by HIF inhibitors. Godet et al. recently showed through an alternative 
hypoxia lineage tracing system, that post-hypoxic tumour cells in mice maintain a ROS-
resistant phenotype. This provides a survival advantage in the blood stream therefore 
4
A lineage-tracing tool to map the fate of hypoxic tumour cells
119
promoting their ability to form distant metastases (Godet et al., 2019). One limitation of 
the aforementioned systems is the relatively long time in continuous hypoxia needed 
before labelling of cells was achieved, limiting the systems predominantly to areas of 
sustained chronic hypoxia. These studies also did not visualise individual hypoxic tumour 
cells within the tumour microenvironment. 
In this present study we developed an alternative approach to lineage trace the fate 
of hypoxic tumour cells that directly reports HIF-1α stabilization rather than the hypoxia 
transcriptional response. The continuous expression of the system we created allows 
identification of cells experiencing acute as well as chronic hypoxia and is achieved 
through a genetically encoded hypoxia sensor composed of a GFP-tagged HIF-ODD-GFP-
CreERT2 fusion protein herein known as MARCer. Once HIF-1α is stabilised the addition of 
tamoxifen leads to the Cre-mediated activation of a ubiquitously expressed tdTomato, 
labelling hypoxic cells and their progeny. These fluorescent markers enabled intravital 
imaging using window chambers (Kedrin et al., 2008), tracing the fate of hypoxic tumour 
cells at the single cell level within the primary tumour.
Results
Hypoxia induces eGFP and tdTomato expression in HIF-MARCer reporter 
cells
To establish a HIF-cell-tracing method (HIF-MARCer) amenable for  in vivo  hypoxia 
imaging, H1299 non-small cell lung carcinoma cells were transduced with HIF-1α-eGFP-
CreERT2 complementary DNA (cDNA) (MARCer fusion protein) expression vector and with 
a loxP-flanked STOP tdTomato cassette (H1299-MR cells;  Fig.  1A). Thus, under hypoxia, 
the tamoxifen-regulated HIF-Cre fusion protein will excise the STOP cassette leading 
to tdTomato expression, which will persist under normoxia. To test this system, H1299-
MARCer cells were exposed to hypoxia (0.2% O2) or deferoxamine mesylate (DFO; a 
hypoxia mimetic)  in vitro, resulting in induction of eGFP and HIF-1α protein expression, 
which was degraded within minutes after re-exposure to normoxia and corresponded 
with the levels of the endogenous HIF-1α protein (Fig. 1B,C).
H1299-MR cells were also cultured under hypoxia in the presence of 4-hydroxytamoxifen 
(4-OHT) (Fig. 1D; Fig. S1B), and eGFP and tdTomato expression were measured by flow 
cytometry (Fig.  1C-F). Hypoxia (0.1% O2) induced the expression of eGFP from 6 h of 
treatment onwards (Fig.  S1A,C,E). MARCer stabilisation is visualised through eGFP 
expression after 24 h exposure to hypoxia (0.2%, Fig. 1C) and cytoplasmic distribution of 
eGFP after treatment with DFO is visualised in Fig. S1D. tdTomato expression was not visible 
immediately after exposure to hypoxia and was therefore assessed after re-oxygenation 
for up to 24 h, and until then tdTomato expression kept increasing, whereas eGFP rapidly 
decreased upon re-oxygenation (Fig. 1D,F; Fig. S1B). In the absence of 4-OHT, tdTomato 
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expression was not induced (Fig. S1C,F). The HIF-1 target gene VEGF was induced by 0.2% 
hypoxia and 4-OHT only slightly further induced these levels (Fig. S1E).
Figure1: H1299-MARCer reporter (H1299-MR) cells were created. 
(A) Constructs used for transduction of H1299 cells. (B) Western blot analysis of HIF-1α-MARCer 
and endogenous HIF-1α (HIF-1α-E) after exposure of H1299-MARCer cells to hypoxia (0.2% O2)  in 
vitro  and re-oxygenation. Lamin A was used as a loading control and the HIF-stabilising agent 
DFO was used as a positive control. (C,D) Fluorescence-activated cell sorting (FACS) plots of eGFP 
and tdTomato expression after exposure to hypoxia (0.1% O2) for 24 h (C, left) and 24 h of hypoxia 
followed by 24 h of re-oxygenation (D, left). Representative images of MARCer stabilisation via eGFP 
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taken after 24 h exposure to hypoxia (0.2% O2) (C, right) and after a further 24 h of re-oxygenation 
of tdTomato expression (D, right) are also shown. Scale bars: 200 µm. (E) Flow cytometric analysis 
of eGFP and tdTomato expression after exposure to increasing times of hypoxia (0.1% O2) in the 
presence of 4-hydroxytamoxifen (4-OHT). Time point ‘0’ is showing cells cultured under normoxia in 
the presence of 4-OHT for 24 h. Dots represent independent experiments carried out in duplicate 
and coloured bars indicate averages. ##P<0.01 indicates a difference in tdTomato expression between 
no hypoxia and 2 h, and ###P<0.001 shows the difference in tdTomato expression for 0 versus 4, 6, 
and 24 h. *P<0.05 and **P<0.01 show a difference for eGFP expression as indicated, and ***P<0.001 
indicates a significantly higher eGFP expression after 24 h compared to 0, 2 and 4 h, as calculated by 
one-way ANOVA followed by Bonferroni’s multiple comparison. (F) Flow cytometric analysis of eGFP 
and tdTomato expression after exposure to 24 h hypoxia (0.1% O2) followed by increasing times of 
re-oxygenation. It should be noted that time point ‘0’ is showing the same data presented in E as 
24 h. Dots represent independent experiments carried out in duplicate and coloured bars indicate 
averages.
Once tdTomato expression was induced, it was stably expressed in H1299-MR cells 
under normoxic conditions in the absence of 4-OHT for up to at least 4 weeks (Fig. S1F). 
When tdTomato+ cells were re-exposed to hypoxia, tdTomato expression remained stable 
(Fig. S1G); however, the fluorescence intensity gradually and significantly declined over 
time (Fig. S1H).
We conclude that the HIF MARCer allele reliably reports on endogenous hypoxia and 
HIF activity, and only slightly increases the HIF transcriptional response when 4-OHT is 
present. By stably inducing tdTomato expression upon administration of tamoxifen we 
created a reliable tracer of cells exposed to hypoxia with little background fluorescence.
A single administration of tamoxifen induces tdTomato expression in 
H1299-MR xenografts
H1299-MR cells were injected subcutaneously into the flank of female Balb/c nude mice to 
grow as xenografts. Once tumour size reached ~100 mm3, tamoxifen was administered by 
oral gavage and eGFP and tdTomato expression were assessed by flow cytometry 2 days 
later (Fig.  2A). eGFP expression could not be detected as this is rapidly degraded after 
exposure to oxygen (Fig. 1B,F) during sample processing. tdTomato was induced by both 
5 mg and 10 mg tamoxifen, and 10 mg was used in further experiments as expression 
appeared more robust (Fig.  2A). tdTomato expression was followed over time and 
significantly induced from 5 days after tamoxifen administration onwards and expression 
did not significantly increase beyond 5 days (Fig. 2B).
Chapter 4
122
Figure 2: eGFP and tdTomato expression and quantification of immunofluorescent staining of 
H1299-MR xenografts. 
(A) One single administration of tamoxifen by oral gavage induced tdTomato expression in 
H1299-MR xenografts as measured by flow cytometry 2 days after administration. Dots represent 
individual mice and bars indicate averages. (B) From 5 days after administration of 10 mg tamoxifen, 
tdTomato expression was significantly induced. ###P<0.001 compared to no tamoxifen, ***P<0.001 
as determined by one-way ANOVA and Bonferroni’s multiple comparison. (C) Micrograph of EF5 
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Scale bar: 30 µm. (D) EF5 quantification showing hypoxic area as a percentage of total tumour area. 
(E) Distance of tdTomato+ cells to EF5+ areas normalised to all cells (Hoechst; Fig. S2C). (F) Cells inside 
hypoxic areas as a percentage of all cells or tdTomato+ cells. (G) CD31 staining showing vessel density 
as a percentage of total tumour area. (H) Distance of tdTomato+ to CD31+ areas normalised to all 
cells (Hoechst; Fig. S2D). For staining (D-H), one to five sections per tumour, separated by ~1 mm, 
were analysed and the average was indicated by the dots, whereas the bars indicate the average of 
all mice in the group. TAM, tamoxifen.
tdTomato expression does not significantly correlate with severe hypoxia
To assess whether expression of tdTomato correlated with the extent of hypoxia and 
vascularisation, we stained frozen tumour sections for EF5 (an exogenous hypoxia marker) 
(Fig. 2C; Fig. S2A) and CD31 (PECAM1) (Fig. S2B). The EF5+ area did not change over time 
(Fig.  2D) and did not significantly correlate with tumour size as assessed by a Pearson 
correlation test on all time points combined (Fig.  S3A). EF5+  areas were located both 
in proximity to and more distant from necrotic areas (Fig. 2C; Fig. S2A). The distance of 
tdTomato+ cells to EF5+ regions was not different from the general population, nor did it 
change over time (Fig. 2E; Fig. S2C). tdTomato+ cells were also equally likely to be inside an 
EF5+ area as the total cell population (Fig. 2F). From these results we conclude that post-
hypoxic cells are not more likely to reside in hypoxic areas than other tumour cells. Also, 
the number of tdTomato+ cells did not correlate with the EF5+ area for any of the assessed 
time points (Fig.  S3B). Finally, eGFP+  cells were occasionally visible (Fig.  2C;  Fig.  S2A,B). 
Quantification of eGFP expression appeared impossible due to high autofluorescence of 
necrotic areas (Fig. 2C, dashed line), and staining for GFP protein did not clearly improve 
eGFP+ cell detectability (not shown).
Tumour sections were stained for CD31 (Fig. S2B) and the percentage of the tumour 
area covered by vessels was determined. The percentage of vessel area did not change 
over time (Fig.  2G), nor did the closest distance of each of the tdTomato+  cells or of 
all cells to the nearest vessel (Fig.  2H;  Fig  S2D). Surprisingly, the total areas of EF5 and 
CD31 positivity did not significantly correlate (Pearson correlation test on all time points 
combined, Fig. S3C), as we would expect a larger EF5+ area to correlate with a lower vessel 
density and therefore the CD31 area. This could be due to areas of increased oxygen 
demand, limited perfusion or vessel leakiness, in addition to cycling hypoxia.
RFP staining and tdTomato fluorescence show a similar expression 
pattern after administration of tamoxifen
Tumour sections were stained using antibodies against RFP by immunofluorescence 
in order to detect the tdTomato protein (Fig.  S4). More RFP+  cells were detected by 
immunofluorescence than by imaging intrinsic tdTomato, indicating that not all 
tdTomato+  cells are detected by direct fluorescence (Fig.  3A). However, tdTomato 
fluorescence and RFP immunofluorescence showed a strong correlation (Fig.  3B) and 
the same expression pattern after tamoxifen (Fig.  3A), a trend that was also similar to 
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tdTomato detection by flow cytometry (Fig. 3C). With imaging on consecutive sections, 
tdTomato+ and RFP+ cells were equally likely to be detected inside or outside EF5+ areas 
(Fig. 3D). Therefore, even though not all tdTomato cells can be detected with a certain 
method, this should not introduce bias with regard to lineage tracing of hypoxic cells.
Figure 3: Immunofluorescent staining of H1299-MR xenografts. 
(A) Quantification of RFP staining showing that more tdTomato+ cells can be detected after staining 
than when only intrinsic tdTomato was imaged by epifluorescence microscopy. Dots represent the 
average of one to five sections per tumour, separated by ~1 mm. ***P<0.001 as determined by two-
way ANOVA followed by Bonferroni’s multiple comparison. (B) RFP staining and intrinsic tdTomato 
on frozen sections significantly correlate. (C) RFP staining and intrinsic tdTomato significantly 
correlate with tdTomato cells measured by flow cytometry. (D) Micrographs of consecutive sections 
showing that CD31 staining (left) and RFP staining (right) do not show a clear correlation with EF5 
staining (middle). Scale bars: 500 µm (top row), 50 µm (bottom row). TAM, tamoxifen.
Post-hypoxic H1299-MR cells proliferate faster than non-hypoxic tumour 
cells
Next, we assessed the fate of the tdTomato+  post-hypoxic tumour cells. 5-Ethynyl-2’-
deoxyuridine (EdU) was administered to mice 3 h before sacrifice, and proliferation in 
xenografts was measured by flow cytometric analysis of EdU incorporation. At all measured 
time points, tdTomato+  cells proliferated faster than tdTomato–  cells, comprising both 
non-hypoxic tumour cells and host cells within the tumour microenvironment (Fig. 4A). 
This was confirmed by immunofluorescent staining of EdU on 4% paraformaldehyde 
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is not significantly higher in tdTomato cells than in all cells. When tumour cells were gated 
separately from host cells using a human-nuclei-specific antibody (Fig. 4C), tdTomato+ cells 
also proliferated faster than tdTomato− cells (Fig. 4D). These results indicate that tumour 
cells that were exposed to hypoxia proliferate faster than tumour cells that were not.
Figure 4: Post-hypoxic H1299-MR cells proliferate faster than non-hypoxic tumour cells. 
(A,B) EdU assay showing that tdTomato+  cells proliferated faster than the tdTomato−  population 
as measured by flow cytometry (A) and immunofluorescence (B). (C) Gating strategy of EdU 
incorporation in tdTomato−  and tdTomato+  human cells (RL1-A+). (D) EdU proliferation assay 
showing that tdTomato+  human cells proliferated faster than the tdTomato−  human cells. Dots 
represent individual mice and paired observations were connected with a line. n.s., non-significant; 
*P<0.05, **P<0.01, ***P<0.001 as determined by two-way ANOVA followed by Bonferroni’s multiple 
comparison. TAM, tamoxifen.
Increased proliferation of post-hypoxic H1299-MR tumour cells is a non-
cell-autonomous feature
To address whether the increased proliferation was a cell-autonomous acquired and 
stable feature of post-hypoxic tumour cells, H1299-MR xenografts were excised at 
5-17 days after administration of tamoxifen and single-cell suspensions were cultured ex 
vivo. Antibiotic selection enriched for tumour cells and the percentage of tdTomato+ cells 
in culture increased initially, after which it stabilised (Fig. 5A). EdU incorporation showed 
that tdTomato+ and tdTomato– cells proliferated at the same rate at all passages (Fig. 5B). 
H1299-MR cells were also incubated at 21% and 0.2% O2  with 200 nm 4-OHT for 24 h, 
mixed in a 1:1 ratio and grown in Dulbecco’s modified Eagle medium (DMEM) containing 









































































1% foetal bovine serum (FBS). Approximately 20-30% of the cells were tdTomato+  and 
expression did not change as measured by flow cytometry after 3 and 15 days, indicating 
that proliferation of tdTomato+  and tdTomato–  cells was similar  in vitro  (Fig.  5C). These 
results show that tumour cells previously exposed to hypoxia  in vivo do not proliferate 
faster ex vivo, and that the observed increased proliferation of post-hypoxic tumour cells 
is influenced by factors in the tumour microenvironment.
Figure 5: Post-hypoxic tumour cells and non-hypoxic cells proliferate at similar rates  ex 
vivo and in vitro. 
(A,B) Cells isolated from H1299-MR xenografts were cultured ex vivo under geneticin and blasticidin 
selection. Individual tumours were depicted and connected with a line. (A) tdTomato expression 
initially increased and stabilised after several cultured passages as measured by flow cytometry. (B) 
In ex vivo culture, tdTomato+ and tdTomato− cells proliferate similarly, as shown by EdU incorporation 
measured by flow cytometry. (C) H1299-MR cells were incubated at 21% and 0.2% O2 with 200 nm 
4-OHT for 24 h before being mixed in a 1:1 ratio and grown in DMEM containing 1% FBS. tdTomato 
expression was then analysed and proved similar after 3 and 15 days.
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Figure 6: H1299-MR xenografts visualised using intravital microscopy. 
(A) 3D maximum-intensity projection (left) and one slice of the same tumour (right) imaged 4 days 
after administration of tamoxifen. Perfused vessels are shown in purple, eGFP+  cells in green, 
tdTomato+ cells in red and collagen in cyan (second harmonic generation microscopy, right panel 









































tdTomato channel and tdTomato bleed through into the Qtracker 705 channel. Scale bars: 500 µm 
(B) Vessel segmentation (grey) and tdTomato+ cells shown in the colour spectrum, indicating the 
distance to perfused vessels (0 µm in purple to 151 µm in red). Scale bars: 500 µm (left) and 50 µm 
(right). (C) Perfused vessel volume as a percentage of total tumour volume in four mice followed 
over time. TAM, tamoxifen.
Intravital imaging visualises hypoxic cell tracing at the single-cell level in 
xenografts
Next, we used intravital microscopy to identify hypoxia lineage tracing in vivo in xenograft 
tumours. H1299-MR xenografts were covered by an imaging window to allow intravital 
imaging by multiphoton microscopy and tumours were followed for up to 18 days 
after administration of tamoxifen (Fig.  S6). FITC-Dextran or qTracker 705 were injected 
intravenously and tumours were imaged for vessel perfusion, eGFP and tdTomato, and by 
second harmonic generation microscopy (Fig. 6A; Fig. S6A-D). Fig. 6A shows an example 
of a tumour imaged 4 days after administration of tamoxifen and other time points 
are shown in  Fig.  S6D. tdTomato was not observed before administration of tamoxifen 
(Fig.  S6B-D). Occasionally eGFP+  cells were observed (Fig.  6A, arrows). These results 
demonstrate that we were able to track post-hypoxic tumour cells in a spatiotemporal 
manner using intravital microscopy.
To assess tumour perfusion, we injected qTracker 705 and segmented and 
reconstructed the vessels with Imaris (Fig. 6B). The colour spectrum indicates the distance 
of tdTomato+  cells to perfused vessels. The median distance of tdTomato+  spots in this 
tumour was 27.4 µm, with a distribution of 0-151 µm. These results indicate that tdTomato 
cells were located in proximity to, as well as further away from, the vessels (Fig. 6B, right); 
however, this was not normally distributed. Cells were more likely to be close to a vessel, 
with 50% of the cells being within 27.4 µm of a vessel in the displayed tumour and an 
average of 35.5 µm for all tumours (not shown). Purple cells (Fig. 6B, right) with a distance 
of 0 µm from a vessel appeared to be touching the vessel, rather than circulating inside it. 
Total vessel perfusion was calculated from the segmented vessels and remained constant 
over time in two of the four mice (Fig. 6C, curve A and B, corresponding to mice represented 
in Fig. S6A,B), whereas vessel volume decreased in mouse C and D (Fig. S6C,D). Overall, 
tumours seemed well perfused, which is in line with total vessel area as shown by CD31 
staining (Fig. 2G).
Discussion
Here, we describe a novel system to lineage trace hypoxic cells. We show that the system 
is robust  in vitro  with hypoxia-regulated eGFP expression and constitutive tdTomato 
labelling upon addition of tamoxifen in the progeny of these hypoxic tumour cells. 
We also see that the MARCer reporter system does not interfere with endogenous 
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HIF-1α protein expression and the transcription of the HIF target gene  VEGF, and this 
expression is only mildly affected by tamoxifen and only during the short period of 
tamoxifen administration.  In vivo, tdTomato expression was induced; however, the 
amount of expression or the distribution did not correlate with EF5 positivity at any of the 
investigated time points. Intravital imaging showed that the tumours were well perfused, 
which is supported by the regular distribution of vessels throughout the tumour and the 
lack of correlation between vessels and EF5+  areas, as shown by immunofluorescence, 
suggesting also alternative mechanisms of HIF stabilisation.
With the H1299-MR model,  in vitro  exposure to hypoxia induced eGFP expression. 
However, eGFP was barely detectable in vivo with our microscopy systems However, given 
the clear presence of hypoxic areas as shown by EF5 staining, lack of HIF-1α – and thus 
eGFP – seems unlikely. This is likely to be due to the requirement of O2 for GFP folding and 
fluorescence (Heim et al., 1994; Kumagai et al., 2013), making it a suboptimal fluorescent 
marker to track current hypoxia. On the other hand, Godet et al. were able to visualise 
GFP under 0.5% O2 (Godet et al. 2019). Also, processing of the samples exposes them 
to atmospheric oxygen, possibly introducing enough oxygen for GFP maturation  ex 
vivo. Despite these limitations we were able to detect eGFP in H1299-MR xenografts using 
immunofluorescence and intravital microscopy.
Whether limited eGFP expression in our model is related to lack of expression or lack 
of visibility requires further investigation. An alternative approach could be to replace 
eGFP with fluorescent proteins not requiring oxygen such as UnaG (Kumagai et al., 2013). 
Possibly, eGFP expression is truly low in the currently studied tissues, which could be due 
to the length of time the cells are exposed to cycling hypoxia, not allowing enough time 
for sufficient MARCer accumulation before re-oxygenation and MARCer degradation. 
This is supported by our current finding that the amount of EF5 expressed in the tissue 
does not correlate with the number of tdTomato+ cells found in the tissue. An alternative 
explanation is that H1299 NSCLC cells express high levels of ROS, a potent activator of HIF-
1α (Jung et al., 2008; Lee et al., 2010). Activation of HIF via ROS could partially explain the 
lack of overlap and correlation between EF5, HIF-eGFP and tdTomato labelling.
Surprisingly, neither the fraction of tdTomato+ cells and extent of EF5, nor the distance 
of those cells to EF5 correlated significantly, indicating that post-hypoxic tumour cells are 
randomly distributed with regard to the current hypoxic status of the tumour. This may 
be due to the dynamic nature of hypoxia in tumours and the time of assessment, i.e. the 
time after which the labelled cells were exposed to hypoxia, at least 48 h after tamoxifen 
administration. Because the MARCer construct is constitutively expressed, short episodes 
of hypoxia could induce labelling, but this might not be seen in proximity to EF5 due to re-
oxygenation between the time tamoxifen was given and injection of EF5. Other research 
has also shown that hypoxic cells move out of hypoxic EF5+ or pimonidazole+ areas (Harada 
et al., 2012;  Erapaneedi et al., 2016;  Conway et al., 2018;  Godet et al., 2019), followed 
by random distribution. The transient nature of the hypoxic state may explain that the 
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induction of tdTomato expression does not correlate with the level of acute hypoxia 2, 5, 
9, 16 or 21 days later. One way to further investigate this would be through the use of a 
second marker of hypoxia, given together with tamoxifen. This would allow visualisation 
of the hypoxia dynamics and see the change in hypoxia between labelling and endpoint. 
Taken together, EF5 reports on chronic severe hypoxia and anoxia, whereas HIF labelling 
captures also transient tumour hypoxia at moderate O2 levels. It also seems evident that 
many cells that have previously been exposed to hypoxia have redistributed to much less 
hypoxic regions.
In preliminary results with this system, it was apparent that a greater proportion of 
post-hypoxic cells tdTomato+ cells were undergoing proliferation compared to the non-
hypoxic cells. In a range of common cancer types, HIF-1α was positively associated with 
the proliferation marker Ki67 (Mki67) (Zhong et al., 1999), and several studies report that 
HIF overexpression in cells can promote cell proliferation (Medici and Olsen, 2012).
While many cell types including cancer cells proliferate more slowly under hypoxia, 
here we are tracking the uptake of EdU by cells previously exposed to hypoxia. Whether 
this enhanced proliferation proves to be generalisable remains to be investigated, but 
might help explain why hypoxia may trigger more aggressive tumours. (Hubbi and 
Semenza, 2015; Al Tameemi et al., 2019). Blouw and co-workers found a microenvironment-
dependent effect of HIF-1α knockdown on tumour progression which might be relevant 
here. Koshiji et al. (Koshiji et al., 2004) and Hubbi et al. (Hubbi et al., 2013) showed HIF-
1α stabilisation induced cell cycle arrest, whereas in our model, HIF-1α was most likely 
degraded at the time we measured proliferation. It remains to be investigated what 
mechanisms are responsible for the long-term effect of hypoxia on proliferation in post-
hypoxic tumour cells and whether this is dependent on HIF-1α. The H1299-MR model 
proves to be a promising tool to study this and other long-term effects of hypoxia 
including its role in metabolic plasticity and metastasis. Moreover, our finding that post-
hypoxic tumour cells proliferated faster in vivo but not in vitro or ex vivo demonstrate that 
this acquired feature is un-stable and non-cell autonomous. It will be of interest to identify 
what factors in the tumour microenvironment contribute to this.
Other approaches exploiting fluorescent markers driven by hypoxia-responsive 
elements and oxygen-dependent degradation domains have been described (Erapaneedi 
et al., 2016; Wang et al., 2016). Using intravital microscopy, Wang et al. visualised migration 
of individual normoxic and hypoxic MDA-MB-231 cells in a xenograft model. Similar to our 
findings, they also reported the presence of hypoxic cells both in proximity and distant 
from blood vessels. However, they did not quantify whether the distance was different 
from normoxic cells and different to our current study, Wang et al. studied cells currently 
experiencing hypoxia whereas we mainly focused on post-hypoxic cells (Wang et al., 
2016). Tracing of recently re-oxygenated cells was also performed by Erapaneedi et al. 
(Erapaneedi et al., 2016), however their system using the fluorescent marker mOrange 
is dependent on PEST-sequence-dependent decay, making it less robust and more 
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challenging to visualise by intravital microscopy, whereas we show stable expression 
of tdTomato for at least 4 weeks in post-hypoxic cells. Thus, the HIF-MARCer system is a 
useful addition to the armamentarium to visualize hypoxic, HIF-expressing cells. We show 
here that H1299-MR cells are a valuable tool to study the long-term fate of hypoxic cells, 
for example by using intravital microscopy.
In conclusion, our results demonstrate that single-cell lineage tracing of post-hypoxic 
tumour cells using the H1299-MARCer system allows visualisation of their behaviour 
in living tumours using intravital microscopy. We provide a valuable tool to study the 
dissemination and treatment response of post-hypoxic tumour cells in vivo and ex vivo at 
a single-cell resolution. Using this system, we provide evidence that post-hypoxic tumour 
cells may have a proliferative advantage over non-hypoxic tumour cells and that this is 
influenced by the tumour microenvironment.
Materials and Methods
Generating the Lenti MARCer system
First, an eGFP CreERT2  fusion single primer PCR was performed on plasmid pL451-
Dll1(GFP-ires-CreERT2), a kind gift from Johan van Es (van Es et al., 2012), with primer 
5’-GGCATGGACGAGCTGTACAAGTCCAATTTACTGACCGTACAC-3’ and on pEGFP-C1 
(Clontech) with primer 5’-GGCATGGACGAGCTGTACAAG-3’. After the reaction, these template 
plasmids were digested with DpnI, before mixing 1 μl of each reaction for a fresh PCR with 
primer pair 5’-GTGAGCAAGGGCGAGGA-3’ and 5’-CCAGACATGATAAGATACATTGATGAG-3’ 
to amplify the fusion product with proofreading Phusion DNA Polymerase (FynnZyme). 
This GFP-CreERT2  PCR fragment was gel purified, and T overhangs were added with 
normal Taq polymerase before sub cloning it in a pCR-XL-TOPO®  vector (Invitrogen), 
generating pCR-GFP-CreERT2  vector. Afterwards, this vector was used as a template 
to generate in a similar approach the fusion with HIF-1α. A HIF-1α ’1.5 kb guide DNA 
fragment was amplified from BAC clone RP11: 618G20 (GenBank:  AL137129.4), using 
primers 5’-TGGATCCGAGCTCGGTACCATAGATCTGAACATTATAACTTGATAAATGAGG-3’ 
and 5’-AGCTCCTCGCCCTTGCTCACCTGGAATACTGTAACTGTGC-3’. The product, a 
fusion of HIF-1α in exon 12 with 20 nucleotides of the cDNA GFP, was cloned by use 
of the NEBuilder®  HiFi DNA assembly cloning kit in the pCR-GFP-CreERT2  plasmid, 
generating pCR-HIF-LHA-GFP-CreERT2. On this plasmid, a single primer PCR with primer 
5’-GCAAGCCCTGAAAGCGCAAG-3’ and the cDNA human HIF-1α in a p3XFLAG-CMV™-10 
expression vector (Sigma-Aldrich, St Louis, MO, USA) (Gort et al., 2008) was used as a template 
with a complementary single primer PCR with primer 5’-CTTGCGCTTTCAGGGCTTGC-3’. 
After the reaction, the template plasmids were digested with DpnI, before mixing 1 μl 
of each reaction for a fresh PCR with primer pair 5’-GATATCGGTACCAGTCGACTC-3’ and 
5’-GTGGTACCCGTCATCAAGCTGTGGCAGGGA-3’, amplifying the MARCer cDNA (Fig.  1A, 
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top), which was subcloned in a pCR®-Blunt II-TOPO®  vector, generating pCR-BluntII-
MARCer. Flanked by BstXI sites, the MARCer cDNA was, after digestion, retrieved by gel 
purification to replace luciferase in the BstXI-digested pLenti CMV V5-LUC Blast (w567-1), 
Addgene plasmid #21474, deposited by Eric Campeau (Campeau et al., 2009), generating 
pLenti-CMV-MARCer-Blast. This plasmid expresses amino acids 1-603 of the human HIF-1α 
protein fused to eGFP-CreERT2.
The Ai65(RCFL-tdT) targeting vector, Addgene plasmid #61577, deposited by Hongkui 
Zeng (Li et al., 2015), was digested with BstBI-AscI, and a 6267 bp fragment was isolated 
and cloned into an empty BstBI-AscI-digested pLVX-puro vector with an introduced 
unique AscI site to fuse proteins to FLAG and HA tags at the carboxy terminus (Groot et al., 
2014). Next, the FLAG-HA-PGK-Puro-WPRE fragment was removed from this vector with an 
AscI-KpnI digest followed by blunting of the DNA ends with Mung Bean and ligated back. 
Finally, the FRT-STOP-FRT cassette was removed with a digest with XhoI and the vector 
was back ligated to generate the pLV(cmv)-NEO-SFS-tdTomato Cre reporter plasmid. The 
full integrity of all constructs was confirmed by DNA sequencing.
Generation of the H1299-MR cell line
Viral particles were produced using viral vectors and packaging plasmids in 293FT cells as 
previously published (Groot et al., 2014). H1299 cells on which we performed STR analysis 
were first transduced with MARCer viruses and cells were selected with 10 µg/ml blasticidin 
in the 10% FBS RPMI culture medium, supplemented with penicillin/streptomycin. 
Transduced cells were single-cell seeded to form clones on 15 cm dishes. Next, clones 
were harvested by use of glass clonal cylinders (Sigma-Aldrich) with Baysilone-Paste (GE 
Bayer Silicones) and expanded. Clones were split and transiently transfected with the 
reporter plasmid described above and screened for their switching capacity with the 
addition of 100 nM DFO and 100 nM 4-OHT (H7904-5MG, Sigma-Aldrich). We identified 
clone number 12 to show most tdTomato expression after treatment. Next, clone 12 was 
subsequently transduced with SFS-tdTomato viruses and clones were selected after this 
second transduction and were selected with 10 µg/ml blasticidin and 1000 µg/ml G418 
in the 10% FCS RPMI culture medium, supplemented with penicillin/streptomycin. The 
polyclonal cell population was exposed to 1% of oxygen for 24 h in a Russkinn INVIVO 
1000 hypoxic chamber. Next, the recovered cells were passed in culture at normoxic 
conditions for 2 days. To these cells, 100 nM 4-OHT was added to the medium for 24 h. To 
select for cells without leakage, cells were single-cell seeded and colourless clones were 
picked as described above. Clones were expanded and split into 250,000 cells per six-
well plate and exposed to 200 nM 4-OHT under hypoxia and normoxia for 24 h, before 
being trypsinised and expanded for 3 days in culture flasks. We identified H1299 clone 
12.3 (H1299-MR) as a robust hypoxia reporter cell line that we characterised and used in 
our further experiments.
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Cell culture and hypoxia
H1299-MR cells were cultured in 10% FBS (Gibco) RPMI culture medium (Sigma-Aldrich) 
supplemented with 1% penicillin/streptomycin (Sigma-Aldrich), 10 µg/ml blasticidin 
(InvivoGen) and 1000 µg/ml G418 (Sigma-Aldrich). Cells were regularly tested for 
mycoplasma and incubated in a humidified incubator or hypoxia chamber Ruskinn InVivo 
300 (Fig. 1C, left, D, left, E,F; Fig. S1A,B,G,H) or InVivo 1000 (Fig. 1B,C, right, D, right, Fig. 
5C; Fig. S1C-F) with or without 4-OHT. Images during cell culture were taken with a Nikon 
eclipse Ts2 microscope.
Western blotting
Cells were lysed in RIPA buffer, containing 50 mM Tris·HCl, 0.5% DOC, 0.1% SDS, 1 mM EGTA, 
2 mM EDTA, 10% glycerol, 1% Triton X-100, 150 mM NaCl and 1 mM PMSF, and protease 
inhibitors (ROCHE pill Complete Inhibitor). Protein concentrations were determined with 
the Bradford Protein Assay (Bio-Rad). Proteins (30 g) were separated by 6% SDS-PAGE and 
transferred to a PVDF membrane. The membrane was blocked with 5% non-fat dry milk 
(Marvel) and subsequently incubated (overnight, 4°C) with primary antibodies anti-HIF-1α 
(1:1000; #610959, BD Biosciences) and anti-lamin A (1:1000; #L1293, Sigma-Aldrich), and 
then horseradish peroxidase-linked secondary antibodies (horse anti-mouse and horse 
anti-rabbit; 1:2500; Cell Signaling Technology). ECL Prime Western Blotting Detection 
Reagent (GE Healthcare) was used for visualisation.
RNA isolation and quantitative PCR
mRNA was extracted using the Nucleospin RNA II kit (Bioke), and cDNA conversion was 
performed using an iScript cDNA synthesis kit (Bio-Rad), according to the manufacturer’s 
instructions. Quantitative PCR was performed on a CFX96 (Bio-Rad). The expression of 
VEGF (F: 5’-GACTCCGGCGGAAGCAT-3’; R: 5’-TCCGGGCTCGGTGATTTA-3’) was detected 
with SYBR Green I (Eurogentec). Gene expression was normalised to  Rpl13a  (F: 
5’-CCGGGTTGGCTGGAAGTACC-3’; R: 5’-CTTCTCGGCCTGTTTCCGTAG-3’) mRNA expression.
Mice
All animal studies were performed according to the Animals Scientific Procedure Act 
1986 (UK) and approved by local ethical review. Female Balb/c nude mice were obtained 
from Envigo and kept in individually ventilated cages with unlimited supply of food and 
water and 12 h light-dark cycles, and mice were weighed twice a week. H1299-MR cells 
were harvested, dissolved in a single-cell suspension with Matrigel (Corning Life Sciences, 
1:1) and 106 cells were injected subcutaneously into the flank of 6- to 10-week-old mice. 
Once tumours reached ~100 mm3, tamoxifen (TAM, Sigma-Aldrich) was dissolved in 
vegetable oil containing 5% ethanol and administered through oral gavage. At the end 
of the experiment, mice were injected intraperitoneally with EF5 [2-(2-nitro-1/-/-imidazol-
l-yl)-N-(2,2,3,3~-pentafluoropropyl)acetamide], a nitroaromatic compound stabilised in 
Chapter 4
134
the absence of oxygen (Lord et al., 1993), a kind gift from Prof. Cameron Koch (University 
of Pennsylvania, Philadelphia, PA, USA) and EdU (Santa Cruz Biotechnology) 3 h before 
sacrifice. Tumours were harvested, rinsed in PBS, cut in half and processed for flow 
cytometry or immunofluorescence.
Flow cytometry
Tumours were collected, halved, kept in Hanks’ balanced salt solution (HBSS; Gibco) and 
chopped into small pieces using a scalpel. Tumours were then digested in HBSS (Gibco) 
containing Collagenase Type 2 (Worthington Biochemical Corporation) and DNAse I 
(Thermo Fisher Scientific) for 40 min at 37°C in a shaking incubator. Cells were filtered 
through a 50 µm strainer (Sysmex Partec) and rinsed with FACS buffer (PBS containing 
5% FBS) and centrifuged for 5 min at 300 g, 4°C and rinsed again. Cells were incubated 
for 15 min with LIVE/DEAD Fixable Violet Dead Cell Stain (Thermo Fisher Scientific), and a 
maximum of 2×106 cells was used for EdU staining using the Click-iT EdU Alexa Fluor 488 
Flow Cytometry Assay according to manufacturer’s instructions (Thermo Fisher Scientific). 
The remaining cells were fixed using intracellular fixation buffer (1:1 in PBS, Thermo Fisher 
Scientific) for ~10 min at room temperature (RT). Cells were stored in IC fixation buffer 
at 4°C until analysis on the Attune NxT Flow Cytometer (Thermo Fisher Scientific), when 
they were centrifuged for 5 min at 400 g and dissolved in FACS buffer. For compensation 
purposes, H1299-MR cells were cultured  in vitro and subjected to DFO treatment (eGFP, 
channel BL-1), TAM+ hypoxia and re-oxygenation (tdTomato, channel YL-1), 5 min at 65°C 
(LIVE/DEAD, channel VL-1, 1:1 with untreated cells), EdU (Click-iT assay, channel BL-1) or left 
untreated (unstained control and human nuclei, channel RL-1). When stained for human 
nuclei (1:100; MAB1281, Merck Millipore; Fig. 4C,D), this was performed for 30 min at RT 
in the dark after EdU staining (Click-iT Assay) and blocking. AF647 donkey anti-mouse IgG 
(1:500; Thermo Fisher Scientific) was used as a secondary antibody.
Cells cultured in vitro that were used for flow cytometry were rinsed and scraped in PBS, 
and added to IC fixation buffer (1:1 in PBS) inside the hypoxia chamber. They were then 
taken out of the chamber and incubated, together with cells not exposed to hypoxia, 
for ~30 min at RT. Cells were stored in IC fixation buffer at 4°C until analysed, they were 
centrifuged for 5 min at 400 g  and dissolved in FACS buffer. An example of the gating 
strategy was shown in Fig. 1C,D and analyses were performed in FlowJo (BD).
Ex vivo cell culture
When cells from xenografts were cultured ex vivo, tumours were harvested and put in RPMI 
complete medium without selection antibiotics. They were then digested as described 
above. From this point, cells were kept under sterile conditions, filtered through a 30 µm 
strainer (Sysmex Partec) and rinsed with PBS containing 2% BSA and 5 mM EDTA (both 
Sigma-Aldrich). After centrifugation for 5 min, 300 g at 4°C, the pellet was resuspended 
and incubated for 3 min in red cell lysis buffer (155 mM NH4Cl, 12 mM NaHCO3, 0.1 mM 
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EDTA). Cells were rinsed twice with PBS/BSA/EDTA and dissolved in PBS. Half of the 
cells was taken into culture with RPMI complete medium and 10 µg/ml blasticidin and 
1000 µg/ml G418 and the other half was stained for LIVE/DEAD, fixed and analysed by 
flow cytometry. At several culture passages, cells were harvested with Trypsin/EDTA 
(Sigma-Aldrich), filtered through a 30 µm strainer and stained for LIVE/DEAD and EdU as 
described above, and analysed by flow cytometry.
Immunofluorescence and microscopy
Tumour halves were rinsed in PBS and fixed for 3-4 h in 4% PFA at 4°C. They were transferred 
to 30% sucrose in PBS solution and kept overnight in the fridge and consecutively snap 
frozen in OCT embedding medium (Thermo Fisher Scientific) and stored at −20°C until 
cutting. Cryosections (10 µm) were cut using a Bright Cryostat or a Leica CM1950, dried 
overnight at 37°C and stored at −80°C until staining.
Sections were allowed to dry at room temperature for at least 30 min, rinsed in PBS and 
permeabilised with 0.5% Triton X-100 in PBS. For staining of CD31, 5% BSA (Sigma-Aldrich) 
and 5% donkey serum (Sigma-Aldrich) were added to the permeabilisation solution and 
this was also used for blocking for 1 h at RT. Blocking for RFP staining was done with 10% 
normal goat serum (Sigma-Aldrich) in PBS for 1 h at RT and with TNB blocking buffer 
(PerkinElmer) for 30 min for EF5 staining. Staining was performed overnight at 4°C with 
Cy5-conjugated EF5 antibody or Cy5-EF5 antibody containing competitor (both purchased 
from University of Pennsylvania and diluted 1:1 in PBS), rabbit anti-RFP (600-401-379, 
Rockland) or rabbit IgG (BD Biosciences) at 1:500 in PBS, and goat anti-CD31 (AF3628, 
R&D Systems) or goat IgG (R&D Systems) at 1 µg/ml. Sections stained for EF5 were washed 
with PBS/Tween 20 0.3% twice for 45 min. Sections stained for RFP and CD31 staining 
were washed 3× in PBS and incubated for 30 min at RT with secondary antibodies AF633 
goat anti-rabbit and AF647 donkey anti-goat, respectively, at 1:500 dilution. The Click-iT 
EdU Cell Proliferation Kit for Imaging (Thermo Fisher Scientific) was used according to the 
manufacturer’s instructions, and a solution containing only the Alexa Fluor picolyl azide in 
PBS/BSA 3% was used as a negative control. All sections were counterstained with Hoechst 
33342 (Thermo Fisher Scientific) and mounted in Prolong Diamond Antifade Mountant 
(Thermo Fisher Scientific). Entire sections were imaged using a Nikon-NiE epifluorescence 
microscope with a 20× objective. Images were stitched with NIS Elements (Nikon) and 
processed with Imaris software (Bitplane). To get an overview of the entire tumour, one 
to five sections per tumour, separated by ~1 mm, were analysed and the average was 
displayed.
Abdominal imaging window and intravital microscopy
Under inhalation anaesthesia with isoflurane, an imaging window was placed onto the 
abdominal wall of a mouse as previously described (Ritsma et al., 2013) with the following 
adjustments. A titanium window was used and a coverslip was glued on top with BBRAUN 
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Histoacryl (Akin Global Medical). Vetergesic was injected subcutaneously as analgesic. 
An incision was made in the skin, after which 5×105 H1299-MR cells in 30% Matrigel in 
5 µL were injected into the thin fat layer above the abdominal muscle. The window was 
stitched to the muscle layer using 5-0 silk and then secured to the skin with 5-0 prolene 
sutures (Ethicon). After ~6 weeks, when tumours became visible by eye, 10 mg tamoxifen 
in 100 µl 5% ethanol/oil mixture was administered by oral gavage. At every imaging 
session, windows were carefully cleaned with an insulin syringe using 0.9% NaCl and all 
liquid and air between the coverslip and the tumour was removed. FITC-Dextran (MW 500, 
Sigma-Aldrich) or Qtracker 705 (Thermo Fisher Scientific), diluted 1:10 in sterile saline, was 
administered via the cannulated tail vein by a bolus injection of 2×12.5 µl, followed by a 
rate of 70 µl/h using an automated pump (Harvard Instruments). Tumours were imaged 
using a ZEISS LSM 880 microscope with a Mai-Tai laser (Newport Spectra-Physics, 940 nm 
excitation) using a ZEISS 20×/1.0 NA water objective covered with ultrasound gel. For 
detection of Qtracker 705, a 670 nm shortpass filter was used, whereas bandpass filters 
of 457-487 nm were used for collagen (second harmonic generation microscopy, 2-HG), 
of 488-512 nm for eGFP/FITC and of 562.5-587.5 nm for detection of tdTomato. Tile scans 
were taken up to 350 µm deep with a voxel size of 0.83×0.83 in x-y and 5 µm in z, and 
stitched using ZEN Black Software (Carl ZEISS AG). Quantitative analyses were performed 
using Imaris.
Image analyses
All analyses were performed using Imaris software. First, the total tumour was outlined, 
background such as folds were excluded as much as possible and signal outside the 
tumour area was removed. For EF5 staining, hypoxic areas directly underneath the skin 
were excluded from the analysis. For stained sections, masks were created for Hoechst, 
tdTomato, and staining using the ‘surfaces’ or ‘spots’ functions and thresholds adjusted 
for each imaging session. All analyses were checked by eye and when the mask did 
not visually represent the positively stained area, the data were excluded from the 
analysis. A distance map from CD31+ and EF5+ areas was created using MATLAB and the 
median distance of tdTomato+  spots and Hoechst+  spots to CD31+  and EF5+  surfaces 
was calculated. For analyses of EdU, Hoechst+  cell surfaces were masked. These were 
filtered for an EdU+  threshold, either or not preceded by the tdTomato+  threshold and 
expressed as a percentage of total. RFP+ cells were also filtered by an intensity threshold 
on Hoechst+ surfaces.
For intravital images, channel arithmetic was applied using MATLAB to subtract GFP bleed 
through into the tdTomato channel and tdTomato bleed through into the Qtracker 705 
channel. A surfaces mask was created on the Qtracker 705 signal and the perfused-vessel 
volume was expressed as a percentage of total tumour volume. A distance map from 
vessels was created using MATLAB and the distance of tdTomato+ spots to vessels was 
represented as a colour spectrum (0-151 µm).
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Statistical analyses
Statistical analyses were performed using GraphPad Prism software. This was also used 
to create the figures that are showing the mean and individual measurements carried 
out in duplicate unless stated otherwise. Paired observations are displayed with a 
connecting line. The statistical tests performed are indicated for each figure and P<0.05 
was considered significant.
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Figure S1: H1299-MR characteristics. 
Gating strategy of eGFP and tdTomato expression after exposure to hypoxia (0.1% O2) for 24h (A) 
and 24h of hypoxia followed by 24h of re-oxygenation (B) (C) Flow cytometric analysis of tdTomato 
expression 72 hours after 0.2% O2 and different concentrations of 4-OHT. *** p<0.001 as indicated 
using 2-way ANOVA followed by Bonferroni post-test. ## p<0.01, 4-OHT versus without 4-OHT under 
normoxia using 1-way ANOVA followed by Bonferroni’s multiple comparison. (D) Distribution of 
eGFP after 24h treatment of H1299-MR with 100μM DFO. Scale bar: 20μm. (E) VEGF gene expression 
normalised for the housekeeping gene RPL13A after exposure to tamoxifen in the parental H1299 
cell line and H1299-MR Dots represent independent experiments carried out in triplicate and bars 
indicate averages. (F-H) H1299-MR cells stably expressing tdTomato were re-exposed to hypoxia. (F) 
Stable expression of tdTomato in normoxia once it was induced by hypoxia (0.2% O2) and 4-OHT 
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tdTomato was induced with 4-OHT and 24h (circles) or 48h (squares) of 0.1% O2 as indicated. Re-
exposure to hypoxia for up to 72 hours did not significantly affect the percentage of tdTomato+ cells. 
Dots represent independent experiments carried out in duplicate and bars indicate averages (H) Re-
exposure to hypoxia gradually reduced the tdTomato median fluorescence intensity. Dots represent 
independent experiments carried out in duplicate and bars indicate averages #p<0.05, ###p<0.001 
compared to no hypoxia re-exposure and *p<0.05, **p<0.01 as indicated and calculated by One-
way ANOVA followed by Bonferroni’s multiple comparison.
Figure S2: Immunofluorescent staining of H1299-MR xenografts at different time points after 
administration of tamoxifen. 



























































(A) Micrographs of EF5 staining. An EF5-Cy5 antibody mixture containing a competitive inhibitor 
of the antibody was used as a negative control (competitor). (B) CD31 and IgG control staining (C) 
Distance of tdTomato-positive cells and all cells to EF5-positive areas. (D) Distance of tdTomato-
positive cells and all cells to CD31-positive areas. Scale bars overview: 500 μm, scale bars zoom and 
controls: 50 μm. 
Figure S3: Quantification of immunofluorescent staining of H1299-MR xenografts. 
(A) Correlation between EF5 and tumours size (not significant). (B) Correlation between EF5 and 
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Figure S4: Immunofluorescent RFP staining. 
(A) Staining of GFP-positive cells, cultured in vitro with 100 μM DFO, confirming the antibody against 
RFP does not recognise GFP. (B) Micrographs of RFP staining and IgG control on xenograft sections. 











Figure S5: EdU staining. 
(A) Micrographs of xenograft sections stained for EdU and a negative control with only the AF-
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Figure S6.














Figure S6: H1299-MR xenografts in 4 mice were followed by intravital microscopy. 
(A-D) Perfused vessels are shown in green (days -7, 1, and 2) or purple, tdTomato-positive cells in 
red, and collagen in cyan (second harmonic generation microscopy, top panels only). Days indicate 
the time after tamoxifen administration and scale bars are 500 μm. Channel arithmetics was applied 
using MATLAB to subtract GFP bleed through into the tdTomato channel and tdTomato bleed 
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Tumour hypoxia and high levels of HIF have long been known to be negative prognostic 
and predictive factors in cancer patient outcome, due to its contributions to therapy 
resistance, invasiveness, metastasis, altered metabolism, angiogenesis, vasculogenesis, 
cell survival and genomic instability. Intratumoral hypoxia is a general feature of many 
solid tumours and one of the strongest independent prognostic and predictive factors 
for patient outcome. In chapters 4-6 we develop a new system for lineage tracing 
hypoxic and post-hypoxic cells. In chapter 4 we used the MARCer (HIF-CreERT2) protein 
in combination with a tdTomato reporter in a H1299 non-small cell lung cancer model. 
We demonstrate that this system can be used to lineage trace hypoxic and post-hypoxic 
cells in vivo and live microscopy can be achieved with the use of intravital microscopy. We 
find a proliferative advantage in vivo for labelled post-hypoxic cells than unlabelled cells. 
In chapter 5 we use the MARCer system in combination with a floxed ‘dsred’ DTR-eGFP 
reporter which allows us to ablate labelled cells with diphtheria toxin. We generated the 
metastatic 4T1 mammary carcinoma cell line with our system. We characterise this model 
in vitro and in vivo and test its ability to report on hypoxia and the efficiency of ablation 
of labelled cells with diphtheria toxin. We find that the model can report on hypoxia 
when tamoxifen is added and (post) hypoxic labelled cells can be efficiently ablated. 
The model in this chapter will be used in future experiments to investigate the effects of 
radiotherapy on hypoxic cells and the benefits that hypoxia targeting therapies may have 
on radiotherapy efficacy. In chapter 6 we generate a transgenic mouse which has the 
MARCer gene inserted into one allele of the HIF-1A locus. We characterise the embryonic 
stem cell clone that was used to create these mice. We find that the MARCer fusion protein 
is stabilised under hypoxic conditions and when 4-hydroxy tamoxifen is added is able to 
label hypoxic cells when combined with a reporter. The lineage tracing system developed 
in these chapters should provide a useful tool to study hypoxic cells and their behaviour 
as well as therapies designed to target the hypoxic fraction in a tumour. 
Due to the fact that hypoxia has a negative prognostic and predictive outcomes for 
patients, this has led to intense research into strategies that target this population of 
cells in tumours. A broad range of strategies have been developed from small molecule 
inhibitors to oxygen supplementation and have been around for the past 3 decades. In 
1912 Swartz first observed the enhancing effects of oxygen on irradiation. He noted that 
the skin reaction caused by radium was reduced when it was pressed into the arm, which 
he attributed to reduced blood flow and therefore less oxygen. 40 years later Gray et al. 
did the first formal experiments to investigate the efficacy of radiotherapy at different 
oxygen concentrations on cancer cells (Gray et al., 1953). They observed that tumour cells 




Early clinical studies measured the oxygen concentrations in tumours using the 
Eppendorf pO2 histograph which utilised needle oxygen electrodes. These studies 
showed that tumour progression and response to radiotherapy was dependent on the 
oxygenation of tumours in breast cancer (Okunieff et al., 1993), squamous cell carcinoma 
metastases (Gatenby et al., 1988), cervical cancer (Hockel et al., 1996; Höckel et al., 1993) 
and head and neck cancer (M Nordsmark, 1996). Collectively, these studies show that 
the more hypoxic tumours lead to worse patient outcome. These and other studies also 
showed that tumour oxygenation was linked to tumour progression. Since then it has 
been found that patients whose primary tumour is poorly oxygenated have increased risk 
of metastasis and poorer prognosis (Bos et al., 2003; P Vaupel et al., 2007; Peter Vaupel et 
al., 2004). Many steps in the metastatic cascade have been linked to hypoxia including 
epithelial to mesenchymal transition, local tissue invasion, intravasation into the blood 
and survival in the bloodstream and extravasation into distant organs and formation of a 
secondary tumour (Godet et al., 2019; Rankin et al., 2016). 
As well as radiotherapy resistance, hypoxia also contributes to the reduced efficacy of 
chemotherapeutics for several different reasons. First, like oxygen, the chemotherapeutics 
must diffuse a large distance which is further hampered by the composition of the 
extracellular matrix leading to a reduced concentration in less perfused areas (Minchinton 
& Tannock, 2006). Furthermore, hypoxia is known to upregulate drug efflux proteins 
further reducing the intracellular concentration of chemotherapy drugs in a number of 
cancers (Ding et al., 2010; Kruh & Belinsky, 2003; L. Liu et al., 2008). Reduced proliferation 
and downregulation of apoptotic proteins in hypoxic cells also reduces the efficacy of 
chemotherapy because the rapid proliferation of tumour cells is often required for 
DNA damaging chemotherapy drugs to work efficiently. Additionally, the increased 
acidity of the tumour microenvironment reduced the capacity of small molecules to 
pass through the cellular membrane, and can also lead to localisation in unfavourable 
cellular compartments and the altered pH can also directly lead to reduced activity of pH 
dependant drugs (Stubbs et al., 2000).
While early cancer research focused on chronic hypoxia, Brown et al. showed evidence 
of a second type; Acute hypoxia (Brown, 1979). This is hypoxia that was postulated to be 
caused by intermittent opening and closing of tumour blood vessels leading to intermittent 
periods of hypoxia and re-oxygenation. Further research since then has shown the 
negative prognostic effects that acute/cycling hypoxia can have. Re-oxygenation leads 
to the production of reactive oxygen species which as well as producing DNA damage, 
also lead to stabilisation of HIF-1α, and thus the HIF-1 transcriptional complex, which can 
protect the cells from cytotoxic therapies. Cycling hypoxia can also alter the function and 
activity of HIF1 which can influence tumour development and progression, response to 
therapy and promote tumour cell survival (Dewhirst, 2009). Acute hypoxia can last from 
a few minutes to a few hours making the distinction between acute and chronic hypoxia 




a very dynamic tumour oxygenation profile, which is constantly changing (Peter Vaupel 
et al., 2004). 
While the HIF family of proteins is the most well-studied oxygen regulated protein, 
general protein expression itself is also downregulated in hypoxia via a different 
mechanism. Hypoxia leads to the accumulation of misfolded proteins, due to the oxygen-
dependent nature of disulphide formation post-translation (Koritzinsky et al., 2013). This 
activates the unfolded protein response (UPR) which results in autophosphorylation of 
protein kinase RNA-like endoplasmic reticulum kinase (PERK). PERK in turn phosphorylates 
the translation initiation factor eIF2α kinase (Koumenis et al., 2002). This leads to transient 
attenuation of protein translation, increased expression of chaperones to aid folding and 
increased degradation and autophagy. This reduces ER stress to increase cell survival, 
however, if ER stress persists apoptosis is induced. This reduction in protein synthesis is 
essential to reduce energy use, with the ATP demand for protein synthesis reducing about 
10 fold compared to normoxic cells (Hochachka et al., 1996). Cancer cells also use the UPR 
as a mechanism to survive oncogenic and environmental stress and even though they 
experience extended ER stress, cancer cells are able to bypass the apoptotic signalling and 
avoid apoptosis. This allows cancer cells to exploit the UPR to promote cancer progression. 
The UPR has also been shown to contribute to the development of chemoresistance via 
various downstream mechanisms (Daishi Chen et al., 2017; Feng et al., 2011; Jiang et al., 
2009; Salaroglio et al., 2017). 
Targeting Hypoxia
Hypoxia modification
Hypoxia modification has been the focus of therapeutic investigation since the 60s. It 
aims to re-sensitise areas of tumour hypoxia to irradiation through different strategies 
from using hyperbaric oxygen to mitochondrial inhibitors (Fig. 1). Clinical trials utilising 
hyperbaric chambers with radiotherapy found significant improvements in local tumour 
control in carcinoma of the head and neck and the uterine cervix (Dische, 1978). However 
due to the complexities of this strategy and the schedules of hyperfractionation used as 
well as the sensitisation and toxicity of normal tissue this technique was not generally 
accepted. However, it did show that hypoxia modification can lead to improved patient 
outcome. 
Oxygen mimetics are compounds that like oxygen, are able to ‘fix’ radiation-induced 
DNA damage leading to cell death. Unlike oxygen however, the compounds are not 
consumed by cells during respiration and therefore have increased diffusion into areas 
of anoxia and hypoxia. Nitroimidazoles are the most well studied and showed promise 
in pre-clinical studies. However, in clinical trials, misonidazole caused severe central and 
peripheral neuropathy which reduced the tolerable dose making it ineffective (Rosenberg 
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& Knox, 2006). Hence a second generation of these drugs were developed with better 
pharmacokinetics and less toxicity. Of these drugs only nimorazole has shown a benefit 
for patients in clinical trials (Overgaard et al., 1998). Improved locoregional control was 
found in a phase III clinical trial in 414 patients with pharynx and supraglottic carcinoma in 
patients who were treated with nimorazole in combination with radiotherapy as opposed 
to radiotherapy alone. Another phase III clinical trial in head and neck squamous cell 
carcinoma is currently ongoing (NCT01950689)
Another strategy to increase tumour oxygenation that has been tested is the 
combination of nicotinamide (a vasodilator) in combination with breathing carbogen 
(95% oxygen 5% carbon dioxide). This both improved tumour perfusion which has the 
benefit of decreasing levels of acute hypoxia (Chaplin et al., 1990) while also increasing 
blood oxygenation, reducing the levels of chronic hypoxia. This technique was used in the 
clinical trials, ARCON (Accelerated Radiation, CarbOgen, and Nicotinamide) (Janssens et 
al., 2012) and BCON (Bladder, CarbOgen, and Nicotinamide) (Peter J. Hoskin et al., 2010). 
ARCON showed limited success in a Phase III clinical trial with improved 5-year regional 
control specifically in patients with hypoxic laryngeal carcinoma tumours, however, no 
improvement in disease-free or overall survival was found. The lack of improvement in 
overall survival is likely due to the high local and regional control rates in both treatment 
arms and the ability to perform salvage surgery in case of recurrence. The results of the 
BCON trial showed improvements in overall survival, risk of death and local relapse in 
bladder cancer. These trials show the benefit of combining oxygen modification strategies 
to improve tumour oxygenation to further radio sensitise the tumour.
Another vasodilator that has been tested is nitroglycerin. A Phase II clinical trial in 
NSCLC used nitroglycerin with chemotherapy and cisplatin showed improved overall 
response, time to disease progression and survival time. This was thought to be due to a 
decreased hypoxic fraction however levels of hypoxia were not measured (Yasuda et al., 
2006). A second phase II trial in NCLS combining nitroglycerin with chemo/ radiotherapy 
was stopped early when no reduction in tumour hypoxia or increased overall survival was 
seen (Reymen et al., 2020). The lack of overall survival was in part due to the heterogeneous 
treatment modalities and small sample size, but this cannot explain the lack of decreased 
hypoxia.
Giving patients erythropoietin (EPO) to stimulate red blood cell production, reducing 
anaemia and increasing blood and tumour oxygenation has also made it to clinical trials. 
However no significant benefits of EPO have been found, and in a number of trials, it led 
to poorer patient outcomes (Lazzari & Silvano, 2020).
Another method for reducing hypoxia is to reduce the oxygen consumption of tumour 
cells. Metformin, which has the off-target effect of inhibiting mitochondrial complex I, 
has been used to decrease oxygen consumption in tumours and has been shown in pre-
clinical studies to sensitise tumours to radiation. Metformin was also tested in patients 




biochemical relapse rates (Zannella et al., 2013). It is also currently in phase II clinical trial 
in cervix cancer in combination with cisplatin and radiation (NCT02394652). Whether 
the concentration needed to sufficiently inhibit O2 consumption can be reached without 
serious side effects is uncertain. Metformin was first used in the treatment of diabetes 
and a meta-analysis found that metformin was associated with a 14% reduction of cancer 
incidence and a 40% reduction in cancer mortality (Wu et al., 2015) likely through the 
activation of AMP-activated protein kinase (Zhou et al., 2001) and reducing the expression 
of cyclin D1 (Sahra et al., 2008).  
Other drugs that were initially used to treat other diseases have also found a new 
lease of life as ways to combat cancer. This brings with it the advantage that they are often 
already approved for use and more is known about their toxicity profiles and mechanisms 
of action reducing the cost of reaching the clinic. Atovaquone, originally an anti-malarial 
drug has been found to reduce tumour hypoxia by inhibiting mitochondrial complex III. 
in vivo studies showed a significant reduction in tumour hypoxia and a significant growth 
delay when combined with radiotherapy (Ashton et al., 2016). Atovaquone is currently in 
clinical trials (NCT02628080). Papaverine, originally used as smooth muscle relaxant was 
found to have the off-target effect of inhibiting mitochondrial complex I. Papaverine both 
increases perfusion by acting as a vasodilator as well as reducing oxygen consumption 
alleviating hypoxia. In vivo studies showed that it was able to sensitise tumours to 
irradiation (Benej et al., 2018). Phase I clinical trials in combination with stereotactic 
radiation therapy are currently recruiting for patients with non-small cell lung cancer or 
lung metastases (NCT03824327). 
A systematic review of 10,108 patients across 86 trials designed to modify tumour 
hypoxia in patients receiving primary radiotherapy alone showed that modification of 
tumour hypoxia significantly improved the effect of radiotherapy, but had no effect on 
metastasis (Overgaard, 2007). Another meta-analysis looking specifically in squamous cell 
carcinoma of the head and neck found similar results using data from 4805 patients in 32 
randomised clinical trials (Overgaard, 2011). Overall, hypoxia modification in combination 
with radiotherapy resulted in significantly improved therapeutic benefit in loco-regional 
control, disease-specific survival and to a lesser extent overall survival while no benefit 
was seen to distant metastasis. Despite the benefits, no hypoxia modification strategies 
are currently in routine global use.
HAPs
Another strategy is to eliminate hypoxic tumour cells is the use of hypoxia-activated pro-
drugs (HAPs) (Fig. 1). These drugs are inert until they are activated through enzymatic 
reduction under hypoxic conditions, most commonly via two, one-electron reduction 
steps. The first one-electron reduction happens readily, but in the presence of oxygen is 
rapidly converted back to the pro-drug. When oxygen is not present the second reduction 
is able to occur, which causes the pro-drug to fragment, releasing the active moiety. The 
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majority of HAPs work through inducing DNA damage leading to apoptosis especially 
when combined with chemo/radiotherapy. 
Figure 1: 
Tumour microenvironment and hypoxia. The high rate of tumour growth coupled with aberrant 
tumour vasculature leads to areas distant from vessels becoming hypoxic. This reduces the efficacy 
of radiotherapy and chemotherapy. Hypoxia modification strategies aim to increase tumour 
oxygenation, alleviating hypoxia to increase the sensitivity to radio and chemotherapy. Hypoxia 
targeting strategies aim to produce or increase DNA damage in the hypoxic regions to produce cell 
killing or increase the efficacy of radio and chemotherapy. Created with BioRender.com. 
The first HAP to be clinically tested was Tirapazamine (TPZ) (Doherty et al., 1994). TPZ 
has shown promise in a number of clinical trials, however only one Phase III trial has had 
a positive outcome; the addition of TPZ to cisplatin was shown to be superior to cisplatin 
alone (Reddy & Williamson, 2009). The only other completed trial, however, was negative, 
possibly due to the large deviations in the radiotherapy dose delivered. A further sub-study 
of the data from a phase II clinical study showed that TPZ was able to dramatically lower 
locoregional failure if the patients were selected based on tumour hypoxia (Rischin et al., 
2006). Studies have shown that the there is a large range of hypoxia levels within tumours 
and so stratification of patients based on hypoxia biomarkers is essential, however more 
studies are needed to standardise these biomarkers and optimise the hypoxia threshold 









Unfortunately, the hypoxic status was also left out of the design of another HAP in clinical 
trials; TH-302 (Evofosfamide). Both clinical trials conducted failed, with the MAESTRO trial 
(NCT01746979) only just failing to reach significance (p = 0.0588). Differences between 
murine and human drug tolerance, tumour size and levels of hypoxia also play a factor 
in the clinical failure of HAPs. Because areas of hypoxia are not well perfused, the HAPs 
must diffuse large distances to reach their intended target and lowering the dose can 
significantly affect the local concentration of the drug in the tumour. TPZ has been shown 
to not diffuse to the most hypoxic regions and this is likely one factor that led to the failure 
in clinical trials (Abou-Alfa et al., 2011).  Analogues of TPZ with far better tissue penetration 
properties have been created but not reached clinical trials yet (K. O. Hicks et al., 2010). 
Another factor that must be considered in the design of HAPs is the expression and 
tissue specificity of the reductase or reductases that are able to activate the HAP. PR-104 
was another HAP that showed promising pre-clinical data and had the advantage over 
TPZ that its stable cytotoxic metabolite had a bystander effect and could diffuse to more 
oxygenated areas of the tumour enhancing its cytotoxic properties (Kevin O. Hicks et al., 
2007). However, upon initiation of clinical trials, it was found in multiple trials that the 
drug was poorly tolerated in patients leading to the termination of the trials (Abou-Alfa 
et al., 2011; McKeage et al., 2012). Further investigation showed that as well as being 
activated in hypoxia, aldo-keto reductase 1C3 (AKR1C3) was able to reduce PR-104 into its 
active form in the presence of oxygen.  AKR1C3 was also shown to have high expression 
in several cancers but it was also expressed in some normal tissues and this was likely the 
reason for the failure of the dose-escalation studies (Guise et al., 2010). This highlights the 
difficulty of designing HAPs that are tumour specific as many cell types express reductases 
and they are often not hypoxia-induced. 
The failure of these drugs highlights the complex properties that HAPs need to 
possess, for them to be successful. The optimal HAP should have good tissue penetration, 
strong oxygen inhibition, be selective for reductases highly expressed in tumours only 
and ideally have a moderate bystander effect so that it can affect a greater proportion of 
the tumour without increasing normal tissue toxicity. To create and test new candidates 
requires the use of in vitro assays and in vivo models that can model these properties. 
Selection of an optimal HAP has been shown to benefit from the use of multi-parameter 
modelling to optimise the balance between drug diffusion and consumption so that the 
drug can penetrate far enough for optimal hypoxic cell killing (Kevin O. Hicks et al., 2003, 
2006, 2007). Key to their success will also be the use of hypoxia biomarkers that can guide 
the decision to use them or not based on the hypoxia status of individual tumours. This 





Part of the reason for the lack of patient stratification was the lack of reliable hypoxia 
biomarkers. Tissue based biomarkers such as pimonidazole have been used which is 
reduced and deposited in areas of hypoxia. This has been used in trials such as ARCON and 
hypoxia levels measure by pimonidazole correlated with ARCON benefit. Pimonidazole 
has also been used to find endogenous markers such as CAIX and GLUT-1 which correlated 
with pimonidazole deposition (Airley et al., 2003; P. J. Hoskin et al., 2003). 
Hypoxia signatures have also been developed which look at the expression of 
a cluster of genes and these have proven to be highly prognostic (Buffa et al., 2010; 
Winter et al., 2007). They have also been used to successfully predict the response to 
agents such as nimorazole that specifically sensitise hypoxic cells to radiation (Toustrup, 
Sørensen, Alsner, et al., 2012; Toustrup, Sørensen, Lassen, et al., 2012). The major issue 
with these biomarkers is the requirement of a biopsy, which is not always possible and 
repeat measurements are not always possible. Markers found in blood serum such as 
Osteopontin have also been used in clinical trials and allow easier samples acquisition 
(Overgaard et al., 2005). However, both of these methods can not give information on 
the heterogeneity of hypoxia across the tumour which is important when testing hypoxia 
targeting therapies. Several studies have used a median oxygen measurement of HP2.5 
(2.5mmHg) or the tumour fraction HP2.5>19% as a cut off for hypoxia as these fractions 
have been linked to poor treatment outcome (Graves et al., 2011; Marianne Nordsmark et 
al., 2005), however, no threshold has been commonly accepted. 
As such non-invasive techniques to measure tumour hypoxia may be a better method 
in many situations as it allows repeated measurements and the evaluation of hypoxia 
across the entire tumour. At the moment, PET-based methods are the most well developed 
but bioluminescence and photoacoustic imaging methods are being developed (Carolina, 
2017; O’Connor et al., 2019). To date, no hypoxia imaging techniques are used routinely in 
the clinic but they have been utilised within clinical trials. 18F-fluoromisondazle (18F-FMISO) 
is the most extensively studied hypoxia tracer and is based on nitroimidazole reduction 
in hypoxic cells resulting in deposition of the tracer. 18F-FMISO accumulation has been 
found to correlate with hypoxic regions in gliomas, head and neck, breast, lung and renal 
tumours, however, 18F-FMISO did not work in sarcomas, rectal and pancreatic tumours 
due to variable 18F-FMISO retention, normoxic accumulation or lack of any detectable 
retention (Fleming et al., 2015). Despite the utility of 18F-FMISO it has not been generally 
accepted due to slow pharmacokinetics and moderate contrast impeding diagnostics. 
Other tracers are being developed with improved pharmacokinetics that will be more 
clinically applicable. These include 18F-HX4, 18F-FETNIM and 18F-FAZA which generally have 
improved clearance from normoxic tissues improving the hypoxia-normoxia contrast and 
tumour blood ratio. They have been tested in a selection of tumours and the results have 
been promising with improved clinical characteristics as compared to 18F-FMISO. 18F-




therapy-induced decreases in hypoxia during treatment (Zegers et al., 2014). CAIX, VEGF 
and osteopontin blood biomarkers were also sampled, and interestingly both CAIX and 
VEGF remain unchanged while only a weak correlation between hypoxia and osteopontin 
was observed. This raises questions about the utility of these blood biomarkers for the 
detection of treatment-associated decreases in hypoxia. 
[18F]FDG PET is the most frequently used clinical imaging technique for the detection 
and staging of cancer. It is dependent on the rate of glycolysis and the upregulation of 
glucose transporters. Because glycolysis is upregulated in hypoxia and subvolumes of 
tumours displaying high glucose metabolism were shown to often be responsible for 
local recurrences (Aerts et al., 2009; Due et al., 2014). A clinical study compared [18F]FDG 
PET and 18F-HX4 uptake in head and neck cancer to see whether [18F]FDG PET could be 
used to image tumour hypoxia (Zegers et al., 2015). While there was some correlation on 
a general tumour level between [18F]FDG and 18F-HX4, the hypoxic volume as measured 
by 18F-HX4 was smaller than the high metabolic tumour volume. This shows that [18F]FDG 
cannot be used as hypoxia marker, but may be of use in concert with a dedicated hypoxia 
imaging modality to guide and predict treatment success (Thorwarth et al., 2006).
Hypoxia biomarkers will be an essential tool for the selection of patients that receive 
hypoxia targeting therapies. The use of PET tracers has already been shown to be predictive 
of treatment response in several cancers and further refinement will only broaden their 
applicability and use in the clinic. Further to this, more biological knowledge is needed to 
improve clinical success. A greater understanding of hypoxia and the phenotypes it elicits 
are crucial to the development of treatments and biomarkers alike. Research to identify 
the optimal window of opportunity for treatment will also be important in increasing the 
efficacy of hypoxia targeting therapies.
Models for tracing hypoxic cells
Models for tracing hypoxic cells in vivo will be of use in the testing of hypoxia targeting 
or modifying therapies by facilitating the analysis of hypoxic cell killing or the hypoxic 
fraction in vivo. Recently several methods for tracing hypoxic cells have been developed 
including in this thesis each with different mechanisms and characteristics(Erapaneedi 
et al., 2016; Godet et al., 2019; Harada et al., 2012; Wang et al., 2016). Both Wang and 
Erapaneedi used the hypoxia-responsive HRE promoter to drive expression of the reporter 
fluorescent proteins, allowing them to visualise hypoxic tumour cells and recently re-
oxygenated tumour cells. Erapaneedi et al., used the properties of UnaG and the oxygen 
requiring mOrange to distinguish between hypoxic cells and recently re-oxygenated 
cells. These are excellent models for studying hypoxic cells while they are still in or have 
recently left the hypoxic niche. However, once cells migrate into more well-perfused areas, 
expression of these proteins stops, making it very difficult to track these cells further and 
study them after re-oxygenation. 
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Similarly, Harada et al. and Godet et al. also used the HRE promoter, but they used 
it to drive expression of an oxygen regulated Cre-ODD similar to our construct. This was 
coupled with a floxed ‘stop’ luciferase reporter (Harada et al., 2012) or floxed ‘DsRed’ GFP 
reporter (Godet et al., 2019). This allows the tracing of cells long after they have left the 
hypoxic niche and enables the study of their behaviour in this setting. One drawback to this 
approach was the relatively low efficiency of cell tagging upon short hypoxia exposure. 
This limits the system to predominantly research into chronic hypoxia as acute hypoxia 
does not allow enough time for expression before re-oxygenation and degradation occur. 
In our system, we make use of constitutive promoters (cmv, EF1α and the endogenous 
HIF1A promoter), which reduces the lag time between the onset of hypoxia and sufficient 
Cre-ODD expression to efficiently label cells. This should allow for more efficient labelling 
of cells in acute as well as chronic hypoxia although further analysis needs to be done 
to confirm this. Each of these systems has its own strengths and weaknesses and a 
combination of approaches may be needed to fully explore the remaining questions 
about the effects of hypoxia on tumours as well as in other physiological and pathological 
contexts.
Optimisation of these strategies will also be important to maximise the utility of these 
systems. Within this thesis, we have been refining our labelling strategy and combining it 
with reporters that can be used to study different questions about hypoxic cells. As talked 
about in previous chapters the use of UnaG as a fluorescent protein is preferable due to 
it not requiring oxygen to fluoresce (Erapaneedi et al., 2016; Kumagai et al., 2013). The 
only co-factor that UnaG requires is bilirubin, which is a metabolite of haem, found after 
degradation of red blood cells and is therefore readily available in serum. Erapaneedi et al. 
were able to show in vivo that enough bilirubin was present in areas of hypoxia for UnaG 
to fluoresce, confirming its utility in vivo. 
Therefore we have further developed a floxed ‘stop’ UnaG-HA reporter. We have tested 
this reporter in the H1299 cell line in combination with the MARCer construct in chapter 5 
(i.e without GFP). Testing of this model in spheroids showed robust labelling of cells within 
the hypoxic core of spheroids (Fig 2), and fluorescence was able to visualised without the 
need for antibody staining although the addition of the HA tag allows antibody staining 
in cases where fixation quenches intrinsic fluorescence. The addition of diphtheria toxin 
receptor in chapter 5 was added to facilitate investigation into the effect that killing 
hypoxic cells has on the tumour and the efficacy of combining therapies that target 
hypoxia with radio and chemotherapy. 
In chapter 6 we developed a new transgenic mouse that can label hypoxic cells in 
tumours that can better mimic the patient due to the spontaneity of tumour development. 
This mouse has been successfully crossed with a PyMT mouse on an FVB background that 
also contained an R26STOP Tomato reporter. This will aid us in studying the behaviour of 






H1299 MARCer + UnaG reporter spheroid, treated with 200nm 4-OHT. Unfixed (Left) or DAPI and 
pimonidazole stained (right). Image shows UnaG labelling of hypoxic cells in the hypoxic core of 
the spheroid. 
Hypoxia / HIF activation also occurs naturally during embryonic development with 
oxygen concentrations varying from 1-5% in the uterus. Also, in adult tissues, physiological 
hypoxia is common (e.g. bone-marrow, kidney) and also occurs in response to wound 
healing and repair, infection and inflammation. For example, HIF is required for the correct 
development of the foetus, and in mice it has been shown that knockout of Hif-1α, Hif-2α 
or Hif-1β leads to embryonic lethality (Dahl et al., 2005) Adult tissue stem cells often reside 
deeper into the tissue architecture in hypoxic niches. HIF is known to maintain stemness 
by activating stem cell transcription factors (i.e Oct4)  and protects against DNA damage 
from ROS produced by oxidative phosphorylation (Covello et al., 2006).  Lineage tracing 
would aid in the detection of these cells that reside in hypoxic areas such as embryonic, 
hematopoietic, mesenchymal, kidney and neural stem cells (Mohyeldin et al., 2010). The 
Notch stem cell pathway and hypoxia are intimately connected in cell fate decisions, 
morphogenesis, vascularisation, proliferation and differentiation in development but 
also in cancer initiation, progression and treatment resistance (Dunwoodie, 2009; Siebel 
& Lendahl, 2017)
Notch and hypoxia  
Notch’s role in cancer has been well studied, acting as both as a driver and as a tumour 
suppressor in cancer with crosstalk with many other signalling pathways. In chapter 2 we 
reviewed the current knowledge on its effect in breast cancer. The evidence overwhelmingly 
shows its correlation with a more aggressive disease and worse outcome. Furthermore, 
Notch plays an important role in the response to radiotherapy, chemotherapy, hormonal 
therapies and targeted therapies. Numerous studies have shown the ability of Notch 
inhibition to re-sensitise treatment-resistant cancers (Domingo-Domenech et al., 2012; 








Both hypoxia and Notch affect the DNA damage response and apoptosis which can 
affect the efficacy of radiotherapy on top of the reduced efficacy of radiotherapy in severe 
hypoxia.  Hypoxia represses DNA repair in chronic hypoxia, however, it also activates ATM 
and ATR in the absence of detectable DNA damage however this activation is transient 
and is repressed following exposure to chronic hypoxia (Isabel M. Pires et al., 2010). ATM 
has also been shown to phosphorylate and stabilise HIF-1α in mild hypoxic (0.2-1% O2) 
conditions (Cam et al., 2010). Furthermore, ATR has been shown to affect HIF-1α, with ATR 
inhibition leading to delayed HIF-1α stabilisation and induction of HIF-1 target genes (I 
M Pires et al., 2012). Notch signalling also plays a role in DNA repair where Notch binds 
to ATM inactivating its kinase activity. This has been shown to contribute to the survival 
of Notch driven human leukaemia and notch inhibition in the presence of DNA damage 
increased radiation sensitivity (Vermezovic et al., 2015). The same study also observed 
that activated Notch1 was inversely correlated with pATM in human primary breast 
cancer by immunohistochemistry and expression microarray datasets. Both pathways 
also affect the tumour suppressor TP53. A number of mechanisms have been postulated 
for HIFs interaction with P53 including direct interaction (An et al., 1998), indirect 
regulation through the ubiquitin ligase Mdm2 (Delin Chen et al., 2003) , competition for 
the coactivator p300 (Schmid et al., 2004) and regulation by HIF target genes such as 
nucleophosmin, which directly interacts with p53 regulating its activation by inhibiting 
p53 phosphorylation at serine 15 (J. Li et al., 2004). On top of this Notch also works in 
synergy with hypoxia to maintain the undifferentiated cell state, which is important for 
stem cell maintenance (Gustafsson et al., 2005; Sahlgren et al., 2008). Notch signalling has 
also been found to mediate hypoxia-induced EMT. Notch regulated expression of Snail-1 
and LOX both of which are critical for EMT (Sahlgren et al., 2008). 
Hypoxia and Notch also play roles in angiogenesis. Notch signalling is crucial for the 
correct formation of the (neo) vasculature and both over and underexpression of Notch 
leads to the production of aberrant vasculature. Studies have shown that the Notch ligand 
Delta-like ligand 4 (DLL4) is induced by the HIF target gene VEGF and is highly expressed 
in tumour vasculature (Mailhos et al., 2001). DLL4 acts as a negative feedback loop, 
restraining vascular sprouting and branching. Much research has gone into targeting 
angiogenesis with the best validated being blockade of VEGF signalling. Targeting VEGF 
has been shown to be able to normalise tumour vasculature, and reduce vessel density (R. 
K. Jain, 2005). This normalisation increases oxygen and drug delivery, and has been shown 
in clinical trials to prolong survival in several cancers (Coleman et al., 2017; Hurwitz et al., 
2004; Johnson et al., 2004). 
However not all cancers are sensitive to this blockade and tumours may develop 
resistance, so other targets are needed (Rakesh K. Jain et al., 2006). DLL4 has been shown 
in vivo to be a mechanism of anti-angiogenic therapy resistance in tumours, and therefore 
may be a target to overcome this resistance (J. L. Li et al., 2011). Targeting DLL4, although 




in tumours that are resistant to VEGF targeting (Mailhos et al., 2001; Noguera-Troise 
et al., 2006; Ridgway et al., 2006; Scehnet et al., 2007). This is presumably because the 
vasculature is non-functional, and accordingly an increase in hypoxia was seen in DLL4 
targeted tumours. The combination of VEGF and DLL4 targeting has been shown to be 
greater than either treatment alone (Ridgway et al., 2006). Combining DLL4 or Notch 
inhibition with radiation has been shown in vivo to significantly delay tumour growth 
compared to irradiation alone and lead to extensive necrosis (S. K. Liu et al., 2011).  In a 
H460 NSCLC model with either high or blocked Notch activity, Notch activity did not affect 
proliferation or intrinsic radiosensitivity, however in vivo high Notch activity lead to faster 
tumour growth greater radioresistance and tumours were also more hypoxic (Theys et al., 
2013).  DLL4 has been shown to be present in exosomes from endothelial cells (Sheldon et 
al., 2010) and from high DLL4 expressing tumour cells, which can lead to tubule formation 
in vitro giving an explanation for this observation.
In chapter 3 we extend this work to investigate the interaction between hypoxia 
and Notch signalling on angiogenesis. We incubate H460 ΔE NSCLC overexpressing an 
activated form of Notch1 cells in normoxia, hypoxia, anoxia, or hypoxia with DBZ for 24h 
before collecting this medium and putting it on receiver cells. We find increased Notch 
activity in receiver cells when cultured with conditioned medium from hypoxia and anoxia 
compared with normoxia. 
Due to the synergy between hypoxia and Notch, which increase tumour progression, 
aggression, levels of hypoxia and make tumours more therapy-resistant, we have been 
developing and testing a series of hypoxia-activated gamma-secretase inhibitors (GSIs). 
Unlike most HAPs which work through the creation of DNA damage to induce apoptosis, 
the HAP GSI will be activated in areas of hypoxia releasing the active GSI, inhibiting Notch 
activity. This will have a similar effect to targeting DLL4, due to DLL4s role as a Notch ligand. 
We postulate that reducing Notch activity should have the effect of creating aberrant 
vasculature, slowing tumour growth, and improving the efficacy of other treatments 
and re-sensitising treatment-resistant tumours as well as other anti-tumour effects as 
discussed in chapter 2. Combining this with anti-angiogenic therapies could lead to even 
greater tumour control and overcome resistance to anti-angiogenic therapies. The GSI 
also has the ability to diffuse to nearby cells in a bystander effect to inhibit notch in a 
greater proportion of the tumour. This has the advantage over normal GSIs of allowing 
higher doses and longer treatment schedules to be used by reducing normal tissue 
toxicity which has historically limited the applicability of GSIs in the clinic. Normal tissues 
are also able to tolerate 50% Notch inhibition which is another advantage over other HAPs 




1. Abou-Alfa, G. K., Chan, S. L., Lin, C.-C., Chiorean, E. G., Holcombe, R. F., Mulcahy, M. F., Carter, W. 
D., Patel, K., Wilson, W. R., Melink, T. J., Gutheil, J. C., & Tsao, C.-J. (2011). PR-104 plus sorafenib 
in patients with advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 
68(2), 539–545. https://doi.org/10.1007/s00280-011-1671-3
2. Aerts, H. J. W. L., van Baardwijk, A. A. W., Petit, S. F., Offermann, C., Loon, J. van, Houben, R., 
Dingemans, A. M. C., Wanders, R., Boersma, L., Borger, J., Bootsma, G., Geraedts, W., Pitz, C., 
Simons, J., Wouters, B. G., Oellers, M., Lambin, P., Bosmans, G., Dekker, A. L. A. J., & Ruysscher, D. 
De. (2009). Identification of residual metabolic-active areas within individual NSCLC tumours 
using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan. Radiotherapy and Oncology, 
91(3), 386–392. https://doi.org/10.1016/j.radonc.2009.03.006
3. Airley, R. E., Loncaster, J., Raleigh, J. A., Harris, A. L., Davidson, S. E., Hunter, R. D., West, C. M. L., & 
Stratford, I. J. (2003). Glut-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: 
Relationship to pimonidazole binding. International Journal of Cancer, 104(1), 85–91. https://
doi.org/10.1002/ijc.10904
4. An, W. G., Kanekal, M., & Blagosklonny, M. V. (1998). Stabilization of wild-type p53 by hypoxia-
inducible factor 1 ␣. 392(March), 7416–7419.
5. Ashton, T. M., Fokas, E., Kunz-Schughart, L. A., Folkes, L. K., Anbalagan, S., Huether, M., Kelly, 
C. J., Pirovano, G., Buffa, F. M., Hammond, E. M., Stratford, M., Muschel, R. J., Higgins, G. S., & 
McKenna, W. G. (2016). The anti-malarial atovaquone increases radiosensitivity by alleviating 
tumour hypoxia. Nature Communications, 7. https://doi.org/10.1038/ncomms12308
6. Benej, M., Hong, X., Vibhute, S., Scott, S., Wu, J., Graves, E., Le, Q. T., Koong, A. C., Giaccia, A. J., Yu, 
B., Chen, C. S., Papandreou, I., & Denko, N. C. (2018). Papaverine and its derivatives radiosensitize 
solid tumors by inhibiting mitochondrial metabolism. Proceedings of the National Academy of 
Sciences, 115(49), E11561–E11561. https://doi.org/10.1073/pnas.1818732115
7. Bos, R., Van der Groep, P., Greijer, A. E., Shvarts, A., Meijer, S., Pinedo, H. M., Semenza, G. L., Van 
Diest, P. J., & Van der Wall, E. (2003). Levels of hypoxia-inducible factor-1?? independently predict 
prognosis in patients with lymph node negative breast carcinoma. Cancer, 97(6), 1573–1581. 
https://doi.org/10.1002/cncr.11246
8. Brown, J. M. (1979). Evidence for acutely hypoxic cells in mouse tumours, and a possible 
mechanism of reoxygenation. British Journal of Radiology, 52(620), 650–656. https://doi.
org/10.1259/0007-1285-52-620-650
9. Buffa, F. M., Harris, A. L., West, C. M., & Miller, C. J. (2010). Large meta-analysis of multiple cancers 
reveals a common, compact and highly prognostic hypoxia metagene. British Journal of Cancer, 
102(2), 428–435. https://doi.org/10.1038/sj.bjc.6605450
10. Cam, H., Easton, J. B., High, A., & Houghton, P. J. (2010). mTORC1 signaling under hypoxic 





11. Carolina, N. (2017). Photoacoustic Imaging for the Detection of Hypoxia. 46(5), 527–530. https://
doi.org/10.1097/SHK.0000000000000644.PHOTOACOUSTIC
12. Chaplin, D. J., Horsman, M. R., & Trotter, M. J. (1990). Effect of nicotinamide on the microregional 
heterogeneity of oxygen delivery within a murine tumor. Journal of the National Cancer Institute, 
82(8), 672–676. https://doi.org/10.1093/jnci/82.8.672
13. Chen, Daishi, Rauh, M., Buchfelder, M., Eyupoglu, I. Y., & Savaskan, N. (2017). The oxido-metabolic 
driver ATF4 enhances temozolamide chemo-resistance in human gliomas. Oncotarget, 8(31), 
51164–51176. https://doi.org/10.18632/oncotarget.17737
14. Chen, Delin, Li, M., Luo, J., & Gu, W. (2003). Direct interactions between HIF-1 alpha and Mdm2 
modulate p53 function. The Journal of Biological Chemistry, 278(16), 13595–13598. https://doi.
org/10.1074/jbc.C200694200
15. Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., Kim, B.-
G., Fujiwara, K., Tewari, K. S., O’Malley, D. M., Davidson, S. A., Rubin, S. C., DiSilvestro, P., Basen-
Engquist, K., Huang, H., Chan, J. K., Spirtos, N. M., Ashfaq, R., & Mannel, R. S. (2017). Bevacizumab 
and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-
sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a 
multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 18(6), 779–791. https://
doi.org/10.1016/S1470-2045(17)30279-6
16. Covello, K. L., Kehler, J., Yu, H., Gordan, J. D., Arsham, A. M., Hu, C. J., Labosky, P. A., Simon, M. C., 
& Keith, B. (2006). HIF-2α regulates Oct-4: Effects of hypoxia on stem cell function, embryonic 
development, and tumor growth. Genes and Development, 20(5), 557–570. https://doi.
org/10.1101/gad.1399906
17. Dahl, K. D. C., Fryer, B. H., Mack, F. a, Compernolle, V., Maltepe, E., Adelman, D. M., Carmeliet, P., 
& Simon, M. C. (2005). Hypoxia-Inducible Factors 1 and 2 Regulate Trophoblast Differentiation. 
Mol Cell Biol, 25(23), 10479–10491. https://doi.org/10.1128/MCB.25.23.10479–10491.2005
18. Dewhirst, M. W. (2009). Relationships between cycling hypoxia, HIF-1, angiogenesis and 
oxidative stress. Radiation Research, 172(6), 653–665. https://doi.org/10.1667/RR1926.1
19. Ding, Z., Yang, L., Xie, X., Xie, F., Pan, F., Li, J., He, J., & Liang, H. (2010). Expression and significance 
of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma 
tissue and cells. Journal of Cancer Research and Clinical Oncology, 136(11), 1697–1707. https://
doi.org/10.1007/s00432-010-0828-5
20. Dische, S. (1978). Hyperbaric oxygen: The Medical Research Council trials and their clinical 
significance. British Journal of Radiology, 51(611), 888–894. https://doi.org/10.1259/0007-1285-
51-611-888
21. Doherty, N., Hancock, S. L., Kaye, S., Norman Coleman, C., Shulman, L., Marquez, C., Mariscal, C., 
Rampling, R., Senan, S., & Roemeling, R. V. (1994). Muscle cramping in phase i clinical trials of 
tirapazamine (SR 4233) with and without radiation. International Journal of Radiation Oncology, 
Biology, Physics, 29(2), 379–382. https://doi.org/10.1016/0360-3016(94)90293-3
Chapter 7
210
22. Domingo-Domenech, J., Vidal, S. J., Rodriguez-Bravo, V., Castillo-Martin, M., Quinn, S. A., 
Rodriguez-Barrueco, R., Bonal, D. M., Charytonowicz, E., Gladoun, N., de la Iglesia-Vicente, J., 
Petrylak, D. P., Benson, M. C., Silva, J. M., & Cordon-Cardo, C. (2012). Suppression of acquired 
docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent 
tumor-initiating cells. Cancer Cell, 22(3), 373–388. https://doi.org/10.1016/j.ccr.2012.07.016
23. Due, A. K., Vogelius, I. R., Aznar, M. C., Bentzen, S. M., Berthelsen, A. K., Korreman, S. S., Loft, A., 
Kristensen, C. A., & Specht, L. (2014). Recurrences after intensity modulated radiotherapy for head and 
neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG 
uptake. Radiotherapy and Oncology, 111(3), 360–365. https://doi.org/10.1016/j.radonc.2014.06.001
24. Dunwoodie, S. L. (2009). The Role of Hypoxia in Development of the Mammalian Embryo. 
Developmental Cell, 17(6), 755–773. https://doi.org/10.1016/j.devcel.2009.11.008
25. Erapaneedi, R., Belousov, V. V, Schäfers, M., & Kiefer, F. (2016). A novel family of fluorescent 
hypoxia sensors reveal strong heterogeneity in tumor hypoxia at the cellular level. The EMBO 
Journal, 35(1), 102–113. https://doi.org/10.15252/embj.201592775
26. Feng, R., Zhai, W. L., Yang, H. Y., Jin, H., & Zhang, Q. X. (2011). Induction of ER stress protects 
gastric cancer cells against apoptosis induced by cisplatin and doxorubicin through activation 
of p38 MAPK. Biochemical and Biophysical Research Communications, 406(2), 299–304. https://
doi.org/10.1016/j.bbrc.2011.02.036
27. Fleming, I. N., Manavaki, R., Blower, P. J., West, C., Williams, K. J., Harris, A. L., Domarkas, J., Lord, S., 
Baldry, C., & Gilbert, F. J. (2015). Imaging tumour hypoxia with positron emission tomography. 
British Journal of Cancer, 112(2), 238–250. https://doi.org/10.1038/bjc.2014.610
28. Gatenby, R. A., Kessler, H. B., Rosenblum, J. S., Coia, L. R., Moldofsky, P. J., Hartz, W. H., & Broder, 
G. J. (1988). Oxygen distribution in squamous cell carcinoma metastases and its relationship to 
outcome of radiation therapy. International Journal of Radiation Oncology, Biology, Physics, 14(5), 
831–838. https://doi.org/10.1016/0360-3016(88)90002-8
29. Godet, I., Shin, Y. J., Ju, J. A., Ye, I. C., Wang, G., & Gilkes, D. M. (2019). Fate-mapping post-
hypoxic tumor cells reveals a ROS-resistant phenotype that promotes metastasis. Nature 
Communications, 10(1), 1–18. https://doi.org/10.1038/s41467-019-12412-1
30. Graves, E. E., Vilalta, M., Cecic, I. K., Erler, J. T., Tran, P. T., Sayles, L., Sweet-cordero, A., Le, Q. T., & 
Amato, J. (2011). Hypoxia in Models of Lung Cancer: Implications for Targeted Therapeutics. 16(19), 
4843–4852. https://doi.org/10.1158/1078-0432.CCR-10-1206.Hypoxia
31. Gray, L. H., Conger, A. D., Ebert, M., Hornsey, S., & Scott, O. C. (1953). The concentration of oxygen 
dissolved in tissues at the time of irradiation as a factor in radiotherapy. The British Journal of 
Radiology, 26(312), 638–648. https://doi.org/10.1259/0007-1285-26-312-638
32. Guise, C. P., Abbattista, M. R., Singleton, R. S., Holford, S. D., Connolly, J., Dachs, G. U., Fox, S. B., 
Pollock, R., Harvey, J., Guilford, P., Doñate, F., Wilson, W. R., & Patterson, A. V. (2010). The bioreductive 
prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 




33. Gustafsson, M. V., Zheng, X., Pereira, T., Gradin, K., Jin, S., Lundkvist, J., Ruas, J. L., Poellinger, L., Lendahl, 
U., & Bondesson, M. (2005). Hypoxia requires Notch signaling to maintain the undifferentiated 
cell state. Developmental Cell, 9(5), 617–628. https://doi.org/10.1016/j.devcel.2005.09.010
34. Harada, H., Inoue, M., Itasaka, S., Hirota, K., Morinibu, A., Shinomiya, K., Zeng, L., Ou, G., Zhu, Y., 
Yoshimura, M., McKenna, W. G., Muschel, R. J., & Hiraoka, M. (2012). Cancer cells that survive 
radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nature 
Communications, 3, 710–783. https://doi.org/10.1038/ncomms1786
35. Hicks, K. O., Siim, B. G., Jaiswal, J. K., Pruijn, F. B., Fraser, A. M., Patel, R., Hogg, A., Liyanage, H. D. 
S., Dorie, M. J., Brown, J. M., Denny, W. A., Hay, M. P., & Wilson, W. R. (2010). Pharmacokinetic/
Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with 
Improved Tissue Penetration and Hypoxic Cell Killing in Tumors. Clinical Cancer Research, 16(20), 
4946–4957. https://doi.org/10.1158/1078-0432.CCR-10-1439
36. Hicks, Kevin O., Myint, H., Patterson, A. V., Pruijn, F. B., Siim, B. G., Patel, K., & Wilson, W. R. (2007). 
Oxygen Dependence and Extravascular Transport of Hypoxia-Activated Prodrugs: Comparison 
of the Dinitrobenzamide Mustard PR-104A and Tirapazamine. International Journal of Radiation 
Oncology Biology Physics, 69(2), 560–571. https://doi.org/10.1016/j.ijrobp.2007.05.049
37. Hicks, Kevin O., Pruijn, F. B., Secomb, T. W., Hay, M. P., Hsu, R., Brown, J. M., Denny, W. A., Dewhirst, 
M. W., & Wilson, W. R. (2006). Use of three-dimensional tissue cultures to model extravascular 
transport and predict in vivo activity of hypoxia-targeted anticancer drugs. Journal of the 
National Cancer Institute, 98(16), 1118–1128. https://doi.org/10.1093/jnci/djj306
38. Hicks, Kevin O., Pruijn, F. B., Sturman, J. R., Denny, W. A., & Wilson, W. R. (2003). Multicellular 
resistance to tirapazamine is due to restricted extravascular transport: A pharmacokinetic/
pharmacodynamic study in HT29 multicellular layer cultures. Cancer Research, 63(18), 5970–5977.
39. Hochachka, P. W., Buck, L. T., Doll, C. J., & Land, S. C. (1996). Unifying theory of hypoxia tolerance: 
Molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proceedings of 
the National Academy of Sciences of the United States of America, 93(18), 9493–9498. https://doi.
org/10.1073/pnas.93.18.9493
40. Höckel, M., Knoop, C., Schlenger, K., Vorndran, B., Baußnann, E., Mitze, M., Knapstein, P. G., & 
Vaupel, P. (1993). Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. 
Radiotherapy and Oncology, 26(1), 45–50. https://doi.org/10.1016/0167-8140(93)90025-4
41. Hockel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U., & Vaupel, P. (1996). Association between 
tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer 
Research, 56(19), 4509–4515. http://www.ncbi.nlm.nih.gov/pubmed/8813149
42. Hoskin, P. J., Sibtain, A., Daley, F. M., & Wilson, G. D. (2003). GLUT1 and CAIX as intrinsic markers of 
hypoxia in bladder cancer: Relationship with vascularity and proliferation as predictors of outcome 
of ARCON. British Journal of Cancer, 89(7), 1290–1297. https://doi.org/10.1038/sj.bjc.6601260
43. Hoskin, Peter J., Rojas, A. M., Bentzen, S. M., & Saunders, M. I. (2010). Radiotherapy with 




44. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., 
Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., & Kabbinavar, F. (2004). 
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. 
New England Journal of Medicine, 350(23), 2335–2342. https://doi.org/10.1056/NEJMoa032691
45. Jain, R. K. (2005). Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic 
Therapy. Science, 307(5706), 58–62. https://doi.org/10.1126/science.1104819
46. Jain, Rakesh K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006). Lessons from phase III clinical 
trials on anti-VEGF therapy for cancer. Nature Clinical Practice Oncology, 3(1), 24–40. https://doi.
org/10.1038/ncponc0403
47. Janssens, G. O., Rademakers, S. E., Terhaard, C. H., Doornaert, P. A., Bijl, H. P., Van Ende, P. Den, 
Chin, A., Marres, H. A., De Bree, R., Van Der Kogel, A. J., Hoogsteen, I. J., Bussink, J., Span, P. N., & 
Kaanders, J. H. (2012). Accelerated radiotherapy with carbogen and nicotinamide for laryngeal 
cancer: Results of a phase III randomized trial. Journal of Clinical Oncology, 30(15), 1777–1783. 
https://doi.org/10.1200/JCO.2011.35.9315
48. Jiang, C. C., Yang, F., Thorne, R. F., Zhu, B. K., Hersey, P., & Zhang, X. D. (2009). Human melanoma cells 
under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through 
XBP-1-mediated activation of akt. Neoplasia, 11(5), 436–447. https://doi.org/10.1593/neo.09208
49. Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, 
C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., Holmgren, E., & Kabbinavar, F. (2004). Randomized 
phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and 
paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung 
cancer. Journal of Clinical Oncology, 22(11), 2184–2191. https://doi.org/10.1200/JCO.2004.11.022
50. Koritzinsky, M., Levitin, F., Van Den Beucken, T., Rumantir, R. A., Harding, N. J., Chu, K. C., Boutros, 
P. C., Braakman, I., & Wouters, B. G. (2013). Two phases of disulfide bond formation have differing 
requirements for oxygen. Journal of Cell Biology, 203(4), 615–627. https://doi.org/10.1083/
jcb.201307185
51. Koumenis, C., Naczki, C., Koritzinsky, M., Rastani, S., Diehl, A., Sonenberg, N., Koromilas, 
A., & Wouters, B. G. (2002). Regulation of protein synthesis by hypoxia via activation of 
the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation 
factor eIF2alpha. Molecular and Cellular Biology, 22(21), 7405–7416. https://doi.org/10.1128/
mcb.22.21.7405-7416.2002
52. Kruh, G. D., & Belinsky, M. G. (2003). The MRP family of drug efflux pumps. Oncogene, 22(47 REV. 
ISS. 6), 7537–7552. https://doi.org/10.1038/sj.onc.1206953
53. Kumagai, A., Ando, R., Miyatake, H., Greimel, P., Kobayashi, T., Hirabayashi, Y., Shimogori, T., & 
Miyawaki, A. (2013). A bilirubin-inducible fluorescent protein from eel muscle. Cell, 153(7), 
1602–1611. https://doi.org/10.1016/j.cell.2013.05.038
54. Lazzari, G., & Silvano, G. (2020). From anemia to erythropoietin resistance in head and neck 





55. Li, J. L., Sainson, R. C. A., Oon, C. E., Turley, H., Leek, R., Sheldon, H., Bridges, E., Shi, W., Snell, C., 
Bowden, E. T., Wu, H., Chowdhury, P. S., Russell, A. J., Montgomery, C. P., Poulsom, R., & Harris, A. 
L. (2011). DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer 
Research, 71(18), 6073–6083. https://doi.org/10.1158/0008-5472.CAN-11-1704
56. Li, J., Zhang, X., Sejas, D. P., Bagby, G. C., & Pang, Q. (2004). Hypoxia-induced nucleophosmin 
protects cell death through inhibition of p53. Journal of Biological Chemistry, 279(40), 41275–
41279. https://doi.org/10.1074/jbc.C400297200
57. Liu, L., Ning, X., Sun, L., Zhang, H., Shi, Y., Guo, C., Han, S., Liu, J., Sun, S., Han, Z., Wu, K., & Fan, D. 
(2008). Hypoxia-inducible factor-1α contributes to hypoxia-induced chemoresistance in gastric 
cancer. Cancer Science, 99(1), 121–128. https://doi.org/10.1111/j.1349-7006.2007.00643.x
58. Liu, S. K., Bham, S. A. S., Fokas, E., Beech, J., Im, J., Cho, S., Harris, A. L., & Muschel, R. J. (2011). 
Delta-like ligand 4-Notch blockade and tumor radiation response. Journal of the National Cancer 
Institute, 103(23), 1778–1798. https://doi.org/10.1093/jnci/djr419
59. Mailhos, C., Lewis, J., Ish-Horowicz, D., Modlich, U., Harris, A., & Bicknell, R. (2001). Delta4, an 
endothelial specific Notch ligand expressed at sites of physiological and tumor angiogenesis. 
Differentiation, 69(2–3), 135–144. https://doi.org/10.1046/j.1432-0436.2001.690207.x
60. McAuliffe, S. M., Morgan, S. L., Wyant, G. A., Tran, L. T., Muto, K. W., Chen, Y. S., Chin, K. T., Partridge, 
J. C., Poole, B. B., Cheng, K. H., Daggett, J., Cullen, K., Kantoff, E., Hasselbatt, K., Berkowitz, J., 
Muto, M. G., Berkowitz, R. S., Aster, J. C., Matulonis, U. A., & Dinulescu, D. M. (2012). Targeting 
Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. 
Proceedings of the National Academy of Sciences of the United States of America, 109(43). https://
doi.org/10.1073/pnas.1206400109
61. McKeage, M. J., Jameson, M. B., Ramanathan, R. K., Rajendran, J., Gu, Y., Wilson, W. R., Melink, T. J., 
& Tchekmedyian, N. S. (2012). PR-104 a bioreductive pre-prodrug combined with gemcitabine 
or docetaxel in a phase Ib study of patients with advanced solid tumours. BMC Cancer, 12. 
https://doi.org/10.1186/1471-2407-12-496
62. Meng, R. D., Shelton, C. C., Li, Y.-M., Qin, L.-X., Notterman, D., Paty, P. B., & Schwartz, G. K. (2009). 
gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling 
pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Research, 69(2), 
573–582. https://doi.org/10.1158/0008-5472.CAN-08-2088
63. Minchinton, A. I., & Tannock, I. F. (2006). Drug penetration in solid tumours. Nature Reviews 
Cancer, 6(8), 583–592. https://doi.org/10.1038/nrc1893
64. Mohyeldin, A., Garzón-Muvdi, T., & Quiñones-Hinojosa, A. (2010). Oxygen in stem cell biology: A 
critical component of the stem cell niche. Cell Stem Cell, 7(2), 150–161. https://doi.org/10.1016/j.
stem.2010.07.007
65. Mortensen, L. S., Buus, S., Nordsmark, M., Bentzen, L., Munk, O. L., Keiding, S., & Overgaard, J. 
(2010). Identifying hypoxia in human tumors: A correlation study between 18F-FMISO PET and 




66. Nefedova, Y., Sullivan, D. M., Bolick, S. C., Dalton, W. S., & Gabrilovich, D. I. (2008). Inhibition of 
notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. 
Blood, 111(4), 2220–2229. https://doi.org/10.1182/blood-2007-07-102632
67. Noguera-Troise, I., Daly, C., Papadopoulos, N. J., Coetzee, S., Boland, P., Gale, N. W., Chieh Lin, H., 
Yancopoulos, G. D., & Thurston, G. (2006). Blockade of Dll4 inhibits tumour growth by promoting 
non-productive angiogenesis. Nature, 444(7122), 1032–1037. https://doi.org/10.1038/
nature05355
68. Nordsmark, M. (1996). Pretreatment oxygenation predicts radiation response in advanced 
squamous cell carcinoma of the head and neck. Radiotherapy and Oncology, 41(9), 31–39. 
https://doi.org/10.1016/s0167-8140(96)01811-7
69. Nordsmark, Marianne, Bentzen, S. M., Rudat, V., Brizel, D., Lartigau, E., Stadler, P., Becker, A., Adam, 
M., Molls, M., Dunst, J., Terris, D. J., & Overgaard, J. (2005). Prognostic value of tumor oxygenation 
in 397 head and neck tumors after primary radiation therapy. An international multi-center 
study. Radiotherapy and Oncology, 77(1), 18–24. https://doi.org/10.1016/j.radonc.2005.06.038
70. O’Connor, J. P. B., Robinson, S. P., & Waterton, J. C. (2019). Imaging tumour hypoxia with oxygen-
enhanced MRI and BOLD MRI. British Journal of Radiology, 92(1096). https://doi.org/10.1259/
bjr.20180642
71. Okunieff, P., Hoeckel, M., Dunphy, E. P., Schlenger, K., Knoop, C., & Vaupel, P. (1993). Oxygen 
tension distributions are sufficient to explain the local response of human breast tumors 
treated with radiation alone. International Journal of Radiation Oncology*Biology*Physics, 26(4), 
631–636. https://doi.org/10.1016/0360-3016(93)90280-9
72. Overgaard, J. (2007). Hypoxic radiosensitization: Adored and ignored. Journal of Clinical 
Oncology, 25(26), 4066–4074. https://doi.org/10.1200/JCO.2007.12.7878
73. Overgaard, J. (2011). Hypoxic modification of radiotherapy in squamous cell carcinoma of the 
head and neck - A systematic review and meta-analysis. Radiotherapy and Oncology, 100(1), 
22–32. https://doi.org/10.1016/j.radonc.2011.03.004
74. Overgaard, J., Eriksen, J. G., Nordsmark, M., Alsner, J., & Horsman, M. R. (2005). Plasma osteopontin, 
hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck 
cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet 
Oncology, 6(10), 757–764. https://doi.org/10.1016/S1470-2045(05)70292-8
75. Overgaard, J., Hansen, H. S., Overgaard, M., Bastholt, L., Berthelsen, A., Specht, L., Lindeløv, B., 
& Jørgensen, K. (1998). A randomized double-blind phase III study of nimorazole as a hypoxic 
radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of 
the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology, 
46(2), 135–146. https://doi.org/10.1016/S0167-8140(97)00220-X
76. Pires, I M, Olcina, M. M., Anbalagan, S., Pollard, J. R., Reaper, P. M., Charlton, P. a, McKenna, W. 
G., & Hammond, E. M. (2012). Targeting radiation-resistant hypoxic tumour cells through ATR 




77. Pires, Isabel M., Bencokova, Z., McGurk, C., & Hammond, E. M. (2010). Exposure to acute hypoxia 
induces a transient DNA damage response which includes Chk1 and TLK1. Cell Cycle, 9(13), 
2502–2507. https://doi.org/10.4161/cc.9.13.12059
78. Rankin, E. B., Nam, J. M., & Giaccia, A. J. (2016). Hypoxia: Signaling the Metastatic Cascade. Trends 
in Cancer, 2(6), 295–304. https://doi.org/10.1016/j.trecan.2016.05.006
79. Rasey, J. S., Koh, W. J., Evans, M. L., Peterson, L. M., Lewellen, T. K., Graham, M. M., & Krohn, K. A. 
(1996). Quantifying regional hypoxia in human tumors with positron emission tomography of 
[18F]fluoromisonidazole: A pretherapy study of 37 patients. International Journal of Radiation 
Oncology Biology Physics, 36(2), 417–428. https://doi.org/10.1016/S0360-3016(96)00325-2
80. Reddy, S. B., & Williamson, S. K. (2009). Tirapazamine: A novel agent targeting 
hypoxic tumor cells. Expert Opinion on Investigational Drugs, 18(1), 77–87. https://doi.
org/10.1517/13543780802567250
81. Reymen, B. J. T., van Gisbergen, M. W., Even, A. J. G., Zegers, C. M. L., Das, M., Vegt, E., Wildberger, 
J. E., Mottaghy, F. M., Yaromina, A., Dubois, L. J., van Elmpt, W., De Ruysscher, D., & Lambin, P. 
(2020). Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective 
imaging-based phase II trial. Clinical and Translational Radiation Oncology, 21, 49–55. https://
doi.org/10.1016/j.ctro.2019.12.002
82. Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W. C., Chanthery, Y., Kowalski, J., Watts, R. J., 
Callahan, C., Kasman, I., Singh, M., Chien, M., Tan, C., Hongo, J. A. S., De Sauvage, F., Plowman, 
G., & Yan, M. (2006). Inhibition of Dll4 signalling inhibits tumour growth by deregulating 
angiogenesis. Nature, 444(7122), 1083–1087. https://doi.org/10.1038/nature05313
83. Rischin, D., Hicks, R. J., Fisher, R., Binns, D., Corry, J., Porceddu, S., & Peters, L. J. (2006). Prognostic 
significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia 
in patients with advanced head and neck cancer randomly assigned to chemoradiation with 
or without tirapazamine: A substudy of Trans-Tasman Radiation Oncolog. Journal of Clinical 
Oncology, 24(13), 2098–2104. https://doi.org/10.1200/JCO.2005.05.2878
84. Rosenberg, A., & Knox, S. (2006). Radiation sensitization with redox modulators: A promising 
approach. International Journal of Radiation Oncology Biology Physics, 64(2), 343–354. https://
doi.org/10.1016/j.ijrobp.2005.10.013
85. Sahlgren, C., Gustafsson, M. V., Jin, S., Poellinger, L., & Lendahl, U. (2008). Notch signaling 
mediates hypoxia-induced tumor cell migration and invasion. Proceedings of the National 
Academy of Sciences of the United States of America, 105(17), 6392–6397. https://doi.org/10.1073/
pnas.0802047105
86. Sahra, I. Ben, Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le 
Marchand-Brustel, Y., & Bost, F. (2008). The antidiabetic drug metformin exerts an antitumoral 
effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 27(25), 3576–3586. 
https://doi.org/10.1038/sj.onc.1211024
87. Salaroglio, I. C., Panada, E., Moiso, E., Buondonno, I., Provero, P., Rubinstein, M., Kopecka, J., & 
Riganti, C. (2017). PERK induces resistance to cell death elicited by endoplasmic reticulum stress 
and chemotherapy. Molecular Cancer, 16(1), 1–13. https://doi.org/10.1186/s12943-017-0657-0
Chapter 7
216
88. Scehnet, J. S., Jiang, W., Ram Kumar, S., Krasnoperov, V., Trindade, A., Benedito, R., Djokovic, D., 
Borges, C., Ley, E. J., Duarte, A., & Gill, P. S. (2007). Inhibition of Dll4-mediated signaling induces 
proliferation of immature vessels and results in poor tissue perfusion. Blood, 109(11), 4753–
4760. https://doi.org/10.1182/blood-2006-12-063933
89. Schmid, T., Zhou, J., Köhl, R., & Brüne, B. (2004). p300 relieves p53-evoked transcriptional 
repression of hypoxia-inducible factor-1 (HIF-1). Biochemical Journal, 380(1), 289–295. https://
doi.org/10.1042/BJ20031299
90. Sheldon, H., Heikamp, E., Turley, H., Dragovic, R., Thomas, P., Oon, C. E., Leek, R., Edelmann, M., 
Kessler, B., Sainson, R. C. A., Sargent, I., Li, J., & Harris, A. L. (2010). New mechanism for Notch 
signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. 116(13), 2385–
2394. https://doi.org/10.1182/blood-2009-08-239228.The
91. Siebel, C., & Lendahl, U. (2017). Notch signaling in development, tissue homeostasis, and 
disease. Physiological Reviews, 97(4), 1235–1294. https://doi.org/10.1152/physrev.00005.2017
92. Spiegelberg, L., Houben, R., Niemans, R., de Ruysscher, D., Yaromina, A., Theys, J., Guise, C. P., 
Smaill, J. B., Patterson, A. V., Lambin, P., & Dubois, L. J. (2019). Hypoxia-activated prodrugs and 
(lack of ) clinical progress: The need for hypoxia-based biomarker patient selection in phase III 
clinical trials. Clinical and Translational Radiation Oncology, 15, 62–69. https://doi.org/10.1016/j.
ctro.2019.01.005
93. Stubbs, M., McSheehy, P. M. J., Griffiths, J. R., & Bashford, C. L. (2000). Causes and consequences 
of tumour acidity and implications for treatment. In Molecular Medicine Today. https://doi.
org/10.1016/S1357-4310(99)01615-9
94. Theys, J., Yahyanejad, S., Habets, R., Span, P., & Dubois, L. (2013). High NOTCH activity induces 
radiation resistance in non small cell lung cancer. 108(3), 440–445. https://doi.org/10.1016/j.
radonc.2013.06.020.High
95. Thorwarth, D., Eschmann, S. M., Holzner, F., Paulsen, F., & Alber, M. (2006). Combined uptake 
of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck 
cancer patients. Radiotherapy and Oncology, 80(2), 151–156. https://doi.org/10.1016/j.
radonc.2006.07.033
96. Toustrup, K., Sørensen, B. S., Alsner, J., & Overgaard, J. (2012). Hypoxia Gene Expression 
Signatures as Prognostic and Predictive Markers in Head and Neck Radiotherapy. Seminars in 
Radiation Oncology, 22(2), 119–127. https://doi.org/10.1016/j.semradonc.2011.12.006
97. Toustrup, K., Sørensen, B. S., Lassen, P., Wiuf, C., Alsner, J., & Overgaard, J. (2012). Gene expression 
classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell 
carcinomas of the head and neck. Radiotherapy and Oncology, 102(1), 122–129. https://doi.
org/10.1016/j.radonc.2011.09.010
98. Vaupel, P, Hockel, M., & Mayer, A. (2007). Detection and characterization of tumor hypoxia using 
pO2 histography. Antioxid Redox Signal, 9(8), 1221–1235. https://doi.org/10.1089/ars.2007.1628
99. Vaupel, Peter, Mayer, A., & Höckel, M. (2004). Tumor hypoxia and malignant progression. 




100. Vermezovic, J., Adamowicz, M., Santarpia, L., Rustighi, A., Forcato, M., Lucano, C., Massimiliano, 
L., Costanzo, V., Bicciato, S., & Sal, G. Del. (2015). Notch is a direct negative regulator of the DNA-
damage response. Nature Publishing Group, 22(5). https://doi.org/10.1038/nsmb.3013
101. Wang, Y., Wang, H., Li, J., Entenberg, D., Xue, A., Wang, W., & Condeelis, J. (2016). Direct 
visualization of the phenotype of hypoxic tumor cells at single cell resolution in vivo using a 
new hypoxia probe. IntraVital, 5(2), e1187803. https://doi.org/10.1080/21659087.2016.1187803
102. Winter, S. C., Buffa, F. M., Silva, P., Miller, C., Valentine, H. R., Turley, H., Shah, K. A., Cox, G. J., Corbridge, 
R. J., Homer, J. J., Musgrove, B., Slevin, N., Sloan, P., Price, P., West, C. M. L., & Harris, A. L. (2007). 
Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple 
cancers. Cancer Research, 67(7), 3441–3449. https://doi.org/10.1158/0008-5472.CAN-06-3322
103. Wu, L., Zhu, J., Prokop, L. J., & Hassan Murad, M. (2015). Pharmacologic Therapy of Diabetes and 
Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies. Scientific Reports, 5(December 
2014), 1–10. https://doi.org/10.1038/srep10147
104. Yao, J., & Qian, C. (2010). Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic 
cancer through an inactivation of PI3K/Akt-dependent pathway. Medical Oncology, 27(3), 1017–
1022. https://doi.org/10.1007/s12032-009-9326-5
105. Yasuda, H., Yamaya, M., Nakayama, K., Sasaki, T., Ebihara, S., Kanda, A., Asada, M., Inoue, D., 
Suzuki, T., Okazaki, T., Takahashi, H., Yoshida, M., Kaneta, T., Ishizawa, K., Yamanda, S., Tomita, 
N., Yamasaki, M., Kikuchi, A., Kubo, H., & Sasaki, H. (2006). Randomized phase II trial comparing 
nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously 
untreated stage IIIB/IV non-small-cell lung cancer. Journal of Clinical Oncology, 24(4), 688–694. 
https://doi.org/10.1200/JCO.2005.04.0436
106. Zannella, V. E., Pra, A. D., Muaddi, H., McKee, T. D., Stapleton, S., Sykes, J., Glicksman, R., Chaib, S., 
Zamiara, P., Milosevic, M., Wouters, B. G., Bristow, R. G., & Koritzinsky, M. (2013). Reprogramming 
metabolism with metformin improves tumor oxygenation and radiotherapy response. Clinical 
Cancer Research, 19(24), 6741–6750. https://doi.org/10.1158/1078-0432.CCR-13-1787
107. Zegers, C. M. L., Van Elmpt, W., Hoebers, F. J. P., Troost, E. G. C., Öllers, M. C., Mottaghy, F. M., & 
Lambin, P. (2015). Imaging of tumour hypoxia and metabolism in patients with head and neck 
squamous cell carcinoma. Acta Oncologica, 54(9), 1378–1384. https://doi.org/10.3109/028418
6X.2015.1062913
108. Zegers, C. M. L., Van Elmpt, W., Reymen, B., Even, A. J. G., Troost, E. G. C., Öllers, M. C., Hoebers, F. J. 
P., Houben, R., Eriksson, J., Windhorst, A. D., Mottaghy, F. M., De Ruysscher, D., & Lambin, P. (2014). 
In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18f ]hx4 and [18f ]
fdg-pet/ct imaging. Clinical Cancer Research, 20(24), 6389–6397. https://doi.org/10.1158/1078-
0432.CCR-14-1524
109. Zhou, G., Goodyear, L. J., Moller, D. E., Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-melody, 
J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L. J., & Moller, D. E. 
(2001). Role of AMP-activated protein kinase in mechanism of metformin action Find the latest 
version : Role of AMP-activated protein kinase in mechanism of metformin action. The Journal 






Cancer is the second leading cause of death globally according to the World Health 
Organisation. While survival rates are increasing there is still a high unmet need in many 
cancers for new treatment modalities and personalised treatment to further increase 
survival. New methods to overcome treatment-resistant tumours are vitally important in 
instances where the tumour becomes resistant to a particular therapy. 
In chapter 2 we review the current knowledge on the role of Notch in breast cancer. Notch 
is a cell-cell communication system that, depending on the context, can act as both an 
oncogene and a tumour suppressor. In breast cancer, there is overwhelming evidence that 
Notch plays a role in both development and progression with high Notch activity being 
associated with a more aggressive disease and poor patient outcome. While mutational 
changes in Notch are limited, expression, activity and cross-talk with other oncogenic 
pathways are found in many breast cancers. Furthermore, Notch has been shown to play 
an important role in the response to radiotherapy, chemotherapy, hormonal and targeted 
therapies. Critically, there is strong evidence that treatment-resistant breast cancers can 
be re-sensitised through inhibition of Notch, providing a rationale for combining Notch 
inhibition with current therapies. 
Hypoxia is a common feature found in solid tumours arising from an imbalance between 
oxygen consumption and delivery in the tumour. The high proliferation and metabolic 
activity of tumours coupled with the inefficient tumour vasculature leads to areas of 
hypoxia within the tumour. Hypoxia is associated with worse outcomes in many different 
cancers regardless of treatment type. Notch and hypoxia have also been shown to 
influence several of the same pathways including parts of the metastatic cascade and 
neoangiogenesis. The Notch target gene DLL4 and the hypoxia-inducible factor (HIF) 
target gene VEGF are critical for the formation and maturation of new blood vessels. 
Previous research in our lab has shown a larger hypoxic fraction in Notch overexpressing 
tumours suggesting reduced functional vasculature or increased survival and adaptation 
of hypoxic cancers cells with increased Notch activity. 
In chapter 3 we extend this work to investigate how hypoxia influences Notch activity 
in this model and how this can affect Notch activity in distant cells. We use conditioned 
medium from these cells exposed to different oxygen conditions to see whether Notch 
signalling could be induced in reporter cells independent of cell contact. We find that 
hypoxic cells are able to upregulate Notch activity in recipient cells. Importantly this 
upregulation in activity can be abrogated through the use of Notch inhibitors. This points 
to a possible application  of  Notch inhibitors to reduce the hypoxic fraction of tumours, 
however, whether this holds true in vivo is unknown.  Future research into the effect of 
Notch inhibitors on the hypoxic fraction of Notch expressing tumour cells  and their 
microenvironment is therefore needed.
 In chapter 4 we develop a novel strategy to label hypoxic cells in a temporally controlled 
manner. We created an ‘oxygen sensing’ HIF1α-GFP-CreERT2 fusion protein which also 
incorporates temporal control through the ERT2 domain which translocates the protein 
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to the nucleus when 4-hydroxytamoxifen (4OHT) is present. We coupled this with a 
fluorescent reporter and transduced them into a H1299 non-small cell lung cancer model. 
We characterise this model both in vitro and in vivo showing permanent labelling of hypoxic 
cells only when 4OHT is added. We show that hypoxic cells can be visualised at single-
cell resolution in vivo via intravital microscopy, and ex vivo via immunohistochemistry. 
Using this model we find a proliferative advantage for post-hypoxic cells in vivo when 
compared with unlabelled cells. This implies that hypoxia permanently alters the cellular 
phenotype and behaviour, but what causes this increased proliferation is still unknown. 
Future research should be aimed at finding the (epi)genetic and proteomic changes that 
cause this phenotype.
In chapter 5 we refine this system further with the substitution of the CMV promoter for 
EF1α in the oxygen sensing construct to facilitate its use in cell lines where CMV silencing 
occurs. We coupled this with a reporter construct that also contains the Diphtheria toxin 
receptor protein allowing labelled cells to be selectively ablated upon administration of 
Diphtheria toxin. We characterised this system in vitro using the 4T1 murine metastatic 
breast cancer model, showing oxygen and 4OHT dependent labelling of cells which can 
then be selectively ablated with Diphtheria toxin. Next, we optimised the 4T1 cell line in vivo 
in an immunocompetent orthotopic model. We determined the hypoxic fraction at different 
tumour volumes to determine the timing and dosing of tamoxifen. Next, we optimised 
the dose of diphtheria toxin needed to kill all labelled cells within days after tamoxifen 
administration in tumours and determined the growth response of 4T1 tumours to single 
and fractionated radiotherapy. We show that hypoxic cells can be labelled through the 
administration of tamoxifen and can then be subsequently ablated with diphtheria toxin. 
Our hypothesis is that Diphtheria toxin will function as the ‘perfect ‘ drug or hypoxic cytotoxin 
and will sensitize tumours to RT treatment. Ongoing studies are investigating the benefits of 
hypoxic cell depletion with Diphtheria toxin and tumour control after radiotherapy.
In chapter 6 we describe the generation of a novel knock-in mouse strain which can be 
used to lineage trace hypoxic cells. At present, there are no mouse strains that can identify 
hypoxic cells in vivo at the single-cell level. Such systems would be invaluable in our further 
understanding of the role of hypoxia in normal tissue development, homeostasis, tissue 
regeneration and in pathological processes such as cancer inflammation, tissue ischemia 
including cardiovascular and neurodegenerative diseases. To enable lineage tracing of 
HIF-1 activated cells throughout development and in adult mouse tissues we fused the 
c-terminal oxygen dependent degradation domain of HIF1a HIF-1α (aa 1-603)- to  a eGFP-
CreERT2 into theHIF1 locus in C57Bl/6 embryonic stem cells. We show that the ES cells 
that were used to generate the mice are able to report on hypoxia when a reporter was 
introduced. We obtained germline transmission of the HIF1-Cre-ER allele and obtained 
hemizygous mice that are viable and fertile. The generated mouse strain should provide 
a valuable tool to study hypoxic cell behaviour in vivo and in the assessment of hypoxia 







Cancer is one of the leading causes of death worldwide and rising as a consequence of our 
ageing population. Cancer also has the highest direct and indirect costs of any disease. 
While developments have been made improving the survival rate of less malignant breast 
cancer patients, there is still a need to find new treatment strategies to improve survival 
further especially in patients with metastatic disease. In this thesis, we start by reviewing the 
current evidence for the role of Notch in breast cancer. Notch is cell to cell communication 
system that plays a critical role in development, determining cell fate and the generation 
of new blood vessels. Notch has been shown to act as both an oncogene and a tumour 
suppressor depending on the cancer type and context. Notch plays a role in normal breast 
development, but there is also overwhelming evidence that it also plays a role in the 
development and progression of breast cancer. This is not always due to mutations, with 
Notch signalling found to be active and cross-talking with many other oncogenic signalling 
pathways. For example there is evidence that both ER and EGFR signalling (both targets 
in breast cancer) negatively regulate NOTCH signalling. When inhibited (tamoxifen or anti-
EGFR/ HER2) they activate Notch providing a survival signal. The co-targeting of EGFR and 
ER with Notch would sensitise the tumour to these treatments. 
Scientific relevance:
Hypoxia (low oxygen) is a common feature of tumours due to their high metabolic 
activity, proliferation, and suboptimal vasculature. Hypoxia is also linked to metastasis 
which is the ultimate cause of treatment failure in the majority of cancers. While there 
are sometimes efficient treatments for early disease, the metastatic burden often leads to 
eventual treatment failure. Hypoxia is also known to reduce the efficacy of radiotherapy 
due to the oxygen effect enhancing the DNA damage created by radiotherapy. This means 
that more DNA damage and ultimately cell death is produced in well-oxygenated regions 
than in hypoxic regions. The hypoxic fraction of tumours has also been shown to be more 
resistant to chemotherapeutics through multiple mechanisms. Hypoxia also affects many 
of the same pathways as Notch signalling. Both play major roles in the maintenance of 
(cancer) stem cells and affect tumour progression and response to therapy. Both Notch and 
hypoxia play a critical role in angiogenesis, and in cancer this can lead to the formation of 
aberrant vasculature further increasing the hypoxic fraction of tumours. Overall hypoxia 
is a negative predictive factor and is associated with poor patient outcome.  Due to this, 
there have been several different strategies aimed at relieving tumour hypoxia to increase 
the efficacy of radiotherapy and chemotherapy. In addition to this, hypoxia has also been 
used to target drugs to the tumour to reduce side effects which often limit the dose of 
chemotherapeutics that can be used, reducing their efficacy. Despite many promising 
candidates no hypoxia modification or targeting strategies have reached the clinic. Part 
of the reason for these failures is a lack of knowledge and understanding into how the 
hypoxic population of cells behave and how they contribute to therapy resistance and 
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tumour recurrence as a population and at the single-cell level especially in the complex in 
vivo microenvironment. 
In this thesis, we describe the generation and development of a genetic tool to permanently 
label hypoxic cells in a temporally controlled manner. Using this tool we have shown that 
labelled cells are able to be visualised both in living tumours using intravital microscopy 
and once the tumour has been removed at single-cell resolution. We find that post-
hypoxic cells were more proliferative than unlabelled cells raising questions as to how 
and what effect this may have on the tumour and patient outcome. The hypoxic tracer 
method provides a useful quantitative tool with high specificity and sensitivity to study 
hypoxic and post-hypoxic cell behaviour in vivo at the single-cell level. More information 
on the effect of hypoxia will lead to new and improved strategies for targeting these cells, 
which can eventually translate to the clinic. This tool will facilitate study into the dynamics 
of hypoxic and post-hypoxic cells within the primary tumour and their contribution to 
metastases. The effects of treatments such as radio and chemotherapy on this population 
of cells and how they respond can also be investigated. 
We further developed the tool to allow the selective killing of labelled cells allowing 
investigation into the role of hypoxic cells in therapy resistance. This system will be able to 
show what effects targeting the hypoxic population will have, and what benefits this has 
in combination with established treatments. This tool will also be useful in understanding 
the efficacy of hypoxia modification and targeting strategies. It will facilitate visualisation 
of the hypoxic population with and without these strategies and what effect they have 
on this population of cells. It will help in the optimisation of these strategies and how and 
when they are applied. The timing of these strategies in relation to other treatments such 
as radiotherapy can be investigated to elucidate the most effective schedule.
While cell lines are an indispensable tool in the study of cancer they often do not allow 
the use of immunocompetent mice or effectively replicate the clinical situation even in 
orthotopic models. To overcome this limitation we created a knockin transgenic mouse strain 
with this tool to facilitate the study of hypoxia in spontaneous tumours when crossed with 
mice lines such as MMTV-PYMT; a transgenic mouse model which spontaneously develop 
ductal mammary carcinomas. Spontaneous tumours better imitate the clinical situation 
due to undergoing initiation steps such as immunoediting as well as being influenced by 
organ-specific microenvironmental factors such as hormones and tissue architecture. This 
model can therefore give data that is more relevant to the clinical situation. In addition to 
applications in cancer research, this tool will be of use in other areas where hypoxia is a 
factor. Other problems such as tissue ischemia (heart failure, stroke) lead to hypoxia, where 
this tool can be of use to study the affected cells and tissues. On top of this certain aspects 
of development are dependent on hypoxia and hypoxia-inducible factors, with human 
embryos developing in a predominantly hypoxic environment.
Together, the work in this thesis provides a rationale for the use of Notch inhibitors in the 
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Lorena, your help with my in vivo experiments has been invaluable, I do not think I would 
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even more so during the pandemic. Thanks to you I also now know how to make carbonara 
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and the advice you have given me in and outside the lab has been invaluable.  Organising 
team building with you turned something that  I saw as an inconvenience into a fun and 
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